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“The greatest glory in living lies not in never falling but in rising every time we fall” 
-Nelson Mendela, South African President and Human Rights Activist 
 
The significance of this quote is that it defines greatness and success in how we as 
human beings handle hardship, failure, or unexpectedness in life. Persistence and 
perseverance are important qualities in a scientist, since the essence of scientific research 
almost always implies that our hypothesis may not be right the first time around. 
Moreover, these qualities are not only important for the success of a scientist in the 
workplace but for any human being in his or her personal life since life is unforeseeable 
and unpredictable.           
 The thesis presented herein has been completed in the Department of 
Pharmaceutical Sciences, College of Pharmacy, at the University of Michigan, Ann 
Arbor. The thesis is unique in that it has allowed me to explore and learn various aspects 
of drug disposition (pharmacokinetics) and drug action (pharmacodynamics), broadening 
my exposure to basic science aspects of pharmacology and the quantitative science 
aspects of clinical pharmacology. The half of the thesis related to the PEPT2 transporter 
system has enhanced my understanding of drug transporters and how a transporter may 
modulate the disposition of a drug substrate systemically or locally and how such 
modulation may translate to significant changes of drug pharmacodynamics at the 
biophase. Moreover, it has provided me with the experience in designing 
iii 
 
pharmacokinetic studies and working with experimental animal models in the laboratory, 
the latter which I had not learned before.       
 The half of the thesis related to the utility of subjective continuous and ordinal 
pharmacodynamic scales in early CNS drug development has allowed me to build on the 
pharmacokinetic/pharmacodynamic (PK/PD) priniciples I learned while completing my 
PharmD at the University at Buffalo, extending my training in the pharmacostatistical 
and population aspects of PK/PD modeling and simulation. While different in theme, 
both sections of the split thesis cover an in-depth study of the pharmacokinetics and 
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PHARMACOMETRIC UTILITY OF ORDERED CATEGORICAL AND 
CONTINUOUS PHARMACODYNAMIC SCALES IN EVALUATING 
LORAZEPAM SLEEPINESS AND DIZZINESS 
 
CHAPTER  1 
 INTRODUCTION TO PART I 
 
Subjective Pharmacodynamic Scales 
Subjective pharmacodynamic scales become important in drug development when 
a clinical effect of interest has no alternative objective measure. A good example is pain 
which has been measured in several analgesic trials using ordered categorical (e.g. none, 
mild, moderate or severe) and continuous subjective scales(marking a line with none on 
one end and worst imaginable on the other). In CNS drug development the reliance on 
subjective pharmacodynamic scales increases as clinical endpoints such as anxiety, 
mood, depression and sleepiness, for example are difficult to measure objectively. 
Examples of commonly used subjective scales in CNS drug development are Likert 
questionnaires which use a categorical scale and the continuous visual analog scale both 
of which can be modified to measure a number of subjective effects.  
 The Visual Analogue Scale 
 The Visual Analogue scale (VAS) is a continuous scale typically consisting of a 
10-centimeter line anchored at both ends with words descriptive of the maximal and 
minimal extremes of the dimension being measured. Subjects are asked to indicate 
2 
 
specific feelings at the time by marking the line at the appropriate point between the two 
extreme statements. The scale is scored by measuring the distance from the minimal end-
point to the mark, on a predetermined measurement interval. The most commonly chosen 
interval is millimeters with a 10 centimeter line, producing a 100- point scale 
(McCormack et al, 1988). Although verbal labels define the endpoints of VAS, neither 
numbers nor intermediate labels are used to define intermediate points, as this may cause 
clustering of scores around a preferred digit leading to bias (Scott and Huskisson, 1974). 
Figure 1.1  shows a representation of the VAS scale. 
The VAS is not a novel scale and was first used in psychological research as early 
as the 1920’s (Hayes M. et al, 1921; Freyd M; 1923). Its widespread use in clinical 
research was stimulated by the work of Aitken & Zealley who used it to construct single 
item mood scales (Aitken and Zealley, 1970). They argued that words may fail to 
describe the ‘exactness of the subjective experience’ and that verbal rating scales 
imposed artificial categories on the continuous phenomena of feelings. They proposed 
that VAS offered a sensitivity of scoring which was impossible with digital and ordinal 
rating scales (Aitken et al 1969). 
Most reports describing the use of VAS in the literature are validation studies. 
The majority of these studies focus on VAS developed to measure either mood or pain 
and assess validity by correlating VAS scores with the scores of an established scale 
(McCormack et al, 1988).         
 The re-test reliability of VAS was also established. Robinson et al (1975) asked 
subjects to rate their hunger on two occasions separated by a one hour interval, during a 
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fasting period in their study of the reliability of VAS-Hunger. The correlation between 
the two rating periods was very high (r=0.92, P<0.001). 
The apparent simplicity of the VAS and its adaptability to a wide range of 
research settings has made it an attractive measurement option. Among its advantages 
proponents have claimed that VAS:1)  is simple and quick to construct (Ahles et al, 
1984);  2) quick and easy to administer and score (Rampling et al, 1977); 3) suitable for 
frequent and repeated use (Rampling et al, 1977); 4) is easily understood by subjects 
(Morrison, 1983); 5) is very sensitive with a discriminating capacity superior to other 
scales (Scott & Huskisson, 1976); 5) require little motivation for completion by subjects 
(Rampling et al, 1977); 6) is suitable for use by untrained staff (Folstein & Luria, 1973);  
and 7) allows the use of numerical values suitable for statistical analysis (Robinson et al, 
1975).   
Despite the studies that advocate VAS as a valid, reliable, sensitive, and robust 
measurement instrument, some have highlighted difficulties associated with its use. 
Carlsson et al (1983) questioned the assumption that VAS is an easy scale to use by 
subjects pointing out that the VAS requires an ability to transform a complex subjective 
experience into a visuo-spatial display, involving perceptual judgment and accuracy. 
Older age and the loss of ability to think abstractly (Kremer et al, 1981), mental 
disorganization and confusion (Hornblow, 1976), and decline of perceptual skills and 
memory (Carlsson, 1983) have all been suggested as factors, which may contribute to 
respondent error. The reliability of the VAS may even change as a study progresses. For 
example, results of a study (Hornblow and Kidson, 1976) suggest that the ability to use 
VAS-Anxiety as a continuum and as a valid scale decreases as the psychiatric symptoms 
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of subjects become more severe. In contrast, when Carlsson (1983) explored the impact 
of learning, memory, and perceptual judgment on the reliability and validity of VAS, no 
relationship between these variables and the subject’s ability to make reliable 
assessments on VAS-Pain were found. However these two studies measured different 
effects (anxiety versus pain), therefore alluding to the possibility that, depending on the 
effect measured as well as study conditions (i.e. absence or presence of altering 
medications and disease progression), and the reliability of VAS may be quite different. 
 Moreover, certain studies demonstrated that the same VAS could be treated 
differently by different populations. In their comparison of psychiatric patients and 
medical students on the VAS-Anxiety, Hornblow and Kidson (1976) found that, while 
medical students treated the scale as a continuum, patient scores were tri-modal, with 
clusters at the midpoint and extremes of scales, suggesting interpretation of the scale 
instructions may be different between varying populations. 
 Little and McPhail (1973) also pointed out that patients, while using the VAS-
Depression as a repeated measure, scored the VAS to the maximum before completion of 
the study, leaving themselves no room to record a higher score should their mood worsen. 
 The above studies emphasize the importance of testing the suitability of VAS for 
the population to be assessed prior to application of the technique. 
The Ordered Categorical (Ordinal) Scale 
 The ordered categorical or ordinal scale sorts and ranks the dimension to be 
measured in non-overlapping categories, which usually have a numerical rating scale, 
attached. While the magnitude of change in going from category to category is unknown 
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the direction of change is (Stevens S, 1946; Merbitz C et al, 1989). The ordered 
categorical scale was included in the aforementioned study and was part of a 69-item 
questionnaire called the Subject Rated Drug Effect Questionnaire (SRDEQ, developed by 
Pfizer Inc) that measures subjective effects in 7 distinct ordered categories. As shown the 
categories are described by verbal adjectives that describe an ascending order in effect 
intensity. 
 Ordinal scales have been used in a variety of clinical settings as an instrument 
measuring subjective phenomena, otherwise difficult to measure using objective tests. 
Such phenomena as Pain (Ahles et al, 1984; Seymour et al, 1982; Jensen et al, 1986; 
Sheiner , 1994; Gupta et al; 1999; Mandema et al, 1996; Lundeberg et al, 2001), mood 
(Folstein and Luria, 1973), sleepiness (Mitsutomo et al, 2000), health perception and 
quality of life (Cox et al, 1992; Spilker et al, 1996) and have all been measured using 
single- and multi-item categorical scales.Moreover, the validity (McCormack et al, 1988; 
Jensen et al, 1986) and reliability (Jensen et al, 1986; Lundeberg et al, 2001) of many 
ordinal scales have been established in a number of studies.    
 Some of the advantages of ordinal scales are their: 1) simplicity, ease of use and 
administration (Merbitz et al, 1989; Jensen et al, 1986); 2) ease of comprehension 
providing definite tangible descriptors that require less imagination (Joyce et al, 1975, 
Merbitz et al, 1989); 3) requirement of little training and motivation for the subject to 
complete (Joyce et al, 1975); 4) suitability for frequent and repeated use (Deyo et al, 
1986, 1991; Lundeberg et al, 2001).  The reported disadvantages of ordinal scales are 
their: 1) placement of artificial boundaries on subjective dimensions (Aitken & Zealley, 
1970); 2) decreased sensitivity, responsiveness and discriminating capacity (due to fewer 
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categories) to detect small clinically relevant changes (Joyce et al, 1975; Ohnhaus & 
Adler, 1975; Seymour et al, 1982; McCormack et al, 1988; Svensson et al, 2000); 3) 
inability to quantify change in going from category to category (Merbitz et al, 1989); 4) 
difficulty in manipulating ordinal data for statistical analysis leading to sometimes misuse 
and misinference  (Merbitz et al, 1989;Svensson et al, 1998, 2000). 
Comparison of Ordinal and Continuous Scales     
 A number of comparative studies between continuous scales and ordinal scales 
measuring various types of variables have been performed, however no consensus has 
been reached as to the superiority of one over the other.     
 Ohnhaus & Adler (1975) found their VAS -Pain was more sensitive to increases 
and decreases in reported pain then the five point verbal ordinal (ordered categorical) 
scale that they compared it to. Similar conclusions were reported by Joyce et al (1975) 
that compared a 4-point ordinal scale to a VAS measuring chronic pain and Seymour et al 
that compared the VAS to a 4-point ordinal scale measuring post-operative dental pain. 
While one might logically conclude that the VAS is the more sensitive scale then the 
ordinal scale, which has a small number of response categories, Jensen et al (1986) 
pointed out that scales with more response categories have only the potential to be more 
sensitive, but are not necessarily more sensitive when used in a given study. Moreover, 
sensitivity to detect treatment effects is not necessarily associated with greater construct 
validity.         
 Lundeberg et al (2001) reported that the VAS produced significantly greater 
systematic discrepancies then the categorical scale, the reason being that subjects tended 
to overestimate their baseline pain on the VAS while discrepancies on the verbal scale 
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occurred in both directions.         
 Jaeshke et al (1990) recommended a 7-point ordinal scale over the VAS while 
Mckelvie et al (1978) recommended scales with five or six categories. In a study 
comparing a 7 point ordinal and VAS measures of muscle soreness Vickers et al (2000), 
found that VAS scores plotted recorded concurrently with each Likert score (a categorical 
scale) varied enormously and that their was significant overlap in the VAS scores, 
depicting a high variability in VAS measures. However their deduction that the Likert 
scale is more responsive must be considered with caution as the statistical approaches 
used assume normally continuous distributions and ignore the rank-invariant properties of 
ordinal data          
 In another study highlighting the superiority of the ordered categorical scale, 
Svensson (2000) presented a rank-invariant approach to evaluate the parallel reliability of 
intra-rater assessments made of a VAS scale, a 5-point ordinal scale, and a graphical 
rating scale. The latter is a hybrid of the ordinal and continuous scales consisting of a 
continuous line land marked with verbal categories. Overlapping of the VAS assessments 
on the discrete categories was observed and it was concluded that both ordinal scale and 
graphical rating scale displayed higher intra-scale stability (defined as intra -rater 
agreement and lack of systematic disagreement in assessments between two occasions) 
then the VAS. 
Pharmacokinetic/Pharmacodynamic Applications     
 As mentioned previously, continuous and ordinal scales have been used in a 
variety of clinical PK/PD applications. They have been used extensively as biomarkers in 
clinical pharmacology studies assessing efficacy, safety, comparative efficacy, effect of 
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formulation on phamracodynamics, and pharmacodynamic interaction studies. To 
highlight some examples:  1) A 5 point ordered categorical scale was used to measure 
efficacy of ketorolac as an analgesic for postoperative pain after administration of various 
intramuscular doses. (Mandema el al, 1996); 2) The safety of oxybutynin was 
investigated where the undesirable effect of dry mouth was measured using a 4 point 
categorical scale  (Gupta et al, 1999); 3) In another study by Mitsutomo et al (2000), a 7-
point ordinal scale called the Stanford Sleepiness Scale and a multi-item visual analogue 
scale measuring various dimensions of mood were used to measure and compare the 
residual effects of standard clinical doses of Zolpidem and Zopiclone (two hypnotics) on 
daytime sleepiness and psychomotor function;  4) The time course of sleepiness  in 6 
male subjects was assessed on the Stanford sleepiness scale and a nurse rating sedation 
scale (both ordinal scales) to compare the pharmacodynamics of an intravenous and 
orally administered  1mg dose of alprazolam (Smith R et al 1984); 5) In a 
pharmacodynamic  drug-drug interaction study, the VAS scale was used to measure the 
effect of coadministration of nimodipine on diazepam induced tiredness (Heine R et al, 
1994). 
NonLinear Mixed Effects Modeling (NONMEM) 
NONMEM (Beal and Sheiner, 1002) is a computer program, written in using 
Abbreviated Fortran, designed to fit general statistical (nonlinear) regression models to 
data. Proper modeling of such data involves accounting for both unexplainable inter- and 
intra-subject effects (random effects), as well as measured concomitant effects (fixed 
effects). NONMEM allows for this ‘mixed effects modeling’. 
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In population PK/PD modeling one attempts to describe or model 
exposure/response data obtained from a sample that one believes represents the 
population. The model allows us to make inferences of the population as a whole. Fixed 
effects are estimated with THETA parameters that measure the typical population value 
or central tendency. The random effects consist of two parameter types. Omega 
parameters quantify the magnitude of interindividual or between-subject variability in the 
population, whereas Epsilon parameters quantify the magnitude of residual error (a 
measure of intraindividual variability, measurement error and model misspecification).  
SPLUS 
SPLUS is a statistical software package used for data visualization and 
exploration and statistical programming and simulation, and as such is used frequently in 
the area of pharmacometrics. In the current thesis, S- Plus has been used mostly for 
creating graphics, bootstrapping, and simulation based on bootstrap estimates.  
Modeling Continuous versus Ordinal Data 
Modeling ordered categorical data poses a challenge as this data is not continuous 
and thus cannot be modeled using conventional linear and nonlinear regression 
techniques. The outcome variable (in this case effect) is polytomous (many discrete 
outcome categories) and has a polynomial distribution. The simplest case of an ordinal 
variable is a dichotomous or binary variable, which has a binomial distribution. 
Statistically, the polynomial distribution is different from the continuous 
distribution in that outcome categories may not be equidistant and hence homogeneity of 
variance does not hold in such a case. For example, on the continuous VAS, going from 
5mm to 10mm is the same change in effect as going from 10mm to 15mm, whereas in the 
10 
 
ordinal scale, the change in effect in going from mild to moderate is not necessarily the 
same as going from moderate to significant. Only the direction of change is known but 
not the magnitude. This essentially highlights what statisticians refer to as the rank 
invariant property of ordinal data or that the data remains invariant in all order-preserving 
transformations, which means that the category labels do not represent any mathematical 
value other then the order of responses (McCullagh et al, 1980). 
This is why modeling ordinal data requires a special type of regression known as 
logistic regression. If we convert ordinal pharmacodynamic data into probabilities of 
scoring a particular category as a function of time we can then use the logit 
transformation as follows: 
                                                                         Equation   1 
 
Where m represents the effect category (i.e. 0=none, 1=minimum, 2=mild, etc), P is the 
probability (ranging from 0 to 1) of reporting that effect category at time t and g (x) is the 
function in logits.  
The logit domain is an infinitely continuous domain ranging from -∞ to+∞, and so 
now the data can be manipulated using techniques that apply to continuous data and can 
be modeled using similar principles to those that apply to linear and nonlinear regression. 
However one drawback with the logistic function (and hence ordinal data) is that the final 
model can give information only about the population as a whole. Individual estimates, 











Preliminary Pharmacodynamic Differentiation Profile 
It is clear that continuous and ordered categorical scales have been used as 
measurement instruments in a variety of clinical studies and that they each have 
advantages and disadvantages. However, their standard use and relative suitability for 
measuring pharmacodynamics and subjective experiences in relation to pharmacokinetic 
profiles have not been examined closely in the context of PK-PD modeling analysis, 
especially in smaller study settings. Use of timed assessments with VAS or ordered 
categorical scales to measure commonly occurring adverse events and other drug effects 
may provide useful information from small samples of healthy volunteers. This would 
help in creating a Preliminary Pharmacodynamic Differentiation Profile (PPDP) to 
evaluate new compounds (Moton et al, 2005).While the PPDP would not be a definitive 
assessment of tolerability or other important drug effects, it would be used to provide a 
preliminary characterization of several effects of leading marketed compounds for a 
comparison of those of new compounds in early development.  This profile amongst 
other factors, may also be used to identify doses of the drug candidate that are unlikely to 
achieve a profile of adverse events or other drug effects that are equal to or better than a 
particular drug currently marketed for the same indication.      
 Pharmacometric utility of these psychometric scales in small pharmacology 
studies will depend on the feasibility of pharmacokinetic-pharmacodynamic (PK-PD) 
modeling to develop reliable population models that can accurately compare the relative 
potency of different compounds based on various measures of CNS effects which would 
be used to:1) characterize the time course of pharmacodynamic response in relation to the 
PK profile 2) identification of PD parameters that can be modeled for several compounds 
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or used in clinical trial simulation studies. Pharmacokinetics and pharmacodynamic 
effects measured using both a continuous and ordered categorical scales were obtained in 
a study designed to assess the feasibility of using different subjective scales as 
biomarkers of pharmacodynamic response using model CNS drugs (Moton et al, 2005).  
This study was conducted in 20 healthy volunteers using a randomized, double-blind, 
single dose, 5-way crossover design.  Each subject received 5 treatments administered 
approximately 1 week apart for 5 consecutive weeks. The regimens under investigation 
were: 1) Olanzapine 10mg, 2) Atomoxetine 80mg, 3) Paroxetine 40 mg, 4) Lorazepam 2 
mg, and 5) Placebo. These are prescribed for a spectrum of CNS therapeutic indications- 
atomoxetine for attention deficit hyperactivity disorder, olanzapine for schizophrenia, 
lorazepam for anxiety and insomnia, and paroxetine for depression and Obsessive 
Compulsive Disorder. These model drugs were selected in the study because they: 1) 
have distinct pharmacologies and as such would produce different AE profiles and 2) 
would produce measurable CNS symptoms with single doses. The doses selected 
represent the maximum recommended clinical doses of each drug.     
 Blood concentrations (PK) were measured at various intervals spanning 72 hours 
post dose. As originally reported per protocol analysis (Pfizer Report, data on file), the 
PK  profiles of the 4 model CNS drugs are shown below in Figure 1.3. As seen these 
drugs have distinct PK properties, with Atomoxetine possessing rapid absorption and 
disposition kinetics, lorazepam rapid absorption and slower disposition kinetics, 
olanzapine and paroxetine showing slow absorption and disposition kinetics. The distinct 
PK properties of the model CNS drugs are reflected in the noncompartmental estimates 
shown in Table 1.1. Atomoxetine and lorazepam both showed the shortest Tmax (1.14 hr 
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and 1.71 hr respectively) while olanzapine and paroxetine concentrations peaked at later 
times (7.32 and 6.83 hr respectively). Olanzapine had the longest biological half life 
followed by lorazepam, paroxetine and atomoxetine.    
 The Preliminary Pharmacodynamic Differentiation Profiles (PPDP) of these four 
CNS drugs was created by administering a battery of various instruments after single 
dose administration. These including the VAS;  7 point ordered categorical scales, 4 point 
Likert scales measuring drug strength and likeness, the Digit  Symbol Substitution Test 
(DSST) measuring cognition, a test for extrapyramidal signs and symptoms, and a 
glucose and prolactin assay to measure any hyperglycemic and hyperprolacteneamic 
effects was also applied. The Modified VAS administered was a 9-item VAS measuring 
the following effects (sleepiness, dizziness, nausea, anxiety, forgetfulness, confusion, 
fatigue/weakness, stiffness, blurred vision). The ordered categorical scale as shown in 
Figure 1.2 was administered as a 7-point Likert questionnaire consisting of 69 statements, 
which assessed the subject’s intensity of drug effect experienced, ranging from none to 
extreme, after test drug administration using an ordered categorical scale. The 
questionnaire included a list of statements about various complaints, symptoms, or 
feelings the subjects have experienced.       
 Tables 1.2 and 1.3, shows the VAS effects measured and some of the 69 
categorical effects measured respectively, including p values for significant and highly 
significant differences obtained from an ANOVA analysis of the Time-Averaged Change 
from Baseline (TACB) endpoint when compared with placebo. Due to the number of test 
employed some effects may be significant by chance. No correction for Type I error such 
as a Bonferroni or Tukey’s correction was applied. Bonferroni which involves 
14 
 
determining the actual p-value using the product of the number of tests and the observed 
p-value would disqualify most effects as non-significant due to the large number of tests 
employed. However the procedure is very conservative and assumes independence of 
tests and since most tests employed were dependent (e.g. sleepiness and dizziness) a 
Tukey’s correction would be more appropriate, however this would require measurement 
of dependence between tests which is difficult to perform. Therefore only those effects 
with the lowest p-values (p<0.0001) were considered viable for any further 
pharmacometric analysis. Differential pharmacodynamic (PD) profiles shown in Figures 
1.4 and 1.5 shows the onset and offset of some of the more pronounced PD signals 
recorded on the VAS and ordered categorical scale respectively as well as their 
relationship to plasma concentrations. For example lorazepam shows fast onset of 
sleepiness and slow offset of effect consistent with its rapid absorption kinetics and 
slower disposition kinetics. 
Pharmacokinetic Models  
The time course of drug concentrations of the 4 compounds, lorazepam 2 mg, 
paroxetine 40 mg, atomoxetine 80 mg, and olanzapine 10 mg, were structurally modeled 
using either 1 or 2 compartments with first order absorption with or without a lag time of 
absorption.  For olanzapine and lorazepam, a 2-compartment model with and without a 
lag time for absorption respectively, adequately described the time course of drug 
concentrations while paroxetine and atomoxetine PKs were described with a 
1-compartment model with and without an absorption lag time respectively.  A summary 
of the final PK parameter estimates is provided in Appendix H.  The NONMEM control  
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are provided in Appendix B.. Residual variability was modeled by a combined 
additive/proportional model for olanzapine, atomoxetine, and paroxetine and with a 
proportional model for lorazepam. As a measure of the goodness of fit of the final 
models, different plots were generated (Appendix I) including observed concentrations 
(CONC) versus population predicted (PRED) and versus individual predicted (IPRED), 
weighted residuals (WRES) versus population predicted concentrations, individual 
weighted residuals (IWRES) versus individual predicted concentrations, and weighted 
residuals versus time. In general, for all 4 drugs studied, a good correlation between the 
predicted values and the measured drug concentrations was observed both at the 
population level and with the individual predicted concentrations however, some 
underestimation was seen in the atomoxetine and paroxetine plots at higher 
concentrations.  Generally, the weighted residuals were randomly scattered across the 
range of predicted concentrations with the exception of atomoxetine and paroxetine plots.  
For atomoxetine data, WRES were above the line of concordance at time = 0.5 and 1 hr 
(tmax = 1.14 hr from noncompartmental analysis). Similarly for paroxetine data, IWRES 
were above the line of concordance at time = 6 and 8 hr (tmax = 6.83 hr), supporting the 
finding that peak concentrations are slightly underestimated by the model.  Certain 
outliers are visible in the residual plots.  On the WRES versus PRED and Time plots, for 
olanzapine PK data, Subjects 14 and 20 showed abnormally higher positive residuals at a 
time of 1 hour.  For atomoxetine, Subject 20 was an outlier in the IWRES versus IPRED 
and Time plots with a large negative residual at time = 0.5 hour.  For lorazepam, Subject 
5 showed an extremely lower residual on the WRES versus PRED and TIME plots at 
time = 0.5 hour.  Subject 20 showed a larger negative residual on the IWRES versus 
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IPRED plot and Subjects 1 and 5 showed large negative residuals on the IWRES versus 
TIME plots at time = 72 and 0.5 hour, respectively. 
Although not the primary purpose of the PK analysis, further analysis of the effect 
of covariates on interindividual random effects (unexplained variability) and hence model 
goodness of fit was performed.  Despite the few subjects that were studied, certain 
covariates were observed to be significant and included in the final PK models.  In the 
final olanzapine model, the effect of gender on volume of distribution was significant and 
hence kept in the final model.  For lorazepam, CLcr on clearance and weight on volume 
of distribution were significant and for atomoxetine, a significant effect of gender on 
volume of distribution was observed.  No covariate effects were observed with the 




Study Rationale  
Upon inspection of the pharmacodynamic profiles in Figures 1.4 and 1.5 and their 
relationship to the pharmacokinetic signature profiles in Figure 1.3, the following 
questions were of interest: 
1. Is it feasible to model these PD measures using a mixed effects population 
approach? 
2. If so, which PD measures would be appropriate for modeling? 
3. Can clinically relevant PD parameters be identified and related to a tangible 
known quantity, e.g. using label incidence rates as a benchmark. 
The categorical and VAS PD measures of lorazepam sleepiness and dizziness were 
chosen to initiate an exploratory pharmacometric analysis. These effects were of 
interest because they: 1) showed relatively high signal amplitude on both scales as 
indicated by maximum  mean differences from placebo (VASsleep=30.2 mm, 
VASdizz=9.1 mm and CategoricalSleep=1.6, CategoricalDizz= 1.2) showed high 
statistical significance in ANOVA analyses of TACB, 3) their reported label 
incidence rates are different and based on data from healthy volunteers, i.e., 
Sleepiness (15.7%) has a higher incidence than dizziness (6.9%), 4) there are no  PD 
data published contrasting these effects of lorazepam. In addition, their pharmacology 
is thought to be conferred by benzodiazepine receptor activity in distinctly different 
areas of the brain (Volkow et al) and this may further differentiate these two 
symptoms.          
 Mean olanzapine (difference from placebo) sleepiness signal was also high on 
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both scales (Maximum VAS=35.1 mm, Maximum Categorical Score=2.1) however 
was exluded from the analysis since label incidence data was based on schizophrenic 
patients and not healthy volunteers as in the current study. Atomoxetine and 
paroxetine were not included in the analysis as they showed no strong signals on both 
the VAS and categorical scale (with Atomextine nausea showing the largest signal yet 
recorded very modestly on both scales, Maximum Mean VAS Score=15.3 mm, 
Maximum Average Categorical Score=1.57). 
Study Objectives 
The objectives of the pharmacometric analyses described in the following chapters 
are to: 
1) Determine the feasibility of modeling the categorical and VAS endpoints of 
Lorazepam Sleepiness and Dizziness using a population mixed effect approach, 
thereby assessing the pharmacometric utility of these measures using the current 
study design. 
2) Assess the performance of proposed population models using simulation and 
posterior predictive checking. 
3) Relate data-derived (e.g. Maximum Score) and model-derived (e.g. slope, EC50) 
pharmacodynamic parameters to the label incidence of lorazepam sleepiness and 








Table 1.1 Summary of noncompartmental pharmacokinetic parameter values (%CV) following 
administration of  single dose of atomoxetine 80 mg, paroxetine 20 mg, olanzapine 10 mg and 
lorazepam 2 mg  after single oral dose administration in twenty healthy volunteers (data on 












Tmax (hr) 7.32 (35.8) 1.14 (67.9) 6.83 (17.0) 1.71 (40.8) 
Cmax (ng/mL) 16.4 (31.5) 624 (31.1) 21.5 (38.6) 26.8 (22.9) 
AUC(0-tlqc), ng·hr/mL 502 (28.8) 3233 (42.4) 484 (50.2) 517 (29.3) 
AUC(0-∞), ng·hr/mL 668 (28.0) 3343 (41.7) 514 (51.9) 551 (31.0) 


























Table 1.2. Summary of statistically significant results of the ANOVA analysis on TACB 
(Time Average 0-12 hr Change from Baseline) endpoint of pairwise comparisons with 
placebo. The VAS was applied as a 9 item instrument. Blank cells indicate the absence of 
a statistically significant result (alpha = 0.05). (data on file, Pfizer report).. 
 
 
Olanzapine Atomoxetine Paroxetine Lorazepam
10 mg 80 mg 20 mg 2 mg
VAS - Sleepy p<0.001 p<0.001
VAS - Dizzy p<0.001
VAS - Nauseous p=0.047
VAS - Anxious p=0.009
VAS - Forgetful p=0.067
VAS - Confused p<0.001
VAS - Fatigued/Weak p=0.014 p=0.004
VAS - Stiff p=0.003
































Table 1.3. Summary of statistically significant results of the ANOVA analysis on TACB 
(Time Average 0-12 hr Change from Baseline) endpoint of pairwise comparisons with 
placebo.The 7 point Ordered Categorical Scale was applied as a questionnaire measuring 
69 items measuring various effects,  subject complaints and feelings of which 30 items 
are shown below. Blank cells indicate the absence of a statistically significant result 
(alpha = 0.05). (data on file, Pfizer report).. 
 
 
Question Olanzapine Atomoxetine Paroxetine Lorazepam
10 mg 80 mg 20 mg 2 mg
Q1 - Arousing or Stimulating
Q2 - Depressing or Sedating p=0.035 p<0.001
Q3 - Headache
Q4 - Confused or Disoriented p=0.006 p<0.001
Q5 - Sleepy p<0.001 p=0.053 p<0.001
Q6 - Blurred Vision p<0.001
Q7 - Dry Mouth p<0.001 p=0.012
Q8 - Drooling
Q9 - Difficulty Swallowing p=0.045
Q10 - Sweating p=0.005
Q11 - Limp or Loose p<0.001
Q12 - Rapid Heart Rate p=0.037
Q13 - Problem Walking p=0.039 p<0.001
Q14 - Poor Balance p=0.029 p<0.001
Q15 - Lightheaded or Dizzy p=0.013 p<0.001
Q16 - Queasy or Sick to Stomach p=0.006 p=0.001
Q17 - Vomiting or Throwing Up p=0.041
Q18 - Stomach Pain
Q19 - Lost Appetite p=0.05 p=0.035
Q20 - Diarrhea p<0.001
Q21 - Fatigued or Weak p=0.013 p=0.001
Q22 - Unsteady p=0.013 p<0.001
Q23 - Hot or Flushed p=0.001
Q24 - Difficulty Urinating
Q25 - Difficulty Concentrating p=0.007 p=0.006
Q26 - Slurred Speech p=0.050 p=0.005
Q27 - Mentally Slowed Down p=0.011 p<0.001
Q28 - Muscle Stiffness
Q29 - Body or Limb Shaking p=0.031










Figure 1.1. An illustration of continuous Visual Analog Scales (VAS). Subjects make a 
visual analogy of the dimension being measured by placing a slash on the 10 cm line 
anchored by words descriptive of the dimension being measured. The score is recorded as 




















Figure 1.2. An illustration of 7- point ordered categorical scales. These scale measure the 
pharmacodynamic dimension of interest using non-overlapping categories with a 













































































































Olanzapine 10 mg 
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Figure 1.3. The mean plasma concentration vs. time plots of the four study CNS drugs 
(Lorazepam 2 mg, Olanzapine 10 mg, Paroxetine 20 mg, and Atomextine 80 mg) after 





























































































































Figure 1.4.  Mean VAS effect vs. time pharmacodynamic profiles of sleepiness, 
dizziness, nausea, and blurred vision measured in 20 healthy volunteers after 
administration of single oral dose of Lorazepam 2 mg, Olanzapine 10 mg, Paroxetine 20 



















































































































Figure 1.5.   Mean ordered categorical effect vs. time pharmacodynamic profiles of 
sleepiness, dizziness, nausea, and blurred vision measured in 20 healthy volunteers after 
administration of single oral dose of Lorazepam 2 mg, Olanzapine 10 mg, Paroxetine 20 
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CHAPTER 2  
UTILITY OF AN ORDERED CATEGORICAL PHARMACODYNAMIC SCALE 
TO EVALUATE LORAZEPAM SLEEPINESS AND DIZZINESS 
 
Abstract 
Pharmacokinetic/pharmacodynamic (PK/PD) modeling of ordered categorical scales may 
provide insight into drug response by utilizing relatively small samples of subjects. Two 
lorazepam adverse events (AEs), sleepiness and dizziness, were modeled to identify 
differences in PD parameters and differences compared to relative incidence rates in the 
drug label (15.7% and 6.9%, respectively). Healthy volunteers (n=20) received single 
oral doses of 2 mg lorazepam or placebo in a randomized, double-blind, cross-over 
fashion. A 7 point categorical scale measuring the intensity of AEs was serially 
administered over 24 hr.  PK samples were obtained over 72 hr.  The Maximum Score 
(MaxS), and Area Under the Effect Curve (AUEC) were determined by 
noncompartmental methods and compared using a paired t-test.  Individual scores were 
modeled using a logistic function. AUEC and MaxS for sleepiness were significantly 
higher than dizziness (20.35 vs. 9.76, p<0.01) and (2.35 vs.1.45, P<0.01). Model slope 
estimates were similar for sleepiness and dizziness (0.21 vs. 0.19 logits*ml/ng), but 
baseline logits were significantly higher for sleepiness (-2.81 vs. -4.34 logits). Therefore, 
the higher intensity of sleepiness may be directly related to baseline (no drug present) 





Ordered categorical scales have been used in a variety of clinical settings to measure 
subjective effects and feelings which are clinically relevant but yet difficult to measure 
using objective tests. A good example is pain where several analgesic trials used various 
categorical scales (Jensen et al, 1986; Lundeberg et al, 2001). Such scales have been 
reported to display high validity and reproducibility (Lundeberg et al, 2001; Svensson  
2000) during repeated assessments and are usually quick and easy to administer (Jensen et 
al, 1986; Merbitz et al, 1989). 
Pharmacokinetic-pharmacodynamic modeling of ordered categorical scales may 
provide insight into the PD of drug action utilizing relatively small samples of subjects. 
The feasibility of using different subjective scales as biomarkers of PD response was 
investigated in a small clinical pharmacology study with four model Central Nervous 
System (CNS) drugs (Moton et al, 2005). The rationale was that these responses may be 
used to compare potency and tolerability of new drugs relative to marketed drugs and 
thus be used as biomarkers of adverse event rates in the development of new CNS agents.  
In that study, seven-point ordered categorical scales measuring different types of 
subjective response (e.g. sleepiness, dizziness, etc) were administered serially after single 
dose administration to measure intensity of drug effects over 24 hours. Inspection of the 
effect-time profiles of the more common drug effects showed differential profiles for the 




The current analysis focuses on the categorical measures of two adverse effects 
(AEs) of one of the representative CNS drugs studied (Moton et al, 2005), namely 
lorazepam sleepiness and dizziness, with an aim to identify differences in relevant 
pharmacodynamic parameters using a PK/PD modeling approach. To date, no 
pharmacodynamic data, whether being categorical or continuous, have been published 
contrasting lorazepam induced sleepiness and dizziness in the context of population 
modeling. Their incidence rates in the drug label offer a unique benchmark for 
comparison. Thus, any differences found in PD measures between sleepiness and 
dizziness in the current analysis will be compared to differences in incidence rates in the 
drug label (Ativan Drug Insert). This pharmacometric approach is novel and may have 
significant utility in early clinical development particularly in constructing 
pharmacodynamic and adverse event differentiation profiles (Moton et al, 2005) for drug 
candidates under devolopment and marketed comparators. 
 Moreover, from the spectrum of CNS effects measured in the larger study (Moton et 
al, 2005), lorazepam sleepiness and dizziness were selected as the endpoints of interest 
because: 1) these effects showed a relatively high scale signal amplitude and highest 
statistical significance in the time- averaged- change- from -baseline differences with 
placebo , 2) sleepiness is a more common AE of lorazepam than dizziness according to 
incidence rates in the label, and 3) their pharmacology is thought to be conferred by 
benzodiazepine receptor activity in distinctly different areas of the brain (Volkow et al, 
1995; Schreckenberger et al, 2004) - sleepiness from GABA inhibition of the thalamus 
and sensory cortex and dizziness from the cerebellum. 
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 It must be noted that modeling categorical data can not be performed using 
conventional nonlinear regression because it has a polynomial distribution which violates 
the assumption of homogeneity of variance (Hastie et al, 1989). In shifting from one 
effect category to another, the direction of change is known but not the magnitude, and 
the categories cannot be assumed to be equidistant (Merbitz et al, 1989). However, if the 
probabilities of reporting the effect categories as a function of time are modeled, a special 
type of regression known as logistic regression can be used. The current study employs a 
logistic function (Sheiner,  2004; Mandema and Stanski, 1996)  to model sleepiness and 
dizziness categorical scores and assesses model performance using previously published 




Twenty healthy volunteers were randomized in a double blind, single dose, 5-way 
crossover design (Moton et al, 2005). All subjects gave written informed consent to 
participate in the study. The study was conducted at the Clinical Pharmacology Unit of 
Pfizer (Ann Arbor, MI) in accordance with the principles of the Declaration of Helsinki. 
The study protocol was approved and performed in compliance with the Institutional 
Review Board/Independent Ethics Committee (IRB/IEC) and International Committee on 
Harmonization (ICH) Good Clinical Practice guidelines. Each subject received an oral 
dose of either lorazepam 2 mg, as one of four CNS drugs, or placebo. All study drugs 
were commonly used marketed compounds within their respective therapeutic indications 
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and were selected to produce different AE profiles which could potentially be measurable 
after single dose administration. Each regimen was separated by a one week washout 
period for a total trial period of five consecutive weeks. Blood samples were drawn 
before dosing and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hr after the morning dose.  
Prior to each blood collection during the first 24 hr, a 69 item questionnaire was 
administered. Items on the questionnaire covered various complaints, symptoms, or 
feelings the subject experienced. For each statement the subject was to answer how 
strongly he or she felt the complaint, symptom, or feeling on a seven-point ordered 
categorical scale. The seven effect categories were 0=none, 1=minimum, 2=mild, 
3=moderate, 4=significant, 5=severe, 6=extreme.  
Analytical Assay 
Plasma levels of lorazepam were determined using liquid chromatography tandem 
mass spectrometry (LC/MS/MS). Briefly, 0.1 mL of human plasma containing sodium 
heparin was extracted by a liquid-liquid extraction using methyl t-butyl ether. The 
organic extract was dried and reconstituted in 0.2 mL of formic acid/methanol/5 mM 
ammonium formate (0.1:50:50, v/v/v), and an aliquot was injected into the LC/MS/MS 
system. The compounds were separated by reverse phase on a C18 column (2.0 mm x 50 
mm, 5 µm) by gradient elution using a binary mobile phase consisting of formic 
acid/methanol/water (0.1:10:90, v/v/v) and 0.1% formic acid in methanol (v/v). The 
analytes were ionized in the mass spectrometer in a Turbo IonSpray source with positive 
ion atmospheric pressure electrospray ionization and detected with multiple-reaction 
monitoring modes. The nominal ion transitions monitored were m/z = 321 > 275 for 
lorazepam and m/z 327 > 281 for the internal standard (lorazepam-d4). These transition 
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ions were selected based on predominant fragmentation pathways of lorazepam and 
internal standard and their intensity, as observed in their product ion mass spectra. The 
lorazepam standard was linear over the range of 0.5 to 50 ng/mL when 0.1 mL plasma 
was used for the analysis (r2 > 0.998). The intra- and inter-assay variations were less than 
15% for the spiked standard curve and quality control samples. The variations for the 
long-term study quality control samples were <12%.  
 Data Analyses 
Pharmacokinetics 
A non-compartmental analysis (Benet et al, 1979) was performed using 
WINNONLIN on lorazepam plasma concentration-time profiles to determine maximal 
concentration (Cmax), time to maximal concentration (tmax), Area Under the Curve from 
time zero to infinity (AUC0-∞) and the terminal half-life (t1/2). Compartmental population 
analyses were conducted in NONMEM (Beal and Sheiner, 1992)  using the first order 
conditional estimation method with interaction.  The general model building strategy is 
based on modification of different approaches discussed by Beal and Sheiner (1992), 
Mandema et al, (1992) and Ette and Ludden (1995). During model building, the goodness 
of fit of different models to the data was evaluated using the following criteria: change in 
the minimum objective function (MOF), visual inspection of concordance and residual 
plots, precision of the parameter estimates, and decreases in both inter-individual and 
residual variability. A decrease in the MOF of at least 3.8 upon addition of a parameter 
was considered statistically significant. This corresponds to a nominal p value of <0.05 
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and one degree of freedom in the chi square distribution of the difference of MOF 
between hierarchical models. 
 The initial PK model was a one-compartment model defined in terms of the 
following structural parameters: oral clearance (CL/F), volume of distribution (V1/F), 
and first-order rate of absorption (ka). Other models tested include a term for lag time in 
absorption (tlag) and/or 2-compartments. Inter-subject variability on mean PK parameters 
was modeled using an exponential error term and was estimated sequentially on structural 
parameters such as oral clearance (CL/F), volume of distribution in the central and 
peripheral compartments (V1/F, V2/F), and on the first order absorption rate constant 
(ka). Various models of residual variability were tested including additive, proportional 
and combined additive/proportional error models. During model building, the off-
diagonal elements of the variance-covariance matrix were fixed to 0, i.e., it was assumed 
that there was no correlation between PK parameters.  In the final step, the correlation 
between all parameters was estimated in NONMEM.   
To explain interindividual variability in PK parameter estimates, possible covariates 
were tested serially by including each covariate one at a time in NONMEM and checking 
for statistical significance. Covariates tested included the effects of age, gender, weight, 
and creatinine clearance on CL/F and the effects of age, gender and weight on V1/F. 
Covariates were centered using the mean and modeled initially using a simple linear 
relationship. All covariates found to be statistically significant were included sequentially 
in NONMEM based on their rank order of significance and starting with the covariate 
that resulted in the largest decrease in MOF.   
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Parameter estimates of CL/F and t1/2 were compared to the non-compartmental results 
to ensure that model was adequate.  Confidence intervals around parameter estimates 
were generated using nonparametric bootstrap procedure (n=500 runs) as described by 
Ette et al (2003). 
 Pharmacodynamics 
In order to produce a typical value versus time curve for sleepiness and dizziness 
categorical scores, the expected value at each time point was calculated. The expected 
value or average score of the categorical measure of sleepiness and dizziness at time t can 
be defined by the following equation:           
       Equation 1  
where  X is the discrete random variable denoting the categorical measure of 
sleepiness or dizziness, tx  is the categorical sleepiness or dizziness score at time t with a 
set of possible categorical values m ranging from 0-6 and P(x) is the probability (obtained 
as a frequency) of reporting a categorical score x at time t. This equation is equivalent to 
taking the sum of all categorical scores at each time t and dividing by n (the total number 
of scores). The former definition is preferred due to the categorical nature of the data 
(Merbitz et al, 1989). 
To examine whether or not there were differences in sleepiness and dizziness 
intensities, a noncompartmental analysis of the time course of  average sleepiness and 
dizziness  scores was conducted. Effect intensity endpoints determined were  maximum 
score (MaxS) and area under the effect curve (AUEC) over the entire dosing interval (24 
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hr). A paired t-test was used to determine whether differences in MaxS and AUEC 
between sleepiness and dizziness were statistically signficant. 
Population modeling of the time course of sleepiness and dizziness scores was 
implemented in NONMEM using a logistic function (Sheiner, 1994; Mandema and 
Stanski, 1996) with the second order Laplacian method of estimation (Beal and Sheiner, 
1992). Since the intensity of pharmacodynamic effect was self-rated on the 7-point 
categorical scale (0-6), the logistic function was used to model the probability (P) of 
observing scores P≥m (m = 0 to 6) as a function of baseline effect, drug concentrations, 








)}({     Equation 2 
where )}({ ηmYPg t ≥  is the function describing the probability of being greater than or 
equal to a particular effect category, m; ∑ mβ  is the sum of  baseline parameters (β1, β2, 
β3,… βm) describing the baseline probability of experiencing a particular effect category; 
‘drug’ and ‘placebo’ are model components describing drug and placebo effects; and η  is 
a subject specific random effect parameter quantifying inter-individual variability in 
response assumed to be normally distributed with a mean of 0 and variance ω2. The logit 
transform function was used to convert the function )}({ ηmYPg t ≥  , which is in logits, 
into a probability. 
           Equation 3 
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Initial inspection of sleepiness data showed the highest reported effect category as 5 
(severe). As such, the probabilities modeled over time were (P≥1, P≥2, P≥3, P≥4, P≥5). 
By definition, P≥0 =1, and this is not modeled. For the dizziness data, the highest 
reported category was three, and the probabilities modeled over time were (P≥1, P≥2, 
P≥3). Model building was conducted by adding the model components in Equation 2 
sequentially and observing the change in the MOF.   
 First, baseline probabilities for each effect category were modeled as constants as 
described by Sheiner (1994). From Equation 2, β1 is the Y intercept (in logits) describing 
the baseline for reporting an effect category of at least minimum intensity (1 or more), β2 
is the intercept added to β1 to determine the baseline logit contribution for reporting an 
effect category of at least mild (2 or more), and so forth. The drug component was added 
by beginning with a simple linear slope function as described below: 
E = S*C         Equation 4 
where E is the drug effect, S is the slope describing the relationship between drug effect 
in the logistic domain and drug concentrations C. Originally C was tested as 
concentration in the central compartment determined by posthoc individual PK parameter 
estimates.  Addition of an effect compartment (Sheiner et al, 1979), where C in Equation 
4 now represents concentration in the effect compartment, was tested to account for any 
delay in effect with respect to peak plasma concentrations.   This required addition of an 
extra parameter ke0, the first order rate constant describing lag in effect in the biophase 
(Sheiner et al, 1979) compared to central compartment concentrations. A hill function 
without and with a sigmoidicity constant were also tested. Change in the MOF and 
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inspection of the correlation matrix of estimates to ensure model stability was used to 
select final models.  
For the placebo component of Equation 2, several models were tested including a 
constant modeled as a parameter in logits and a Bateman-like function. Incorporation of 
the placebo component in this manner resulted in the covariance step being aborted. 
However, inspection of the individual placebo profiles revealed some subjects as non- 
responders and others as mild to moderate responders with a Bateman-like response. As 
such a mixture model (Frame et al, 2003) on placebo response was tested. A mixture 
model assumes the population is composed of two or more subpopulations, each having a 
distinct population mean and random effects. Therefore, if the subject belonged to 
subpopulation 1 of non-responders, the placebo response was set to zero. If the subject 
belonged to subpopulation 2, the placebo response was modeled using a Bateman- like 
function with a theta parameter in logits describing the amplitude of placebo effect, and 
first order rate constants describing the onset and offset of placebo effect. 
 Assessment of PK/PD Model Performance       
 Nonparametric bootstrapping (Ette et al, 2003) and simulation based on bootstrap 
estimates were performed using SPLUS VI software (Insightful Corporation, Seattle, 
Washington).  Five-hundred bootstrap runs were conducted to determine confidence 
intervals of parameter estimates. This analysis was repeated using successful bootstrap 
runs only. Simulations were then performed using each set of bootstrap estimates to 
generate five hundred sets of data as described by Ette et al (2003). Using this simulated 
data, cumulative probability plots of reporting at least an effect  intensity m ( P≥m ) as a 
function of time were constructed to show the performance of the model across effect 
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categories. Ninety percent prediction intervals (Mandema et al, 2005) of the time course 
of categorical scores were also constructed to visually depict the degree of uncertainty in 
the models due to random effects and parameter estimate uncertainty. In addition, 
posterior distributions of relevant PD endpoints were constructed and overlaid on the 
observed mean values as described by Yano et al (2001). The PD endpoints selected were 
those determined in the PD noncompartmental analysis -MaxS and AUEC. 
Comparison of PD Parameters and Label Incidence 
 The relative ratio of label incidence of lorazepam sleepiness and dizziness was 
compared to the relative ratio of various data-derived PD parameters including MaxS, 
AUEC, and the maximum probability of reporting at least a particular effect category m 
(P≥1, P≥2, P≥3 ). The relative ratio of model-derived PD parameters such as slope was 
also related to the ratio of label incidence of sleepiness and dizziness. 
Results 
Pharmacokinetics 
Table I shows the demographic information of the twenty study subjects. The 
time course of observed mean ± SD, mean predicted, and individual plasma 
concentrations after single oral dose administration of lorazepam 2 mg are shown in 
Figure 2.1. A noncompartmental analysis yielded mean (CV%) estimates for Cmax of 
26.8 ng/ml (22.9), tmax of 1.7 hr (40.8), t1/2  of 16.8 hrs (21.3) and a total systemic 
exposure or AUC0-∞ of 551 ng*hr/ml (31.0). Significant decreases in the MOF, residual 
and inter-individual variability, and inspection of concordance and residual plots 
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indicated that a two-compartment model with first order absorption adequately described 
the time course of plasma concentrations of 2 mg oral lorazepam. 
Table 2.2 shows the final pharmacokinetic population parameter estimates. 
Significant covariates were determined to be creatinine clearance on CL/F and weight on 
V1/F.  The population mean parameter estimates were in good agreement with 
parameters derived using non-compartmental analysis for both CL/F (3.63 vs.4.02 L/hr) 
and the derived half-life (16.7 vs. 16.8 hrs).  Results of the non-parametric bootstrap 
analysis are included in Table 2.2.  The model was robust with 87% of the runs 
minimizing successfully. The parameter estimates and confidence intervals obtained from 
the bootstrap procedure which included all runs (even those which failed) were generally 
comparable to the estimates derived from NONMEM. Similar bootstrap estimates and 
confidence intervals were obtained using only successful runs. 
Pharmacodynamics 
Noncompartmental analyses conducted on the effect-time profiles of sleepiness 
and dizziness scores showed significant differences between these AEs in the maximum 
score (MaxS) and area under  the effect curve (AUEC) endpoints. The MaxS of 
lorazepam sleepiness (±SE) was significantly higher then dizziness (2.35 ± 0.26 vs. 1.45 
± 0.22, p<0.01), as was the AUEC (20.35 ± 3.58 vs. 9.76 ± 2.45, p<0.01).  The time to 
reach MaxS for lorazepam sleepiness scores was delayed (3.98 hr, Figure 2.3) compared 
to time of maximal lorazepam concentrations (1.71 hr, Figure 2.1). This observation 
justified addition of the effect compartment (Sheiner et al, 1979) to describe drug effect in 
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the lorazepam sleepiness model. In contrast, the dizziness effect peaked (2.55 hr, Figure 
2.3) at time similar to that observed for peak plasma drug concentrations. 
Population PD model-building was initialized by addition of baseline logit 
intercepts for each effect category. As indicated in Equation 2, these are added 
sequentially from i=1 to m in order to quantify the probability of experiencing a score 
category m or more in the absence of drug or placebo. Table III shows the final PD model 
estimates. As shown, β1 (which represents the probability in logits of reporting a score of 
1 or more at baseline) was significantly higher for sleepiness (-2.81) than dizziness (-
4.34) as indicated by the 95% confidence intervals, whereas the baseline intercept 
parameters β2 and β3 were not significantly different across these AEs β4 and β5 were 
included in the sleepiness model as they resulted in significant decreases in the MOF. 
Addition of the drug component of the model as a slope as described in Equation 4  
resulted in a decrease in point reduction in the MOF of 216 and 174 for sleepiness and 
dizziness models, respectively, indicating a significant drug effect. As shown in Table III, 
slope estimates of sleepiness (0.21 logits/ml*ng) and dizziness (0.19) were not 
significantly different on inspection of the 95% confidence intervals. Addition of an 
effect compartment as described in Equation 5 was significant for sleepiness (MOF 
reduction was 3.9) but not dizziness, and the final estimate of ke0, the first order rate 
constant describing lag in effect in the biophase compared to central compartment 
concentrations, was 2.44 hr-1. 
Placebo effect was modeled as a mixture of non-responders and responders in the 
final model, where the responder component was described using a Bateman-like 
function. Modeling the placebo effect as a mixture, remedied the initial problem 
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encountered with abortion of the covariance step and resulted in stabilization of the final 
model as indicated by the correlation matrix of estimates being devoid of high 
correlations (>0.8) among parameters. PLAC describes the amplitude of response and, as 
indicated in Table III, was similar for sleepiness (3.6 logits) and dizziness (4.3 logits) as 
was k1, the first order rate constant describing onset of placebo effect. When k2, the first 
order rate constant describing offset of placebo effect, was modeled for sleepiness 
placebo, it resulted in over-parameterization as determined by inspection of the 
correlation matrix of estimates. However, given that the individual responder profiles 
showed a Bateman pattern of effect and not exponential decay, k2 was modeled as a 
fraction of k1 and the constant used to determine this fraction was determined using a 
sensitivity analysis. The majority of subjects were non-responders to placebo effect as 
indicated by P(1), the subpopulation proportion that was non-responder to placebo, and 
this estimate was similar between sleepiness (63%) and dizziness (71%).  The inter-
individual random effects parameter Ω1 was significantly higher for sleepiness effect 
(3.31 logits) compared to dizziness (0.32 logits).  
As shown in Table 2.3, mean population parameter estimates obtained from the 
bootstrap procedure were generally comparable to the estimates from the final model 
with the exception of the estimate of β5 of the sleepiness model. The bootstrap CI of this 
parameter showed a smaller lower bound (-21.3 logits) compared to the NONMEM lower 
bound.  The success rate of bootstrap runs was 80% for the lorazepam sleepiness model 
and 83% for the dizziness model.  
 Figure 2.2 shows the observed and simulated cumulative probabilities of reporting 
a sleepiness and dizziness effect greater then or equal to a particular effect category over 
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time (P>=m). The simulations describe the data adequately. As shown, the cumulative 
probabilities decrease with increasing effect category (m). Moreover, peak probabilities 
of reporting at least an effect category m at time of maximal effect are higher for 
lorazepam sleepiness (P≥1=1, P≥2=0.45, P≥3=0.25, P≥4=0.1, P≥5=0.05) then for 
lorazepam dizziness (P≥1=0.7, P≥2=0.3, P≥3=0.15) as shown in Figure 2. 
 Figure 2.3, shows the observed (points) and overlaid mean simulated scores 
(lines) and 90% shaded prediction intervals (PIs) obtained from five hundred sets of 
bootstrap parameter estimates. The mean simulations adequately describe the time course 
of sleepiness and dizziness scores with the prediction intervals (shaded region) capturing 
the data and mean simulations. The one exception, however, is a data point of placebo 
sleepiness (at 6 hr) which is not captured by the model and lies slightly outside of the 
shaded interval. The shaded PI for lorazepam sleepiness is wider than that of lorazepam 
dizziness indicating the greater model uncertainty of sleepiness. 
Figure 2.4 shows histograms of the simulated distribution of MaxS and AUEC 
obtained from 500 sets of bootstrap parameter estimates, overlaid on the observed mean 
of these PD endpoints (represented by the vertical black bar). The panels indicate that 
that proposed models simulate posterior distributions of these parameters which are 
centered close to the observed means. 
Finally, Table 2.4 relates the various data-derived PD parameters, and the model-
derived PD parameter, slope, to the incidence rates of the adverse events in the more 
general patient populations, as reported in the drug label. The ratio of the 
sleepiness/dizziness endpoints was calculated across these parameters. As shown by the 
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relative ratios, Max(P≥2), Max(P≥3) and  AUEC, show the greatest concordance to label 
incidence, followed by MaxS and  Max(P≥1). However, the ratio of sleepiness to 
dizziness slope parameters was very close to 1 indicating that drug effect may not explain 
the differences between sleepiness and dizziness across these PD parameters. 
Discusssion 
The current PK/PD analyses of an ordered categorical scale utilized as a 
biomarker of drug effect was used to gain insight into pharmacodynamics using a 
relatively small sample of subjects. Using the representative CNS agent lorazepam, this 
was illustrated by comparing the time course, self-rated on the scale by twenty healthy 
volunteers, of two of the most common AEs of the anxiolytic, sleepiness and dizziness. 
The 2 mg dose of drug selected in this study represents the daily recommended dose of 
lorazepam for maintenance treatment of generalized anxiety disorder.  
PK estimates obtained from the noncompartmental and compartmental analysis of 
the concentration-time profiles are consistent with previous reports (Greenblatt DJ, 1981) 
and showed that lorazepam is rapidly absorbed (Ka=1.04 h-1), has peak plasma 
concentrations occurring at about 2 hours post dose and that it has relatively moderate 
steady state volume of distribution (90 L), low systemic clearance (4 L/h), and moderate 
terminal half-life (16.7 hr). 
The noncompartmental analysis of the effect-time profiles of sleepiness and 
dizziness scores indicated that the MaxS of sleepiness was significantly higher then 
dizziness (2.35 vs. 1.45, p<0.01) as was the AUEC (20.35 vs. 9.76, p<0.01). As shown in 
Table 2.4, The ratios of sleepiness/dizziness of these PD parameters are in concordance 
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to the ratio of label incidence,   with AUEC showing stronger concordance. It must be 
noted that while these parameters are related to label incidence, they reflect effect 
intensity rather then effect frequency.      
 Differences in reporting various effect intensities between these AEs are seen in 
the cumulative effect probability plots in Figure 2.2. Maximum probabilities of reporting 
at least a minimal effect (P≥1) at are higher for lorazepam sleepiness (P=1) then dizziness 
(P=0.7). Likewise, the peak cumulative effect probabilities of at least mild and moderate 
intensity are higher for lorazepam induced sleepiness (P≥2=0.45, P≥3=0.25) than for 
dizziness (P≥2=0.3, P≥3=0.15). Since these parameters may be determined by taking the 
cumulative frequency of categorical scores at a time t, they are data-derived PD 
parameters reflecting the probability of reporting a cumulative, categorical effect 
intensity in a conceptual population. As shown in Table IV, the sleepiness/dizziness ratio 
across these PD parameters are also in concordance to the ratio of label incidence with 
Max (P≥2) and Max (P≥3) showing the highest concordance followed by Max (P≥1).  
Since these represent the cumulative probabilities (which is a frequency) of reporting an 
effect of given intensity in a conceptual population, their relationship to label incidence is 
more direct than MaxS and AUEC.  
The lack of significant difference between the slope estimate of sleepiness (0.21) 
and dizziness (0.19) at the 95% confidence level suggests that lorazepam confers similar 
intensity of sleepiness and dizziness effects and that drug does not contribute to the 
observed differences in the PD of these effects. Nevertheless, the proposed population 
PK/PD model gives possible insight into the differences in PD endpoints between these 
AEs. To understand certain PD model estimates reported in logit units in Table 2.3, it 
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may be helpful to refer to Figure 2.5, which shows the relationship between the logistic 
domain (which is rather abstract) and the probability domain (which is more familiar). On 
inspection of the population CIs of PD parameter estimates in Table 2.3, the only 
parameter that is significantly different between these effects at 95% confidence level is 
β1, the baseline intercept parameter of effect category 1 (likelihood of having a response 
of at least minimum intensity). The difference between this estimate for sleepiness and 
dizziness effects is 1.5 logits. As shown in Figure 2.5, the majority of the probability 
domain (0.1 ≤y≤ 0.9) occurs in the logit range -3≤x≤3, and 0 logits corresponds to the 
inflection point at y=0.5. In this range, 1.5 logits corresponds to a probability of 0.82. 
Since 0 logits corresponds to P=0.5 the difference P=0.82-0.5=0.32 corresponds to the 
greater likelihood of reporting sleepiness then dizziness due to the baseline difference. 
From Figure 2.2, the difference in observed cumulative effect (P≥1) at tmax between 
sleepiness and dizziness is 1-0.7=0.3 equivalent to the value determined above. Since 
(P≥1) is the cumulative effect across all effect categories, differences in this endpoint 
between sleepiness and dizziness at tmax closely resembles differences in Max Score. It 
is unclear from a physiological standpoint why the difference in baseline effect exists 
between sleepiness and dizziness, but one possible explanation may be the time of day in 
which the data was collected. Given that the scale was first applied in the morning, some 
subjects may have experienced a residual sleepiness in the morning that was reported at 
baseline. 
Another explanation may be that subjects may have a greater tendency to report a 
sleepiness effect than dizziness even in the absence of any drug. However, no placebo 
response rates of these effects are reported in the lorazepam label to confirm this. Placebo 
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data in the current study as shown in Figure 2.3, show a slightly greater sleepiness 
response at earlier time points (at 0.5 hrs post dose administration), suggesting that 
differences in reporting sleepiness and dizziness in the absence of drug may be related to 
time of day. 
As mentioned, addition of an effect compartment was significant in the PD model 
of sleepiness (decrease in 3.9 of MOF). From Table 2.3, the ke0 estimate was 2.44 h-1 
and the half- life in the biophase is determined as ln(2) / 2.44 =0.28 h. Approximately 
five half lives in the biophase (1.5 hr) is equivalent to the slight delay in sleepiness effect 
with respect to peak plasma concentrations of lorazepam confirmed by results of the non-
compartmental PD analysis (2.2 hr). Slight delays in psychomotor and cognitive PD 
measures with respect to peak plasma concentrations after single dose administration of 
lorazepam 2mg have been reported previously (Ellinwood et al, 1985; Bin et al, 1999). 
On the other hand, dizziness showed no such significant delay in effect and the time to 
Max Score was close to the tmax of lorazepam concentrations. While this contrast is 
unclear, one plausible pharmacologic explanation may be the distinct anatomical location 
in the brain from which these CNS effects originate. It is known that lorazepam induced 
sleepiness is the result of binding to and inhibition of benzodiazepine receptors of GABA 
complexes in the thalamus and sensory cortex of the brain (Volkow et al, 1995; 
Schreckenberger et al, 2004). The receptor binding causes downstream inhibition of 
glucose metabolism (Volkow et al, 1995; Schreckenberger et al, 2004), which might 
account for the delayed sensation of sleepiness recorded by the scale. On the other hand, 
lorazepam induced dizziness is conferred by benzodiazepine action in receptors of the 
cerebellum (responsible for maintenance of balance) and these receptors may have a 
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different subunit composition (Lunddens et al, 1995), altering rates of downstream 
signaling. 
The performance of the final population models was assessed by a number of 
diagnostics including the simulations in Figure 2.2 which capture the observed 
cumulative probabilities, and the mean simulations in Figure 2.3 which adequately 
capture the time course of drug and placebo scores. As a further check, the invalidity of 
these models was refuted by results of the posterior predictive check (Yano et al, 2001) 
which showed that the simulated distributions of MaxS and AUEC were centered close to 
the observed mean. These PD parameters were selected based on them being clinically 
relevant, data-derived parameters which could be determined using the profile of an 
individual subject (Yano et al, 2001). The 90% PI in Figure 2.3 show the model 
uncertainty conferred by both random effects and uncertainty in estimating the parameter 
estimates. Typically, the 90% as opposed to 95% PI is assessed, because some confidence 
to detect a type I error is compromised to compensate for the increased uncertainty 
incurred by random effects. As shown in Figure 2.3, the PI of lorazepam sleepiness is 
wider then dizziness indicating greater model uncertainty. This may be the result of the 
greater random effects as shown in Table 2.3 (Ω is higher for sleepiness). Since 
overlaying PIs of these effects shows separation beyond 2 hours, one can make the 
conclusion that, given uncertainty in the model estimates and random effects, the models 
can detect a difference between the time course (at tmax and beyond) of these effects at 
the 90% confidence level. 
A particular feature of the logistic function that underscores its quantitative power 
is the ability to quantify a population incidence of a cumulative or specific effect category 
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at a particular time post dose administration using population model estimates, as 
illustrated in the following example. To determine the probability P>=3 of reporting a 
drug induced sleepiness of at least moderate effect intensity at Cmax in the biophase (26 
ng/ml), Equation 2  and final model estimates from Table 2.3 can be used to determine 
the total logits as (β1+β2+β3)+(Slope*Cmax)= (-2.81-2.57-1.79)+(0.21*26)= -1.71 
logits. Referring to Figure 2.5, or by using the logit transform (Equation 3), this logit 
corresponds to a probability of 0.15. Likewise the probability P≥3 of reporting lorazepam 
dizziness effect at tmax is 0.03.Therefore, the model predicts that at time of peak 
lorazepam effect, 15% of the population will experience a sleepiness effect of at least 
moderate intensity while 3% will experience a dizziness effect of at least moderate 
intensity.  
While sleepiness and dizziness are the most commonly reported AEs of 
lorazepam according to the drug label and endpoints obtained in the study (Moton et al, 
2005), the effects show minimal to moderate amplitude on the categorical scale as shown 
in Figure 3. This observation speaks to the power of the approach described, 
underscoring the sensitivity of the categorical scale in discerning small differences 
between relatively mild to moderate PD effects over time, and the ability to model such 
data from a relatively small sample of subjects using the logistic function. Currently, 
tolerability is described in drug labels as AE incidence rates, rates of dropouts associated 
with particular AEs, or label warnings.  The high variability in AE rates in labels due to 
the varying methods of collecting AEs,  varying populations, and varying doses used in 
clinical trials  make them inadequate for assessing relative tolerability between 
compounds unless the sample size is large and there is a within study comparison of  
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drugs. The 7 point categorical scale described in this study can therefore have important 
utility as a biomarker of AE rates in smaller pharmacology studies, and the logistic 
function can be used to model the time course of AEs to provide more insight into the PD 
of AEs.           
 A question that arises, however, is whether less frequent or less intense AEs could 
be quantified using the pharmacometric approach, trial design, and sample size described. 
Clinical trial simulation (Girrard, 2005) studies will therefore be needed to apply 
sensitivity analysis (Girrard, 2005) to the proposed model parameters, such as slope, to 
determine the minimum intensity signal that can be quantified using the current clinical 
trial design. It must also be pointed out that a slope model was used in this study rather 
then an Emax model since only one dose which represents the maximum daily 
recommended dose for maintenance treatment was studied, however an Emax model may 
be used in future clinical studies where dose escalation may be performed on a candidate 
drug until the maximum effect is reached. 
Another question that arises is which of the PD parameters shown in Table 2.4 is 
most adequate to relate to label incidence. As mentioned, AUEC and MaxS are data-
derived PD parameters which reflect effect intensity rather then effect frequency. 
Moreover, AUEC may not always relate directly to label incidence, since the AUEC of 
an effect which has a large intensity but short duration may be similar to that of an effect 
with low intensity and longer duration yet these effects may have different incidence 
rates. Therefore, AUEC may not be adequate to use when comparing the AE rates of 
drugs of vastly different PK profiles. In such situations AUEC normalized to time may be 
better related to incidence. Max (P≥1), Max (P≥2) and Max (P≥3) are also data-derived 
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PD parameters which reflect frequency of reporting a cumulative categorical effect 
intensity in a conceptual population. The stronger concordance of Max (P≥2) and Max 
(P≥3) to label incidence seems to suggest that the frequency of reporting categorical 
effects of higher intensity may be better related to population incidence. The Slope 
parameter, which is model-derived, is very important since it shows whether the 
difference in incidence is drug related or not. If the differences in incidence were entirely 
drug related, in this scenario, a 2 fold greater slope of sleepiness would be expected to 
that of dizziness. More studies using this scale with different AE endpoints, and 
implementing the pharmacometric approach described in this paper will ultimately 
confirm and clarify the PD parameter in Table 2.4 showing the strongest concordance to 
label incidence consistently across studies. 
Lastly, in emphasizing other potential utilities of this ordered categorical scale in 
early clinical development, the approach described in this paper may not be limited to 
comparing effects of the same drug as done in the current study, but can be applied to 
other scenarios as well. If the comparison was conducted between the dizziness AE of an 
anxiolytic under development and lorazepam for example, the relative ratio PD 
parameters in Table 2.4, e.g. Max (P≥3), and the lorazepam label incidence of dizziness 
may be used to extrapolate an estimate of dizziness incidence for the candidate under 
development. This would assist in developing a PD differentiation profile of the 
candidate which would show advantages and disadvantages of the candidate compared to 
marketed comparators early on in development. The scale may not only have utility as 
biomarker of AEs but of Pharmacodynamic effect in general. For example, in another 
scenario, if the comparison was conducted on sleepiness scores between two different 
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hypnotic drug candidates under development, prediction intervals as those shown in 
Figure 2.3 may be used to determine at which level of confidence a difference in 
sleepiness effect (which is now therapeutic rather then AE) between these drugs is seen 
given the uncertainty in model estimates and random effects. Such an analysis would, 
again, show a competitive adavantage/disadvantage of a particular candidate and assist in 
go/no go decision making during early drug development. Other scenarios include PD 
comparisons of different formulations of the same compound, or between different study 
populations (e.g. geriatric vs. non-geriatric), or in assessing PD drug-drug interactions.  
In conclusion, this study has shown that use of an ordered categorical scale as a 
measurement of drug effect, coupled to PK/PD modeling, may be applied successfully in 
a small study setting to gain valuable insight into the pharmacodynamics of drug action. 
This was illustrated by characterizing the exposure-response relationship of two common 
effects (sleepiness and dizziness) of the representative CNS agent lorazepam, and 
showing that differences in the PD endpoints described may be due to differences in 
baseline parameters. Differences between data-derived PD measures of sleepiness and 
dizziness were consistent with differences in incidence rates reported in the label, 









Table 2.1. Subject Demographics (n=20). 
Parameter Mean (SD) 
Gender, n
   Male 5
   Female 15
Race, n
   White 17
   Black 3
Age, y 43 (11)
Weight, kg 72 (12)















CL/F  (L/h)    4.02 3.58 - 4.46 4.02 3.57- 4.47
V1/F  (L) 53.6 48.1-59.1 53.4 45.5-59.0
V2/F  (L) 37.6 33.3-41.9 38.0 33.3-44.7
Ka     (h-1) 1.04 0.82-1.26 1.03 0.79-1.27
Q       (L/h) 10.9 9.00-12.8 11.0 9.13-13.9
TVCL = CL/F+θ1*(CLCR-103) θ1=0.03 0.01 - 0.05 0.03 0.01-0.05
 TVV  = V1/F+θ2*(WGT-72) θ2=1.11 0.87 -1.36 1.13 0.83-1.39
Ω-CL/F      25.4% 12.1- 38.7 24.0% 16.6-30.6
Ω-V1/F  9.24% 2.08- 16.4 8.60% 0.70-14.4
Ω-V2/F  13.1% 3.98-19.1 12.5% 1.08-19.1
Ω-Ka    35.9% 16.4-55.5 34.8% 20.9-45.0
Residual Proportional Error 8.34% 5.54 - 11.1 8.09% 5.79-10.9  
CL is systemic clearance, F is bioavailability, V1 is central compartment volume, V2 is 
peripheral compartment volume, Ka is the first order rate of absorption, Q is 
intercompartmental clearance, TVCL and TVV are typical population value of clearance 
and volume, θ1 and θ2 are covariate parameters on CLCR (creatinine clearance) and 
WGT (weight), and Ω is a random effects parameter estimating inter-subject variability.  
 
 
Table 2.3. Pharmacodynamic Parameters in Healthy Volunteers after a 2mg Oral Dose of 
Lorazepam or Placebo (n=20).  
 
β1- β5 are intercept logistic parameters describing the baseline, PLAC is amplitude of 
placebo effect, k1 and k2 are the first order rates of onset and offset of placebo response, 
P(1) is percentage of  non-responders to placebo, SLOPE describes the  relationship 
between drug effect and concentrations, keo is the first order rate constant describing lag 
in the effect compartment compared to lorazepam concentrations in the central 








Table 2.4. Relationship of Data-Derived and Model-Derived PD Parameters to the Label 
Incidence of Sleepiness and Dizziness in Healthy Volunteers after Administration of a 2 
mg Oral Dose of Lorazepam. 
Endpoint/ Parameter Label Incidence AUEC MaxS Max(P≥1) Max(P≥2) Max(P≥3) Slope
Sleepiness 15.7 20.35 2.34 1 0.57 0.35 0.21
Dizziness 6.9 9.76 1.45 0.7 0.25 0.15 0.19


































































Figure 2.1. Left Panel:.Observed mean ± SD and predicted mean plasma concentrations 
versus time after a 2mg  oral dose  of  lorazepam  in healthy volunteers (n=20).Right 











































































Figure 2.2. Cumulative probability plots of reporting sleepiness and dizziness. P≥1-5 is 
the cumulative probability of reporting an effect of at least minimum, mild, moderate, 

















































































Figure 2.3. Ninety percent prediction intervals of sleepiness and dizziness scores in 
healthy volunteers as a function of time (n=20). Panel one shows lorazepam and placebo 
sleepiness, panel two lorazepam  and placebo dizziness , and panel three lorazepam 
sleepiness and dizziness. Symbols indicate observed data, middle line indicates simulated 



































Figure 2.4. Posterior distributions of MaxS and AUEC for lorazepam sleepiness and 
dizziness in healthy volunteers after a 2 mg oral dose of lorazepam(n=20). Line indicates 
mean observed value. MaxS is the maximum reported categorical score, AUEC is the 
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 PHARMACOMETRIC ANALYSES OF A CONTINUOUS VISUAL- 
ANALOG  MEASURE OF LORAZEPAM SLEEPINESS  
 
Abstract 
A continuous measure of drug effect may have potential advantages over a categorical 
counterpart in pharmacometrics. This study investigates the feasibility of modeling a 
pharmacodynamic measure of the Visual Analog Scale (VAS) using a population mixed 
effects approach Healthy volunteers (n=20) received single oral doses of 2 mg lorazepam 
or placebo in a randomized, double-blind, cross-over fashion. The VAS was serially 
administered over 24 hr to measure the intensity of several effects including sleepiness. 
Lorazepam Cmax (26 ng/ml) occurred at 1.7 hrs while maximal VAS sleepiness (MaxS= 
50.6 mm) was delayed occurring at 3.3 hrs. Lorazepam-induced sleepiness was modeled 
using a linear slope model with an effect compartment implemented in NONMEM. High 
unexplained interindividual and residual variability, poor concordance plots and 
Montecarlo simulations were observed. Inspection of the histograms of VAS scores at 
various time points showed a right- skewed distribution, Logistic transformation of the 
VAS scores produced distributions closer to normal,  greatly improving concordance 
plots, residual plots, and simulations. In conclusion, the logistic transformation well 
handles the skewness and boundedness aspects of the VAS, making such data suitable for 






Continuous and ordered categorical subjective scales have been used to measure 
effects which are clinically relevant yet have no alternative objective measure. The 
Visual Analog Scale (VAS) is an example of a continuous subjective scale which has 
been used in clinical studies to measure relevant effects such as pain (Deloach et al, 1998; 
Lundeberg et al, 2001; McCormack et al, 1998), mood (Aitken et al, 1970; Folstein  and 
Luria, 1973; McCormack et al, 1998), and anxiety (McCormack et al, 1998). It consists 
of a 10 cm line anchored at both ends with words descriptive of the maximal and minimal 
extremes of the dimension being measured. Figure 3.1 shows an illustration of the 
modified VAS drawn to scale.       
 The feasibility of using different subjective scales as biomarkers of 
pharmacodynamic (PD) response was investigated in a small clinical pharmacology study 
with four model Central Nervous System (CNS) drugs (Moton et al, 2005).  The rationale 
was that these scales may be used as biomarkers of efficacy and tolerability to create 
preliminary pharmacodynamic differentiation profiles in the development of new CNS 
agents.  In that Phase I study (Moton et al, 2005) , the VAS and a seven point ordered 
categorical scale measuring different types of subjective response (e.g. sleepiness, 
dizziness, etc) were administered serially after single dose administration to measure 
intensity of drug effects over 24 hours.  Inspection of the effect-time profiles of the more 
common drug effects showed differential profiles for the different CNS agents, the onset 
and offset of response as well as the relationship to plasma concentrations.  
 The criteria for selecting the most ideal subjective scale for pharmacometric 
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utility in a small study setting are unclear. From a clinical outcomes perspective, the 
controversy in the literature over the superiority of categorical versus VAS scales stresses 
the need to closely investigate the suitability of a subjective scale for a particular clinical 
study design. We have previously shown that  7-point ordered categorical  measures of 
lorazepam sleepiness and dizziness reported by twenty healthy volunteers were modeled 
successfully using a logistic function, and demonstrated the potential utility of this scale 
as a biomarker of adverse events. (chapter 2). However, a continuous measure of drug 
effect may have potential, inherent advantages over a categorical counterpart in 
pharmacometrics. Aitken  and Zealley (1970)  popularized use of the VAS  arguing such 
scales can quantify sensitively what subjects wish to convey, however words may fail to 
describe the ‘exactness of the subjective experience’ while   categorical scales impose 
artificial categories on the continuous phenomena of feelings. Moreover, with a 
continuous scale such as the VAS, the change in effect can be quantified, i.e., in going 
from 10 mm to 20 mm the change may assumed to be the same as going from 30 to 40 
mm, however the effect categories in a categorical scale cannot be assumed to be 
equidistant (Merbitz et al, 1989). The VAS also has the potential to be more sensitive 
than a categorical scale in detecting small changes in clinical effect over time (Scott and 
Hiskinsson, 1976). Since a continuous scale provides scores which are amenable to 
parametric analysis using non-linear regression (Robinson et al, 1975), such data may 
also potentially offer a better characterization of interindividual variability compared to a 
categorical scale.         
 From the spectrum of CNS effects measured in the phase I study (Moton et al, 
2005), the endpoint of lorazepam-induced sleepiness was selected for analysis because 
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this measure: 1) showed the largest signal on both VAS and categorical scales, 2) showed 
the highest statistical significance in time-averaged change from baseline differences with 
placebo (p<0.001), and 3) was analyzed previously using the categorical measure 
(Chapter 2). The current study investigates the exposure/response relationship of VAS- 
measured- lorazepam-sleepiness and explores the feasibility of modeling this VAS 
measure using a population mixed effects approach.  
Methods 
Data Collection 
Twenty healthy volunteers were randomized in a double blind, single dose, 5-way 
crossover design (Moton et al, 2005). All subjects gave written informed consent to 
participate in the study. The study was conducted at the Clinical Pharmacology Unit of 
Pfizer (Ann Arbor, MI) in accordance with the principles of the Declaration of Helsinki. 
The study protocol was approved and performed in compliance with the Institutional 
Review Board/Independent Ethics Committee (IRB/IEC) and International Committee on 
Harmonization (ICH) Good Clinical Practice guidelines. Each subject received an oral 
dose of either lorazepam 2 mg, as one of four CNS drugs, or placebo. All study drugs 
were commonly used marketed compounds within their respective therapeutic indications 
and were selected to produce different AE profiles which could potentially be measurable 
after single dose administration. Each regimen was separated by a one week washout 
period for a total trial period of five consecutive weeks. Blood samples were drawn 
before dosing and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hr after the morning dose 
and were assayed for lorazepam concentrations as previously described (Chapter 2).  
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Prior to each blood collection during the first 24 hr, the VAS, as shown in Figure 
3.1, was administered along with the 7 point ordered categorical scale previously reported 
(Kamal et al, in press). Subjects were asked to indicate how they felt at the moment for 9 
separate VAS scales measuring sleepiness, dizziness, nausea, forgetfulness, confusion, 
weakness, stiffness, and blurred vision. The scales consisted of 100 mm line anchored at 
both ends by “Not at all” and “Extremely” as shown in Figure 3.1. Subjects were 
instructed to draw a slash across the line between these anchor points and the effect was 
quantified by measuring the distance of the slash from the minimal extreme, “Not at all”, 
and was recorded to the nearest millimeter.  
Data Analysis 
Logistic Transformation 
Distribution of the lorazepam sleepiness VAS scores at various time points was 
skewed to the right as shown in Figure 3.3A. VAS scores were transformed using the 
following logistic transformation as described by Senn (2002).  
     Equation 1  
 Where Y denotes the transformed score in logits. For this transformation to be 
applied, 1 mm was added to zero data and 1 mm was subtracted from 100 mm data (if 
any). The following reverse logit transform was used to reconvert transformed scores in 
logits to VAS millimeters.  
         Equation 2 
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Where Y denotes the transformed variable obtained by Equation 1. 
Structural PK/PD Model 
PK/PD modeling of the time course of lorazepam concentrations and transformed 
VAS sleepiness scores were conducted in NONMEM (Beal and Sheiner, 1992) using the 
first order conditional estimation method with interaction (FOCE INTERACTION). The 
general model building strategy is based on modification of different approaches 
discussed by Beal and Sheiner (1992), Mandema et al (1992), and Ette and Ludden 
(1995). During model building, the goodness of fit of different models to the data was 
evaluated using the following criteria: change in the minimum objective function (MOF), 
visual inspection of concordance and residual plots, precision of the parameter estimates, 
the distribution of interindividual variability, and decreases in both inter-individual and 
residual variability. A decrease in the MOF of at least 10.83 upon addition of a parameter 
was considered statistically significant. This corresponds to a nominal p value of <0.001 
and one degree of freedom in the chi square distribution of the difference of MOF 
between hierarchical models.           
 The previously reported two-compartment model with first order absorption 
employed in the categorical analysis was used to describe the time course of plasma 
concentrations of 2 mg oral lorazepam (Kamal et al, in press).VAS  sleepiness scores 
were modeled  as a function of baseline effect, placebo effect, and lorazepam drug 
concentrations. The general model describing VAS sleepiness scores was: 
VAS Score=BSL + PLAC + DRUG            Equation 3 
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Where BSL a constant describing baseline sleepiness effect, PLAC is a structural model 
describing placebo sleepiness effect and DRUG is a structural model component 
describing lorazepam sleepiness effect. Exploratory analyses of each component was 
done separately by modeling baseline initially and then adding drug and placebo model 
components sequentially while observing the decrease in MOF.    
 Several models of drug effect were tested including: linear slope models using 
actual concentrations, post hoc PK estimates, and effect compartment concentrations.  
Hill functions with a fixed (Emax = 100) and non-fixed Emax with and without a 
sigmoidicity factor were also tested. Examination of the PK- and PD-time profiles 
showed a lag between concentrations and effect and as such used an effect compartment 
model was proposed. In the final model, the effect of lorazepam (DRUG) is linearly 
related to lorazepam concentrations in the effect compartment and was written as: 
Drug =SLOPE*CE        Equation 4 
Where SLOPE is the slope of the relationship between the increase in VAS 
response and CE, the concentrations of lorazepam in the hypothetical effect 
compartment, as described by Sheiner et al (1979).  Concentrations in this effect site are 
linked to the central compartment with a first order rate process and assume negligible 
mass transfer of drug to that compartment.  Thus, the equilibration between the central 
and effect compartment is driven by a first order rate constant (Ke0) which describes the 
delay between appearance of concentrations in plasma and onset of PD effect.  
Concentrations in the central compartment were predicted from the posthoc Bayesian 
estimates from the final PK model (chapter 2).  
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Many models were tested for placebo response including a simple constant 
response, exponential decay and a Bateman function. Although the Bateman function 
showed the lowest MOF, when k2, the first order rate constant describing offset of 
placebo effect, was modeled for sleepiness placebo, it resulted in over-parameterization 
as determined by inspection of the correlation matrix of estimates. The approach taken 
was to use a single first order  rate constant k using the Equation 5 below:  
PLAC = alpha * k * t * exp (-k * t).           Equation 5 
Where PLAC is placebo response, alpha is a parameter describing amplitude of 
placebo response and k is a first order rate constant. This resulted in stabilization of the 
final placebo model and the lowest MOF. 
Intersubject and Residual Variability 
Intersubject variability was estimated on the mean pharmacodynamic parameter  
θ using an exponential error term.  This was tested sequentially on all structural 
parameters and those parameters that were significant were retained during model 
building.  Residual variability was described using an additive error model as this model 
showed the greatest decrease in the MOF. 
Assessment of PK/PD Model Performance 
In addition to concordance and residual plots, Monte-Carlo simulations were performed 
to assess the final model performance and these simulations were visually compared to 




Table 3.1 shows the demographic information of the twenty study subjects. The time 
course of observed mean ± SD, after single oral dose administration of lorazepam 2 mg 
are shown in Figure 3.2. A noncompartmental analysis yielded mean (CV%) estimates 
for Cmax of 26.8 ng/ml (22.9), tmax of 1.7 hr (40.8), t1/2  of 16.8 hrs (21.3) and a total 
systemic exposure or AUC0-∞ of 551 ng*hr/ml (31.0). Peak lorazepam sleepiness score 
(MaxS) recorded on the VAS was 50.6 mm. The time to reach MaxS for lorazepam 
sleepiness scores was delayed (3.3 hr, Figure 3.2, B) compared to time of maximal 
lorazepam concentrations (tmax=1.71 hr, Figure 3.2, A). This temporal delay in relation 
to plasma concentrations was shown as a counter-clockwise hysteresis in the 
effect/concentration plot (Fig 3.2, C) and justified addition of the effect compartment  to 
describe drug effect in the lorazepam sleepiness model. 
 Figure 3.3A shows the right skewed distribution of  lorazepam sleepiness VAS 
scores at baseline and various time points. Figure 3.3B shows how applying the logistic 
transform shown in Equation 1 remedies the skewness, making the distributions look near 
normal. 
Population PD model-building was initialized by addition of baseline parameter 
(BSL) Addition of the drug component of the model as a slope as described in Equation 4 
resulted in a decrease in point reduction in the MOF > 300 indicating a significant drug 
effect.  Table 3.2 shows the final PD parameter estimates.   Addition of an effect 
compartment as described in Equation 5 was significant for sleepiness (MOF reduction 
was 22 points) and the final estimate of ke0, the first order rate constant describing lag in 
effect in the biophase compared to central compartment concentrations, was 5.17 hr-1. 
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Addition of the k1 parameter as shown in Equation 5 stabilized the model and 
significantly reduced the MOF (by >20 points). 
Improvement in the diagnostics of the model after logistic transformation is seen in 
Figure 3.4. The PRED vs. Observed plots (panel A, Figure 3.4) showed an improvement 
after transformation as well as the IPRED vs. Observed concordance plot (panel B, 
Figure 3.4). The residual plot of WRES vs. PRED also showed great improvement with 
outliers (defined as points lying outside the range -5 to5) seen in the upper panel of C, 
Figure 3.4, but absent in the lower panel.      
 The montecarlo simulations of the model applied to untransformed and 
transformed VAS scores is shown in Figure 3.5.  As shown, a significant improvement in 
the fit is seen after the scores are transformed.       
Discussion 
Although the VAS has been used in several clinical studies to measure subjective 
effects such as pain and mood, its pharmacometric utility in measuring drug effects in 
relation to drug exposure particularly in smaller studies is not well established. The 
current analysis investigates the pharmacokinetic/pharmacodynamic relationship of a 
VAS measure of sleepiness after single oral dose administration of lorazepam 2 mg 
reported by 20 healthy volunteers using a mixed effects population approach. The 2 mg 
dose of lorazepam represents the maintenance dose used in the treatment of generalized 
anxiety disorder. 
Noncompartmental PK estimates of the plasma concentration/time plot shown in 
Figure 3.2, showed oral lorazepam 2 mg displayed rapid absorption kinetics with a tmax 
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of 1.71 hr, Cmax of 26.8 ng/ml, and biological half life (t1/2) of 16.8 hr. The PK model 
which was previously described (Chapter 2) was a 2 compartmental model with first 
order absorption which adequately characterized the time course of lorazepam plasma 
concentrations. 
Mean peak Lorazepam sleepiness score (MaxS) recorded on the VAS was 50.6 
mm at 3.3 .hrs. This delay in effect in relation to plasma concentrations was shown as a 
counter-clockwise hysteresis in the effect/concentration plot (C, Fig 3.2). This temporal 
delay in lorazepam sleepiness observed with the categorical scale (chapter 2)..Peak 
lorazepam dizziness effect measured on the VAS showed no such delay (closed 
hysteresis loop, data not shown) and this temporal relationship was also in agreement 
with the categorical measure of dizziness (chapter 2), suggesting PK/PD temporal 
consistency between the VAS and the 7 point categorical scale. The temporal difference 
between lorazepam sleepiness and dizziness may be explained the presence of the Blood-
Brain-Barrier (BBB). Subjects may be experiencing vertigo which is reported as 
dizziness. Such an effect occurs due to action of the benzodiazepine at GABA receptors 
in the vestibular nuclei of the inner ear and this does not require traversing the blood 
brain barrier. On the other hand, sleepiness may occur due to GABA receptor activity in 
the thalamus and sensory cortex in the brain (Volkow et al) and this requires traversing 
the BBB, which causes the temporal delay recorded on both VAS and categorical 
(chapter 2) scales. 
Although the current VAS analysis uses non linear regression as opposed to  the 
categorical analysis which uses logistic regression, the VAS pharmacodynamic model 
described in the current analysis contained similar structural features to the categorical 
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pharmacodynamic model, i.e. constant baseline, linear slope model with an effect 
compartment to characterize drug effect, and a Bateman-like placebo response.  
The right skewed distribution of VAS scores at various time points at baseline and 
post lorazepam administration is shown in Figure 3.3A. This skewness phenomenon is 
the product of applying a bound scale, and as such there is a need to transform the data to 
make it normal or near normal. Typically, a Log transformation is applied in such 
situations (Senn, 2002), however while the log transformation may address the skewness, 
the transformed scores remained bound on a finite interval. Moreover, since zero data 
exists, there is a need to bias such data using a constant (c) and there is the problem of 
model predictions lying outside the interval Log(c) ≤Y≤ Log (100). A transformation that 
addresses both the skewness and boundedness of the VAS is the logistic transform shown 
in Equation 1. As shown in Figure 3.3B, the distribution of VAS scores after logistic 
transformation approaches normality. The function also accommodates the scale limits at 
0 and 100 mm by unsqueezing the values on both ends of the scale, converting the finite 
interval to the unbound logistic domain. To employ the transformation in the current 
analysis, there was a need to bias the extreme data by adding 1 mm to the minimal 
extreme (0 mm) and subtracting 1mm from the maximal extreme (100 mm) to 
accommodate the minimum and maximum asymptotes of the logistic function.. Since the 
subjects were not instructed to avoid marking anchor points in the current study protocol, 
there is a need in future studies to instruct subjects not to mark the anchor points of the 
VAS so as to avoid the need to induce this bias by the pharmacometrician. This may also 
necessitate modifying the scale, for example, changing the minimum anchor phrase in 
Figure 3.1 from “Not at all” to “ minimally”  to assist the subject in following this 
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directive during a clinical trial. As shown in Figure 3.4, the concordance of the 
population predictions (PRED) and individual model predictions (IPRED) to observed 
VAS sleepiness scores  improved greatly after transforming the data to the logistic 
domain. This is also reflected in the improvement in Montecarlo simulations in Figure 
3.5 when re-converting transformed scores to the original scale using Equation 2.Both the 
lorazepam treatment and placebo response simulations adequately capture the observed 
mean VAS responses.  
Conclusion 
Similar to the categorical measure, the VAS measure of lorazepam sleepiness was 
recorded with a delay compared to peak plasma concentrations. The logistic 
transformation remedied the skewness and boundedness of VAS scores and greatly 













Table 3.1 Subject Demographics 
 
Parameter Mean (SD) 
Gender, n
   Male 5
   Female 15
Race, n
   White 17
   Black 3
Age, y 43 (11)
Weight, kg 72 (12)





















Table 3.2. Pharmacodynamic Parameters in Healthy Volunteers after a 2mg Oral Dose of 
Lorazepam or Placebo (n=20).  
Parameter NONMEM Estimate 95% CI
BSL (logit) -3.53   -3.93 ,-3.13
SLOPE  (logit*ml/ng) 0.07 0.04, 0.1
Keo    ( h-1  ) 5.17 1.3, 9.1
alpha  (logit) 2.03 1.12, 2.94
k    ( h-1  ) 0.36  0.27 ,0.45
IIV-BSL 22.25  9.96, 34.53
IIV-Slope 68.48 22.32,  114.6
IIV-keo 148.32 40.76, 255.75
IIV-alpha 60.17  21.31 , 99.03
Residual Additive Error 0.9 0.26, 1.54  
BSL describes the baseline, SLOPE describes the  relationship between drug effect and 
concentrations, ke0 is the first order rate constant describing lag in the effect 
compartment compared to lorazepam concentrations in the central compartment, alpha, 
describes the amplitude of placebo effect, k is a second order rate constant , IIV 










































































































Figure  3.2.  A: The time course of Lorazepam plasma concentrations after oral 
administration of a 2 mg dose in twenty healthy volunteers.  B: Time course of Sleepiness 
measured on the VAS after administration of 2 mg Lorazepam. C: Counter-Clockwise 
Hysteresis on the Effect-Concentration plot denoting the lag in Sleepiness effect 

























































Figure 3.3A Histograms showing the right skewed distribution of VAS sleepiness scores 
reported by 20 healthy subjects after after oral administration of a 2 mg dose at various 

































































Figure 3.3B Histograms showing the  distribution of Logit transformed  VAS scores  
reported by 20 healthy subjects after after oral administration of a 2 mg dose at various 

































































































Figure  3.4. Concordance Plots. (Top panel: Model applied to VAS Scores in the 
Untransformed Domain. Bottom Panel: Model applied to Transformed VAS scores in the 
Logistic Domain). A  Predicted (PRED) VAS scores versus Observed (OBS). B 
Individual Predicted VAS Scores (IPRED) versus Observed (OBS). C: Weighted  













































Figure 3.5. Monte-Carlo simulations of the VAS untransformed scores and transformed 
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CONCLUSION TO PART I 
Major Findings 
 The pharmacometric analyses have shown that the ordered categorical measures of 
lorazepam sleepiness and dizziness were successfully modeled using a logistic function. 
The performance of the models were shown to be appropriate and verified by simulation 
and various posterior predictive checks. Logistic transformation of theVAS lorazepam 
sleepiness  scores normalized the right skewed distribution of VAS scores, greatly 
improved model diagnostics and simulations compared to those of the model applied to 
untransformed scores.. Although results of these pharmacometric analyses are promising, 
certain limitations of the current study preclude any definite conclusion of standard 
pharmacometric utility of the categorical scale or the VAS in small clinical studies and 
warrant further investigation. The major limitations of the analyses include the inclusion 
of one study drug only (lorazepam) with the exclusion of the other three drugs studied 
(olanzapine, atomoxetine, and paroxetine). Atomoxetine and paroxetine both showed 
very weak PD signals on both scales whereas olanzapine showed a strong sleepiness 
signal on both scales, however, was excluded because sleepiness incidence data in the 
label was based on schizophrenic patients and not healthy volunteers. Another limitation 
of the study was that the order of tests (i.e. categorical vs. VAS) was not randomized at 
each time they were administered which may induce a bias, further complicating any 
direct comparison of these scales.  
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Proposed Future Studies 
Future studies should investigate the following: 
1) Modeling the VAS measure of lorazepam dizziness. Such an analyses would 
allow determination of whether the potency (i.e. slope) ratio between sleepiness 
and dizziness are constant across both categorical and VAS measures. 
2) The measurement of PD differentiation profiles of adverse events in patients as 
opposed to healthy volunteers. To what degree are tolerability and efficacy PD 
profiles similar between actual patients and healthy volunteers?  
3) Since most PD signals recorded on these scales were of fairly low amplitude, 
further investigation into what constitutes the minimum quantifiable signal using 
the current power and study design is justified. The proposed population models 
may serve as a platform for clinical trial simulation studies to conduct sensitivity 
analysis on effect intensity parameters such as slope. Moreover, other factors need 
to be investigated such as the added power of current 5-way cross-over study 
designs and what power would be needed when using other study designs. Since a 
mixture of responder and non-responder sleepiness and dizziness was observed in 
the placebo group, simulation studies should also aim to determine what power is 
necessary to model responder data for a given ratio of responders. 
4) The approach described of relating model-derived PD parameters to label 
incidence in creating preliminary PD differentiation profiles should be explored 
with other drugs and adverse event endpoints to determine the extent to which the 
approach is applicable in early small clinical studies. 
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5) Investigation of the interaction of certain factors such as age and drug effects 
altering mental alertness (e.g. sleepiness) on the ability of the subject to use 
categorical and VAS instruments during the course of a clinical trial are 
























                                                                PART II 
ROLE OF PEPT2 SYSTEM IN NEUROPEPTIDE DISPOSITION, 
DYNAMICS, AND TOXICITY 
CHAPTER 5 
INTRODUCTION to PART II 
 Proton-Coupled Oligopeptide Transporters (POTs) 
Four peptide transporters - PEPT1, PEPT2, PHT1 and PHT2- have been identified in 
mammals and are part of the proton-coupled oligopeptide transporter (POT) superfamily. 
These transporters are responsible for tanslocating small peptide fragments (di- and 
tripeptides) across biological membranes. What is unique about these peptide transporters 
are their driving force and substrate specificity. An inwardly-directed proton gradient and 
negative membrane potential is used as the driving force rather than ATP hydrolysis or 
Na+ concentration gradient for the transporters. PEPT1 was the first mammalian 
oligopeptide transporter cloned, using expression-cloning strategies from a rabbit 
intestinal cDNA library (Fei et al., 1994).  PEPT2 was the next peptide transporter 
identified, which was cloned from a human kidney cDNA library (Liu et al., 1995). 
Recently, two oligopeptide transporters, PHT1 (Yamashita, et al., 1997) and PHT2 
(Sakata, et al., 2001), were cloned from a rat brain cDNA library.  The transporters are 
unique from PEPT1 and PEPT2 in that they were shown to transport the amino acid, L-
histidine, as well as di- and tri-peptides in the same proton gradient-dependent manner 
 The primary physiological function of POTs has long been recognized as the main 
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route for absorbing dietary nitrogen in the intestine and reabsorbing filtered peptide-
bound nitrogen in the kidney. The fact that the absorption of protein digestion products in 
the small intestine occurs primarily in the form of small peptides (Matthews, 1975), and 
that up to 50% of circulating plasma amino acids is peptide bound (Seal et al, 1991; 
Schlagheck  et al., 1984), further exemplifies the nutritional importance of peptide 
transporters. However, the wide expression of transporters in various tissues, especially 
PEPT2, implies the transporters might be involved in transporting peptides into cells for 
cellular metabolism and controlling overall amino acid homeostasis in the body. In 
particular, PEPT2 transcripts (Berger et al., 1999), protein (Novotny et al., 2000; Shu et 
al., 2002) and functional activity (Teuscher et al., 2000; 2001) have been reported in 
choroid plexus and this transporter is believed to play a role in neuropeptide homeostasis 
and the efflux of peptides/mimetics from cerebrospinal fluid.  
The peptide transporters also have important pharmacological relevance because 
of their ability to transport numerous  peptidemimetic drugs including amino β-lactam 
antibiotics of the cephalosporin and penicillin classes, angiotensin-converting enzyme 
inhibitors, aminopeptidase inhibitors (e.g., bestatin), renin inhibitors, photosensitizing 
agents (e.g., 5-aminolevulinic acid) and even non-peptidic compound (e.g., valacyclovir, 
valglanciclovir).  The oral absorption of these substrates is peptide transporter dependent, 
suggesting that their efficacy is at least partially attributable to the peptide transporters.  
Once the drugs are circulating in the plasma, they are filtered through the glomerulus 
then reabsorbed in the kidney via peptide transporters.  This reabsorption lowers the renal 
clearance of drug, thereby increasing its half-life in the circulation. The transporters also 
affect the drug distribution and disposition in the other organs such as the brain, lung and 
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eye. Hence, the peptide transporters play a critical role in the pharmacokinetic profile 
and, ultimately, the therapeutic effect of various peptidomimetic drugs. 
 POT Tissue and Cellular Localization 
PEPT1 protein is localized on the brush border membrane of the absorptive 
epithelia cells of the small intestine (Ogihara et al., 1996) and the kidney (Shen et al., 
1999; Terada et al., 1997) . More specifically, intestinal PEPT1 is confined to duodenum, 
jejunum and ileum of intestine, and S1 segments of the proximal tubule in the kidney 
(Shen et al., 1999). These segments are shown in Figure 5.2.  PEPT1 is thought to be the 
predominant POT located on the brush border membrane of the small intestine, and is 
primarily responsible for the absorption of small peptide fragments from the digestion of 
dietary proteins (Fei et al., 1994).  PEPT1 mRNA is mainly expressed in the small 
intestine and at low levels in the kidney, liver and pancreas (Fei et al., 1994; Gonzalez et 
al., 1998). PEPT1 however, is unable to be detected either as mRNA in rabbit, human or 
rat brain (Fei et al., 1994; Saito et al., 1995; Liang et al., 1995; Doring et al., 1998; and 
Fujita et al., 1999) or as protein in rat brain (Shen et al., 2004). 
PEPT2 exhibits different expression patterns in the kidney when compared to that 
of PEPT1 (Liu et al., 1995; Boll et al., 1996).  More specifically, it is confined to the S2 
and S3 segments of the proximal tubule (Shen et al., 1999) shown in Figure 5.2, and is 
especially enriched in the brush border membrane of the renal villi.  PEPT2 is believed to 
play a more dominant role than that of PEPT1 with respect to conservation of peptide-
bound amino acids in the kidney (Shu et al., 2001; Shen et al., 1999).  PEPT2 mRNA 
expression is not only found in the kidney but also exhibits strong levels of expression in 
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the brain, lung and mammary gland, with weaker signals detected in the pancreas, 
skeletal muscle, heart, liver, spleen and colon (Doring et al., 1998).  In regard to PEPT2 
brain distribution, PEPT2 mRNA has been specifically localized to astrocytes, 
subependymal cells, ependymal cells and epithelial cells of the choroid plexus (Berger et 
al., 1999).  Recently, PEPT2 protein was demonstrated in choroid plexus by Western blot 
analysis (Novotny et al., 2000; Shu et al., 2002) and by functional analysis (Teucher et 
al., 2000; 2001; Shu et al., 2002).  Western blots also show that PEPT2 protein is 
expressed in whole brain homogenates (Novotny et al., 2000) as well as in the peripheral 
nervous system glial cells (Groneberg et al, 2001a).  In the eye, in situ hybridization 
studies have localized PEPT2 mRNA to the retina (Berger et al., 1999).  In the lung, 
PEPT2 protein was demonstrated to be expressed in alveolar type II pneumocytes, 
bronchial epithelium, and endothelium of small vessels (Groneberg et al, 2001b).  As 
previously mentioned, the function of PEPT2 is also confirmed in mammary gland, in 
which it may contribute to the reuptake of short-chain peptides derived from hydrolysis 
of milk proteins secreted into the lumen and may reduce the burden of xenobiotics in 
milk (Groneberg et al, 2002). 
PHT1 mRNA has been found in the brain and eye, particularly in the choroid 
plexus and retina (Yamashita et al., 1997).  PHT2 mRNA transcripts were expressed 
primarily in the lymphatic system, lung, spleen and detected faintly in the brain (Sakata et 
al., 2001).  However, the physiological role of PHT1 and PHT2 in these different organs 
and tissues has yet to be elucidated.  In comparison to PEPT1 and PEPT2, relatively little 




PEPT2 Transport Models 
As early as in 1983, Ganapathy discovered that the transport of peptides via the 
peptide transporters is driven by an inward H+ gradient and a negative transmembrane 
potential difference.  However, this proton motive force is generated by different 
mechanisms depending on the tissue and cell type where the proton-coupled oligopeptide 
transporter is located. 
PEPT2 is assumed to be located on the apical membrane of the epithelium based 
on functional and immunolocalization studies in neonatal CP cells in primary culture 
(Shu et al., 2002). What is unclear, at present, is the mechanism generating the proton 
motive driving force by which peptides and mimetics are transported across apical 
membranes and into choroid plexus epithelial cells. Normally, the pH of bulk CSF is 
similar to that in plasma, but about 0.3 units lower in choroid plexus cells (Johanson, 
1985). Unlike most epithelial cells, the choroid plexus distributes Na+/K+-ATPase to the 
apical membrane and not the basolateral membrane (Ernst et al., 1986). This unique 
distribution is involved in the formation of CSF.  Recently, a model for the transport of 
peptides and peptidomimetics in choroid plexus was proposed by Smith et al. (in press) 
and involves three primary steps: 1) Na+/K+-ATPase in the apical membrane causes a 
sodium efflux from the cell and thus Na+ gradient; 2) this gradient is then utilized by two 
Na+/H+ exchangers. The Na+/H+ exchanger located in the basolateral membrane applies 
this gradient for extruding protons into the blood with pumping Na+ into the cell.  The 
other Na+/H+ exchanger located in the apical membrane also exploits this gradient for 
exporting protons into CSF and creates an acid microenvironment at the choroidial 
epithelial surface between apical microvilli, such as that observed in the intestine and 
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kidney (Lucas, 1983); 3) the acid microenvironment or local hydrogen gradient drives 
uptake of peptides via the proton-coupled oligopeptide cotransport system. Figure 5.1 
shows the transport model of PEPT2 in the choroid plexus epithelial cell. 
While the basolateral localization of Na+/H+ antiporter in the CP has been 
confirmed (Speake et al., 2001), an apical Na+/H+ exchanger need further experiments to 
confirm its presence in CP. Figure 5.1A shows  a representation of the oligopeptide 
transport model in the choroid plexus epithelial cell. Figure 5.1B shows a different 
representation of peptide/mimetic transport in the proximal tubule epithelial cell. As 
shown this model differs from that of the choroid plexus epithelial cell in the distribution 
of transporters on the apical and basolateral side. 
 General Substrate Structure 
After an initial understanding of di-and tripeptide transport via POT, researchers 
began to evaluate the possibilities of transporting drug molecules using these peptide 
transporters. Drugs (and prodrugs) such as amino-cephalosporins and penicillins, 
angiotensin-converting enzyme (ACE) inhibitors, bestatin and renin inhibitors have been 
reported to be transported by the POT transporters. Figure 5.5 shows the structures of 
various substrates of PEPT2 under study in our lab. 
While specific pharmacophore models have been developed for both PEPT1 and 
PEPT2, in general, several structural features of substrates are important for high-affinity 
interactions and binding by PEPT1 and PEPT2. These features include: 1) a peptide 
backbone of 2-3 amino acid residues, 2) both a free amino and carboxyl terminus (with 
free anion group in α-position), 3) the presence of hydrophobic side chains and 4) 
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stereoselectivity (with L-amino acids and trans-conformers being preferred). Still, the 
structural requirements for substrate recognition by the binding sites of oligopeptide 
transporters are even broader than once believed. A peptide bond is not an absolute 
requirement for transport, nor is the presence of a terminal amino or carboxyl group. 
Some significant exceptions have been demonstrated (Han et al, 1998) and, until a three 
dimensional crystal structure of the transporter protein is available, current 
pharmacophore models will continue to be refined by trial and error. 
Choroid-Plexus and the Blood-CSF Barrier 
The brain is an unusual tissue in that the entry of drugs from the circulating blood 
into the central nervous system (CNS) is restricted by presence of the blood-brain barrier 
(BBB) and the blood-cerebrospinal fluid barrier (BCSFB). The blood-brain-barrier, 
formed by the cerebral endothelial cells, is the interface of the circulating blood and the 
brain interstitial fluid (ISF), which surrounds the neurons and glia. The cerebral 
endothelial cells are characterized by presences of tight junctions which connect these 
cells to each other and by the paucity of fenestra or pinocytotic vesicles (Davson et al., 
1989 Fenstermacher et al., 1989). The other barrier, the blood-CSF barrier, is formed by 
the choroid plexus and the arachnoid membrane. The tight junction between the epithelial 
cells, but not the endothelial cells of the choroid plexus, is involved in the functional role 
of this barrier (Cserr et al., 1971). 
Once across these initial barriers, drug accumulation in the brain can be further restricted 
by a number of mechanisms including passive efflux into the bulk flow of cerebrospinal 
fluid (sink effect), metabolic degradation, and active efflux via transporters in the 
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epithelial cells of the choroids plexus and endothelial cells of the brain capillaries. In 
considering the therapeutic and toxic effects of drugs in the CNS, it is important to 
elucidate the routes and mechanisms by which these drugs that enter and leave brain. 
Figures 5.3 and 5.4 show sites of the barriers in the central nervous system.   
 Structure and Function of the Choroid Plexus 
The choroid plexuses (CPs) are located in the two lateral ventricles, and the third 
and fourth ventricles. The CP in the fourth ventricle, like a single sheet of tissue, forms 
the roof of the cavity. Inside these tissues there is a complex, highly permeable, mainly 
venular, capillary network, which supplies the blood gases and nutrients to support the 
active secretion of CSF and the transport processes between blood and CSF. The 
epithelial cells of the CP are joined together by an occluding band of tight junctions close 
to the CSF side of the cell. These junctions are made up of multiple strands yet are more 
permeable than those of the BBB (Meller et al., 1985). The tight junctions do permit the 
flow of water and some salts between the cells (the paracellular pathway) yet restrict the 
passage of small molecules such as mannitol. The fact that the choroid plexus is the 
major site of CSF secretion probably entails that it be a relatively leaky barrier tissue with 
a greater potential for leakage of neuroactive substances from blood. To prevent the entry 
of such agents from blood, transporters or enzyme may be required to remove any 
substances that cross the epithelium. It is possible that paracellular mechanisms may be a 
therapeutic target to enhance drug permeability if such confounding efflux transporters 
and enzymes could be avoided. 
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The cell walls of the basolateral sides of CP cells are highly convoluted, which 
expands the surface area between the cytoplasm and the extracellular fluid (ECF) of CP. 
The cell walls on the apical or CSF side of these cells are covered with microvilli, which 
greatly expands the surface area at the interface between the cytoplasm and CSF. Besides 
containing the apical brush border and basolateral interdigitations mentioned previously, 
the choroid plexus epithelium is endowed with mitochondria, which is required to 
maintain a high rate of oxidative metabolism during secretory and transport processes. 
Moreover, the cells also have well-developed subcellular organelles such as Golgi 
complexes, endoplasmic reticulum, ribosomes and a vesicular network. These structures 
may be involved in peptide and protein disposition such as synthesis, transcytosis, 
endocytosis and degradation. Figure 5.4 shows a representation of the choroid plexus and 
other barriers in the CSF. 
As shown in Figure 5.1A, the epithelial cell membrane of the CP displays 
sidedness, i.e., the basolateral side of the choroid cells or the side facing the plasma has 
structural and functional features strikingly different from those associated with the 
opposite, apical pole of the cell in contact with the CSF. The basolateral side of choroid 
plexus epithelial cells also has a different repertoire of ion channels and pumps compared 
to the apical (CSF) side. Such polarization allows the net secretion of solutes from blood 
to CSF concurrently with net reabsorption of other compounds in the reverse direction. 
This asymmetric two-way traffic of solutes across the BCSFB is finely coordinated so 
that there is resultant homeostasis of both choroidal cellular fluid and the generated CSF. 
By elucidating the physiologic nature for transepithelial fluxes of solute across the 
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choroidal membrane, the pharmacologist and clinician should be better able to 
manipulate the movement of drugs between plasma and CSF. 
The main functions of the choroid plexus are to: 1) secrete CSF.  70-90% of CSF 
is generated by choroidal tissues located in all four ventricles; 2) provide buoyancy and 
protection where the floating of brain on a fluid cushion of CSF within the skull protects 
the brain from injuries that would otherwise result from abrupt movements such as a car 
crash; 3) Control and buffer extracellular fluids composition forming a physical barrier to 
the diffusion of molecules between blood and CSF. 4) Participate in neurohumoral 
signaling in transduction either as a target or a source of synthetic endocrine messenger; 
5) Provide immune privilege acting as is a ‘port of entry’ for many pathogens into brain 
and contains cells of the immune system that can present antigen and stimulate the 
production of peripheral T helper cells to form a critical “arm” of the cellular immune 
system of brain (Cserr and Knopf, 1992).  
Potential for Drug Delivery 
   The blood-CSF barrier route has been considered to have a minor role for drug 
delivery to CNS compared to the blood-brain barrier. The main argument has been that 
the surface area of the CP is three to four orders of magnitude less than the total 
circumferential surface area of the brain capillaries (Pardridge et al., 1981). Another fact 
is that all parenchymal cells are within about 50 μm of a capillary, whereas cells in deep 
brain structures may be substantially further away from the CSF system, especially in 
species with large brain, such as man. However, other blood-CSF barrier studies have 
revealed that the choroid plexus may play a more significant role in brain drug delivery 
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than previously viewed. First, as previously mentioned, the choroidal surface available 
for exchange between the blood and the CSF is largely increased by the basolateral 
infolding, and the apical microvilli of the choroidal cells. (Keep, 1990). As estimated 
from the choroid plexus of 1-month-old rats, which is typically 2-3 mg wet weight, the 
total apical surface area of the choroidal epithelium approximates 75 cm2, about one half 
that of the blood-brain barrier (155 cm2) (Keep, 1990).   
Second, drugs introduced into the ventricular CSF are quickly distributed by the 
flow of this fluid that circulates by different routes within and around the brain to various 
tissues, such as ependymal, leptomeninges, velae, outer layers of pial vessels and 
perivascular spaces of parenchymal vessels (Ghersi-Egea et al., 1996). Thus, CPs 
constitute a direct access to pharmacological targets for diseases (Alzheimer’s, AIDS 
dementia, stroke, epilepsy, cancer and bacterial meningitis).  
Moreover, the paracellular permeability of the choroidal epithelium is higher than 
that of the endothelium forming BBB (Davson and Segal, 1996; Meller, 1985), which 
implies the blood-CSF barrier is somewhat “leakier” than the blood-brain barrier. As 
demonstrated stavudine, a polar antiretroviral agent, can slowly diffuse into the CSF 
through the CPs, whereas its penetration cross the BBB is almost completely prevented 
(Thomas et al., 1998). 
 Finally, the expression of a large number of influx and efflux transport systems 
(e.g. PEPT2) and metabolic enzymes at the choroid plexus has been recently found. For 
many solutes and substances, their main, if not exclusive, route of entry into the brain is 
by the way of the blood-CSF barrier through specific saturable carriers. Such selectivity 
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in the CP affords pharmacological opportunities for manipulating fluxes of therapeutic 
agents into the highly protected cerebral environment. However, the blockade of efflux 
transporters and enzyme has been explored as an alternative approach to increasing CNS 
drug exposure (Wong et al., 1993).  
Transporter Distribution at Choroid Plexus 
The choroid epithelia, unlike the cerebral endothelia, are equipped with channels 
for large-capacity secretion of ions and water into the CNS (Johanson, 1988). 
Additionally, there are specialized carrier transport systems in CP for facilitating the 
movement of micronutrients. Numerous transport systems related to drug delivery at the 
choroid plexus have been identified.  They include organic anion transporters and organic 
cation transporters (OATs and OCTs, SLC22 family) (Ghersi-Egea et al., 2002), organic 
anion transporting polypeptides (OATPs, SLC21) (Choudhuri et al., 2003), 
Na+/dicarboxylate cotransporters, monocarboxylate transporters (MCTs), metal 
transporters (Choudhuri, 2003), bile acid transporters (Choudhuri, 2003), peptide 
transporters (POT, SLC15) (Teucher et al., 2000; 2001; Shu et al., 2002; Choudhuri, 
2003) and glucose transporters. Compounds such as taurine (Keep et al., 1996), amino 
acids, choline, antipyrine and barbital (Johanson et al., 1997), nucleosides, riboflavin, and 
hypoxanthine have been characterized with respect to their uptake at the blood-CSF 
barrier.  In addition, Rao et al. (Rao et al., 1999) determined the expression of the drug 
efflux protein, P-glycoprotein (multidrug resistance, MDR, ABCB) and the multidrug 




Role of PEPT2 in Choroid Plexus Whole Tissue: In Vitro Studies 
  While many in vitro studies have been performed to elucidate the role of PEPT2 
in transport of peptides these studies are confounded by the overlapping substrate 
specificities of the various transporters located on the epithelia of the choroids plexus. 
Thanks to development of the knockout PEPT2 model in our lab, in vitro whole tissue 
studies performed using transgenic knockout mice have provided preliminary evidence to 
the unequivocal role of PEPT2 in the transport of neuropeptides and peptide/mimetics. 
Many in vitro studies have provided preliminary evidence as to the role of PEPT2 
in the uptake kinetics of neuropeptides and peptide/mimetics. The proton-stimulated (pH 
6.5) uptake of the dipeptide, glycylsarcosine (GlySar), in isolated whole choroid plexus 
tissue obtained from PEPT2-/- mice was found to be functionally absent.  Only 10.9% 
and 3.9% of the GlySar uptake present in PEPT2+/+ mice was still present at 5 min and 
30 min in PEPT2-/- mice, thereby providing functional evidence for the successful 
development of the PEPT2 transgenic knockout model and the conclusion that PEPT2 is 
the only transporter responsible for GlySar uptake at the choroid plexus (Shen et al., 
2002). 
 Moreover uptake of the neuropeptide carnosine in rat choroid plexus primary cell 
cultures and choroid plexus whole tissue from PEPT2 knockout mice was investigated 
(Teuscher el al, 2004). Results indicated that carnosine was preferentially taken up from 
the apical as opposed to basolateral membrane of monlayers, and that this uptake process 
was characterized by a high affinity (Km=34 uM), low capacity (Vmax=73 pmol/mg 
protein/min) process consistent with that of PEPT2. Studies demonstrated that PEPT2 
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was responsible for over 90% of carnosine’s uptake in choroids plexus whole tissue while 
the non-saturable component was small and only accounted for 3% of total uptake. 
To further investigate the relative importance of PEPT2 in the transport of 
peptide-like drugs, as opposed to model peptides and/or neuropeptides, uptake studies 
were performed with radiolabeled cefadroxil in the isolated choroids plexus of wild-type 
and PEPT2 knockout mice. At normal pH (pH 7.4) and temperature (37 °C), the uptake 
of 1 μM cefadroxil was reduced by 83% in PEPT2-/- mice as compared with PEPT2+/+ 
mice (p < 0.001). Although a proton-stimulated uptake of cefadroxil was demonstrated in 
PEPT2+/+ mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in 
PEPT2-/- mice. Based on kinetic and inhibitor analyses, it was determined that (under 
linear conditions), 80 to 85% of cefadroxil's uptake in choroid plexus is mediated by 
PEPT2, 10 to 15% by organic anion transporter(s), and 5% by nonspecific mechanisms 
(Ocheltree et al., 2004a). These findings demonstrate that PEPT2 is the primary 
transporter responsible for cefadroxil uptake in the choroid plexus. Moreover, the data 
also suggest a role for PEPT2 in the clearance of peptidomimetics from cerebrospinal 
fluid.  
Role of PEPT2 in Peptide/Mimetic Disposition: In Vivo Studies 
While great improvements have been made in the design of in vitro studies they 
are still limited by in vitro experimental designs which employ non-physiologic 
conditions, such as the lack of an intact blood supply. Moreover, as alluded to before the 
presence of multiple transport systems in a tissue or organ of interest, some of which are 
even unknown at time of study, makes it difficult to accurately determine the significance 
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of a single specific transporter relative to other transporters. Such a situation exists in the 
brain where multiple POT transporters are present with overlapping substrate specificities 
(e.g., PEPT2, PHT1 and PHT2) (Yamashita et al., 1997; Sakata et al., 2001). Thus, it is 
difficult to accurately define the function and significance of PEPT2 in relation to other 
peptide transporters. 
The studies using wild type and PEPT2-deficient mice offer a unique opportunity 
to study the role and relevance of PEPT2 under physiological in vivo conditions. As both 
a nutrient and drug transporter, we believe that PEPT2 will play a pivotal part in affecting 
the pharmacodynamics, tissue distribution and systemic exposure of peptides, 
neuropeptides and therapeutically important peptide/mimetic drugs. This contention is 
supported by preliminary data from our laboratory (Ocheltree et al, 2004b) in which 
GlySar was administered as an iv bolus dose (0.05 μmol/g body weight) to wild type and 
PEPT2 null mice. In the study, the AUC was lower in PEPT2-/- mice than in wild-type 
animals, as a result of the approximately two-fold difference in total clearance values 
(0.46 ml/min in PEPT2-/- mice vs. 0.27 ml/min in PEPT2+/+ mice). However, no 
differences were observed in the volume of the central compartment (~3.8 ml) or volume 
of distribution steady-state (~10 ml) between genotypes. PEPT2-/- mice demonstrated a 
shorter half life (18 min vs. 25 min) and mean residence time (24 min vs. 34 min), and a 
faster central compartment elimination rate (0.12 min-1 vs. 0.07 min-1) as compared to 
PEPT2+/+ mice. Greater tissue concentrations of GlySar (nmol/g) were observed in the 
kidney (5 fold), lung (3-fold) and liver (1.5 fold) of PEPT2+/+ mice compared to PEPT2-
/- mice. In contrast, PEPT2-/- mice demonstrated a 2-fold greater concentration of GlySar 
in cerebrospinal fluid (CSF) and 4-fold greater CSF/choroids plexus ratio. Although 
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Glysar is a synthetic substrate with no physiological significance, these preliminary 
results suggest that the pharmacokinetics of a peptide/mimetic or peptide-like drug can be 
significantly altered by the presence and functional activity of PEPT2 in the body, 
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Figure 5.1. Sequential models of peptide/ mimetic transport in the choroid plexus [A] 
and renal proximal tubule epithelium [B] by PEPT2 showing the concerted action of 





Figure 5.2. Schematic of the kidney and nephron functional unit. PEPT1 is localized in 
the S1 segment of the cortex (convoluted proximal tubule), while PEPT2 is localized in 
the  later segment of the proximal tubule (corresponding to theS2-S3 segments of the 
outer medulla). Adapted from: Kriz W, Bankir L, Bulger RE, et al. A standard 
nomencalature for structures of the kidney.The Renal Commission of the International 







Figure 5.3. Sites of the barriers of the nervous system.  Specialized endothelial cells with 
tight junctions form the blood-brain barrier (BBB). Tight junctions of the choroidal 
epithelium and the arachnoid epithelium form the blood-CSF barrier (BCSFB). ECF = 
























Figure 5.4. Illustration of the the Blood-Brain and Blood-CSF Barriers. The leaky 
ependyma separates the CSF and extracellular fluid surrounding the brain parenchymal 
cells. PEPT2 (shown as P2 above) is localized on the apical side of the choroid plexus 












Figure 5.5. Structures of various substrates of PEPT2 under study. Glysar is a synthetic 
dipeptide, while L-carnosine, 5-ALA, and L-Kyotorphin are physiologically relevant 
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A PHYSIOLOGICAL PERSPECTIVE OF PEPT2: THE DISPOSITION OF 
CARNOSINE IN WILD-TYPE AND PEPT2 KNOCKOUT MICE  
 
Abstract 
Carnosine (β-alanyl-L-histidine), an endogenous dipeptide substrate of the proton-
coupled oligopeptide transporter PEPT2, plays an important role in many physiological 
processes.  This study investigated the in vivo relevance of PEPT2 on the systemic 
exposure, tissue distribution, and renal handling of [3H]carnosine (1 nmol/g intravenous 
dose) in wild-type and Pept2 null mice.  A marked increase in the systemic clearance of 
carnosine was observed in Pept2 null versus wild-type animals (0.50 vs. 0.29 ml/min;  
p<0.001), resulting in the decreased systemic exposure of dipeptide (AUC=43.7 vs. 73.0 
min•µM;  p<0.001).  Carnosine uptake was substantially reduced in the kidney of Pept2 
null mice and renal clearance increased 17-fold in this genotype (206 vs. 11.5 µl/min;  
p<0.001).  Fractional reabsorption of carnosine in Pept2 null mice was only one-fifth of 
the fraction reabsorbed in wild-type animals (0.20 vs. 0.94;  p<0.001).  This finding 
reflected the ability of PEPT2 to mediate 83% of carnosine’s total reabsorption from 
tubular fluid, while PEPT1 mediated 17% of the reabsorption process.  PEPT2 also had a 
substantial impact in brain where the cerebrospinal fluid/plasma concentration ratio of 
carnosine was 8-fold greater in Pept2-deficient versus Pept2-competent mice (0.70 vs. 
0.08; p<0.001).  The results demonstrate that PEPT2 is the predominant peptide 
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transporter in the physiological handling of carnosine in kidney, and that this protein 
significantly limits carnosine exposure in cerebrospinal fluid.  These findings suggest that 
Pept2 may act as a gene modifier for a variety of pathophysiological conditions in the 
kidney and brain, and that the gene product may serve as a potential target for 
pharmacological interventions.   
Introduction 
Carnosine (β-alanyl-L-histidine), an endogenous dipeptide, is abundantly expressed in the 
skeletal muscle and central nervous system (Flancbaum et al, Teuscher et al).  Carnosine 
has many physiological roles including its action as a cytosolic buffer (Quinn et al), 
neurotransmitter/neuromodulator (Biffo et al), and metabolic reservoir of histidine which 
is converted to histamine during physiological stress in mammals (Flancbaum et al).  The 
dipeptide also possesses strong antioxidant and free radical scavenging activities 
(Hartman et al, Quinn et al), and has been shown to be neuroprotective when 
administered intraperitoneally in rodent models of global and focal cerebral ischemia 
(Rejanikant et al, Stvolinsky et al).  More recently, protective effects of carnosine have 
been demonstrated in ischemia/reperfusion-induced acute renal failure (Fujii et al, Kurata 
et al) and diabetic nephropathy (Janssen et al).  Having favorable structural attributes, 
such as a β-amino group and L-conformation, the dipeptide is a substrate of PEPT2 
(Terada et al) which is a member of the proton-coupled oligopeptide transporter family 
SLC15A.   
 PEPT2 is primarily localized in the apical membrane of kidney epithelial cells, with 
immunolocalization studies specifically identifying the transporter in S2 and S3 segments 
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of the proximal tubule (Shen et al, 1999).  In brain, PEPT2 is expressed at the apical side 
of choroid plexus epithelial cells of the blood-cerebrospinal fluid (CSF) barrier (Berger 
and Hediger), and in astrocytes (newborns) and neuronal cells (newborn and adults) of 
brain parenchyma (Shen et al, 2003).  PEPT2 protein has also been identified in the 
alveolar lining of lung tissue, mammary glands, as well as retina and spleen (Doring et 
al).  The primary physiological roles of PEPT2 include:  1) the reabsorption of peptides 
from glomerular filtrate in renal proximal tubules, 2) the maintenance of brain 
homeostasis by controlling peptide trafficking in brain interstitial fluid and peptide 
removal from CSF, and 3) the facilitation of peptide uptake for action by intracellular 
peptidases.  However, the significance and interplay of these physiological roles in vivo 
are not entirely clear.   
 A previous study has demonstrated that carnosine is taken up into choroid plexus 
primary cell cultures and choroid plexus whole tissue by PEPT2 (Teuscher et al).  
However, the in vivo significance of PEPT2 in mediating this dipeptide’s disposition has 
not been investigated.  It is hypothesized that PEPT2 ablation will have a profound 
impact on the systemic pharmacokinetics of carnosine, as well as on the regional 
exposure of carnosine in kidney and brain.  Differences in PEPT2-mediated disposition 
may also alter the physiological and pharmacological benefits of carnosine, including its 
renal (Fujii et al,, Kurata et al) and neuroprotective (Rejanikant et al, Stvolinsky et al) 
effects after ischemic insult. 
 The current study aims to demonstrate the physiological relevance of PEPT2 by 
contrasting the systemic exposure, tissue distribution, metabolic stability, and renal 
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handling of carnosine in wild-type and Pept2 knockout mice after an intravenous bolus 
dose of the dipeptide.   
Materials and Methods 
 Chemicals.  [3H]Carnosine (sp act: 7.0 Ci/mmol), [3H]histidine (sp act: 44 
Ci/mmol), and [14C]dextran-MW 70,000 (sp act: 79 mCi/mmol) were purchased from 
Moravek Radiopharmaceuticals (Brea, CA).  Unlabeled carnosine was obtained from 
Sigma-Aldrich (St Louis, MO).  Cytoscint scintillation fluid and hyamine hydroxide were 
obtained from ICN (Irvine, CA).  All other chemicals were obtained from standard 
sources.   
 Animals.  Gender- and weight-matched wild-type (Pept2+/+) and null (Pept2-/-) mice 
(>99% C57BL/6 genetic background), 8 to 10 weeks of age, were generated in-house 
(Shen et al, 2003) and used for all study designs.  Animals were housed in a temperature-
controlled environment with a 12-hour light, 12-hour dark cycle and given ad libitum 
access to food and water.  All experiments with mice were performed in accordance with 
the guidelines from the National Institutes of Health for the care and use of animals, and 
were approved by the Institutional Animal Care and Use Committee.   
 Systemic Pharmacokinetic and Tissue Distribution Studies.  Wild-type and Pept2 
null mice were anesthetized with sodium pentobarbital (65 mg/kg ip).  [3H]Carnosine was 
injected into the tail vein of mice as a single bolus injection (1 nmol/g body weight; 5 
μl/g in normal saline).  Serial blood samples (~20 μl, via tail clipping) were collected at 
0, 0.25, 1, 2, 5, 10, 20, and 30 min, placed in 0.2 ml thin-wall PCR tubes (United 
Laboratory Plastics; St. Louis, MO) containing 1 µl of 7.5% potassium EDTA, and 
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centrifuged at 3,000 g for 3 min at room temperature.  A 5-μl aliquot of plasma 
supernatant was collected for each sample, mixed with 6 ml of scintillation fluid, vortex-
mixed for 5 sec, and then allowed to stand for 24 hr at ambient temperature.  
Radioactivity (measured in dpm/ml) for each plasma sample was measured by a dual-
channel liquid scintillation counter (Beckman LS 3801; Beckman Coulter, Fullerton, 
CA).   
An intravenous bolus of [14C]dextran-MW 70,000 (1 μCi/mouse) was 
administered 2 min prior to harvesting the 30-min tissue samples in order to correct for 
the vascular space (Shen et al, 2007).  A skin incision was made in the dorsal neck region 
to allow insertion of a 30-gauge needle into the cisterna magna for CSF sampling (~5-10 
μl).  The mouse was immediately decapitated and a 10-μl blood sample was obtained.  
Various organs/tissues were harvested at this time including the cerebral cortex, olfactory 
bulb, combined lateral and fourth ventricle choroid plexuses, kidney, liver, eye, lung, 
spleen, small and large intestines, and skeletal muscle.  The tissue samples were blotted 
dry and weighed, solubilized in 1 M hyamine hydroxide, and then incubated for 48 hr at 
37°C.  Solubilized tissue samples (and CSF) were mixed with 6 ml of scintillation fluid 
and left to stand for 24 hours at room temperature.  Radioactivity (measured in dpm/ml) 
in the blood, CSF, and tissue samples was measured by a dual-channel liquid scintillation 
counter.   
 Renal Clearance Studies.  Following sodium pentobarbital anesthesia (65 mg/kg 
ip), Pept2+/+ and Pept2-/- mice were administered [3H]carnosine (1 nmol/g body weight; 5 
μl/g in normal saline) by tail vein injection.  Blood samples (~20 μl, via tail clipping) 
were collected serially over 30 min and the plasma harvested.  The total urine of each 
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animal was aspirated directly from the bladder with a 28G1/2 U-100 insulin syringe at 30 
min.  Radioactivity in the plasma and urine was determined by dual-channel liquid 
scintillation counting.   
 Plasma Protein Binding Studies.  The protein binding of carnosine was determined 
by an ultrafiltration method (Ocheltree et al), with minor modification.  Blank plasma 
from each genotype was spiked with unlabeled and radiolabeled carnosine (0.1 µCi/ml) 
to produce concentrations of 0.1, 1, and 10 µM, values that represent the plasma 
concentration range observed after a 1 nmol/g intravenous dose of carnosine.  A 0.5-ml 
aliquot of each standard was added to a disposable Microcon YMT-30 centrifugal filter 
device (Millipore Corporation, Billerica, MA) using an anisotropic hydrophilic 
membrane that excluded molecules greater than 30 kDa.  The device was capped, 
equilibrated for 15 min at 37°C in a 35° fixed angle rotator, and centrifuged at 1,800 g for 
25 min at 37°C.  The protein free ultrafiltrate was then collected for each sample.  The 
unbound fraction in plasma was calculated as the ratio of carnosine concentration in the 
ultrafiltrate to that in the original plasma standard.  Liquid scintillation counting was used 
to determine radioactive counts in the samples.   
 Stability Studies.  [3H]Carnosine and [3H]histidine  peaks were detected using a 
high-performance liquid chromatography (HPLC) system consisting of a pump (model 
616 with 600S controller; Waters, Milford, MA), a Rheodyne injector port (Rohnert Park, 
CA) with 20 µl sample loop, a reversed-phase column stationary phase (Supelco C-18, 5 
µm, 25 cm x 4.6 mm), and a radiochemical detector (FLO-ONE 515TR Series Flow 
Scintillation Analyzer; Perkin Elmer Life and Analytical Sciences, Boston, MA).  The 
mobile phase was comprised of 0.10 M NaH2PO4 buffer (pH=3.2) and 0.10% 
123 
 
heptafluorobutyric acid, pumped isocratically at 1.0 ml/min under ambient conditions.  
Peaks were identified by injecting known standards of radiolabeled carnosine and 
histidine.   
 The metabolic stability of [3H]carnosine was determined in plasma, kidney, and 
urine samples following an intravenous dose (1 nmol/g body weight) in wild-type and 
Pept2 null mice.  Blood samples (100 µl) were collected by cardiac puncture at 2, 5, 10, 
20 and 30 min, and the plasma harvested.  Kidney samples (200 mg) were obtained at 30 
min and homogenized in 1 ml of water (4°C).  A 0.2-ml volume of trichloroacetic acid 
(10% w/v) was added to one volume of plasma or kidney homogenate, vortex-mixed for 
1 min, and then centrifuged at 15,000 g for 10 min at room temperature.  Urine samples 
were also centrifuged at 15,000 g for 10 min (ambient conditions) to remove any 
particulates.  Resultant supernatants were injected into the HPLC, and stability was 
evaluated by the ratio of carnosine area to the total area of carnosine and histidine (x100 
for percent).  The physicochemical integrity of [3H]carnosine stock solution (1 µCi/ml) 
was also determined at 25°C and 37°C following 0.5 and 24 hr incubations.   
 Data Analysis of Carnosine Systemic Pharmacokinetics.  The plasma concentration-
time profiles of carnosine displayed biexponential pharmacokinetics and were best 
described by a 2-compartment open model with first order elimination and uniform 
weighting (WinNonLin v 5.1; Pharsight Inc., Mountain View, CA).  The model goodness 
of fit was determined by evaluating the coefficient of determination (r2), the coefficient of 
variation of parameter estimates, and by visual inspection of the residuals.  
Pharmacokinetic parameters included AUC, area under the plasma concentration time 
curve;  CL, total systemic clearance;  V1, volume of the central compartment;  Vdss, 
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volume of distribution steady state;  t1/2, terminal half-life;  and MRT, mean residence 
time.   
 Data Analysis of Carnosine Renal Pharmacokinetics.  The renal clearance (CLR) of 
carnosine was calculated as:  CLR=Ae30/AUC30 where Ae30 is the amount of carnosine 
excreted unchanged in the urine over 30 min and AUC30 is the area under the carnosine 
plasma concentration-time curve from 0-30 min (determined noncompartmentally by 
partial areas using WinNonLin).  In the absence of tubular secretion (of which there is no 
evidence for this dipeptide), the renal clearance of carnosine can be expressed as (14):  
CLR=fu•GFR•(1-F) where fu is the fraction of carnosine unbound in plasma, GFR is the 
glomerular filtration rate (a measure of functional nephron mass) and F is the fraction of 
available dipeptide that is reabsorbed from tubular fluid.  The excretion ratio (ER) and 
fraction reabsorbed (F) was determined according to the following:  
ER=CLR/(fu•GFR)=1-F.  Based on the sequential expression of PEPT1 and PEPT2 in the 
proximal tubule of the nephron (Shen et al, 2003), the renal clearance equation can be 
transformed to (Shen et al, 2000):  CLR=fu•GFR• (1-F1) • (1-F2) where F1 is the 
available fraction of carnosine reabsorbed by PEPT1 and F2 is the available fraction 
reabsorbed by PEPT2.  Since F2=0 in PEPT2-/- mice, an estimate of F1 can be made in 
these mice.  An estimate of F2 can then be made in PEPT2+/+ mice with the assumption 
that F1 is unchanged in wild-type animals.  The relative contribution of each transporter 
to the reabsorption of carnosine can then be calculated as % PEPT1=100•(F1/F) and % 
PEPT2=100• [F2• (1-F1)/F]. 
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 Statistics.  The data are reported as mean±SE.  Statistical comparisons between the 
two genotypes were performed using an unpaired t-test (GraphPad Prism v4.0;  GraphPad 
Software, Inc., San Diego, CA).   
Results 
 Systemic Pharmacokinetics and Tissue Distribution of Carnosine.  As shown in 
Figure 6.1, the plasma concentrations of carnosine were significantly lower in Pept2-/- 
mice as compared to Pept2+/+ animals.  The altered plasma profiles are reflected in the 
pharmacokinetic parameters shown in Table 6.1.  The systemic clearance (CL) of null 
animals is 2-fold higher compared to wild-type animals (p<0.001), resulting in a 2-fold 
lower systemic exposure (AUC) (p<0.01).  PEPT2 had no affect on volume of 
distribution in the central compartment (V1), however, the steady-state volume (Vdss) 
was somewhat higher in null mice (p<0.05).  In contrast, no significant differences were 
observed in the terminal half-life (t1/2) and mean residence time (MRT) of carnosine.  
These last two parameters are not statistically different since they reflect changes in both 
distribution and elimination (which increase in Pept2-/-).  Figure 6.2 shows the tissue 
concentrations of carnosine, normalized for plasma concentrations, 30 min following an 
intravenous bolus dose of dipeptide.  PEPT2 ablation had a significant effect on the 
ability of many tissues to accumulate carnosine.  Most notably, lower tissue/plasma 
concentration ratios of carnosine were observed in the kidney (5-fold), choroid plexus (8-
fold), spleen (12-fold), eye (3-fold), lung (3-fold), cerebral cortex (3-fold), olfactory bulb 
(3-fold) and muscle (2-fold) of Pept2 knockout mice.  In contrast to these results, PEPT2-
/- mice had an 8-fold higher CSF/plasma concentration ratio (p<0.001).   
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 Renal Clearance of Carnosine.  An analysis of the renal tubular handling of 
carnosine is shown in Table 6.2 and Figure 6.3.  The renal clearance of carnosine (CLR) 
was approximately 17-fold higher in the Pept2 null mice as compared to wild-type mice 
(p<0.001), resulting in a significantly higher fraction of dipeptide being excreted 
unchanged in the urine at 30 min (fe30) (p<0.001).  Ultrafiltration studies showed no 
protein binding of carnosine across the relevant plasma concentrations of 0.1-10 µM and, 
as such, the fraction unbound (fu) for carnosine in plasma was unity.  GFR was fixed at 
250 µl/min based on the consistent values between genotypes in two previous studies by 
our group in gender-matched mice of similar age and weight (Ocheltree et al; Shen et al, 
2007).  Since the excretion ratio (ER) of carnosine represents its renal clearance, 
corrected for filtration clearance (fu•GFR), the significantly higher ER in null mice 
reflects the reduced reabsorption of carnosine in Pept2-deficient mice (i.e., F=0.94 vs. 
0.19 for wild-type and null mice, respectively).  Moreover, of the two oligopeptide 
transporters expressed in kidney, PEPT2 was responsible for the great majority of 
dipeptide reabsorption.  In this regard, PEPT1 accounted for only 17% of carnosine’s 
reabsorption from tubular fluid while PEPT2 accounted for 83% of dipeptide 
reabsorption in the kidney.   
 Stability of Carnosine.  Analysis of the HPLC chromatograms showed [3H]histidine 
eluting at 5.5 min and [3H]carnosine eluting at 9.1 min.  The physicochemical integrity of 
[3H]carnosine stock solutions was maintained during 0.5 and 24 hr incubations, at 
ambient temperature and 37°C (data not shown).  While the 30-min urine collections of 
both genotypes were stable (<5% degradation), about 12% of carnosine was degraded in 
the 30-min kidney samples of wild-type, but not Pept2 null, mice (Figure. 6.4).  
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Likewise, serial plasma samples from Pept2-/- mice were stable over 30 min (<3% 
degradation), as were the 2-, 5- and 10-min plasma samples from Pept2+/+ mice (<10% 
degradation).  However, the 20 and 30 min plasma samples showed about 15 and 20% 
degradation, respectively, in wild-type mice.  As a result, the plasma concentrations of 
carnosine in Pept2+/+ mice were corrected for the degradation observed at these times 
(Figure  6.1 and Table 6.1).   
Discussion 
Studies using wild-type and knockout mice offer a unique opportunity to study the role 
and relevance of a particular protein under physiological in vivo conditions.  By 
challenging Pept2-competent and Pept2-deficient mice following an intravenous dose of 
carnosine, the significance of gene disruption can be revealed in regard to dipeptide 
disposition.  In our studies, we found:  1) that PEPT2 was the major oligopeptide 
transporter responsible for dipeptide reabsorption in the kidney, 2) that the regional 
effects of PEPT2 in several organs, including the brain (e.g., choroid plexus and CSF), 
were greater than the systemic effects on dipeptide exposure, and 3) that transport-
metabolic coupling of dipeptide occurs to retain amino nitrogen.  These findings may 
have important physiological, pharmacological and pathophysiological implications 
including those related to nutrition, drug delivery and targeting, and ischemia.   
 Most notably, the results show that PEPT2 had a predominant role in the renal 
tubular reabsorption of carnosine.  Specifically, the fraction of dipeptide reabsorbed in 
Pept2 null mice was only one-fifth of that reabsorbed in wild-type animals.  This finding 
reflected the ability of PEPT2 to mediate 83% of carnosine’s total reabsorption from 
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tubular fluid.  In addition to differences in renal handling, PEPT2 ablation led to 
substantially decreased levels of carnosine in tissues where the peptide transporter is 
predominantly localized (e.g., cerebral cortex, olfactory bulb, choroid plexus and CSF, 
kidney, eye, lung, spleen and skeletal muscle).  The differences observed in olfactory 
bulb and skeletal muscle were particularly interesting since these tissues concentrate 
endogenous carnosine in abundance (Flancbaum et al, Teuscher et al).  As a result, 
PEPT2 may play an important role in regulating the neurotransmitter/neuromodulator 
action of carnosine in the olfactory pathway (Biffo et al) and in modulating the cytosolic 
buffering capabilities of carnosine during muscle fatigue (Quinn et al).  Given the 
predominance of PEPT2 on dipeptide transport in kidney, this oligopeptide transporter 
may also influence the renoprotective effects of carnosine during ischemic acute renal 
failure (Fujii et al, Kurata et al) and diabetic nephropathy (Janssen et al).   
 PEPT2 ablation had a significant influence on the influx of carnosine from CSF into 
choroid plexus as demonstrated by the 8-fold greater CSF/plasma concentration ratios of 
dipeptide in Pept2 null versus wild-type mice.  The greater CSF ratios of carnosine in 
Pept2-/- animals reflect the directionality of PEPT2 transport from the apical, CSF-facing, 
side of choroid plexus epithelial cells.  These differences were even more dramatic for 
carnosine than that observed in similarly-designed experiments for the synthetic dipeptide 
glycylsarcosine (Ocheltree et al) or the aminocephalosporin cefadroxil (Shen et al, 2007).  
Moreover, the results with carnosine, along with previous studies from our group 
(Ocheltree et al; Shen et al, 2007), point to the fact that PEPT2-induced changes in the 
regional disposition of peptides/mimetics in CSF are more dramatic than the PEPT2-
induced effects on systemic exposure.  While the PEPT2-induced renal accumulation of 
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carnosine might facilitate the renoprotective effects of dipeptide in renal failure, the 
limiting effect of PEPT2 on CSF exposure might diminish its reported neuroprotective 
effects (Rejanikant et al, Stvolinsky et al).  It is unclear whether or not the PEPT2-
mediated changes in regional carnosine disposition will translate into significant changes 
in the dipeptide’s neuroprotective effects after focal and global brain ischemia.  However, 
we have shown that PEPT2 expression in brain does protect against 5-aminolevulinic 
acid neurotoxicity (Hu et al, 2007).   
 Finally, results from the metabolic stability studies point to another physiological 
role of PEPT2 in facilitating the exposure of peptide substrates to tissue and serum 
dipeptidases.  Carnosine is hydrolyzed to its constituent amino acids by carnosinase 
(Harding et al, Margolis et al), a non-specific dipeptidase with high enzymatic activity in 
the cytosol of proximal tubule renal epithelia (Margolis et al).  Although C57BL/6 mice 
express low levels of carnosinase in their kidneys (Margolis and Grillo), some instability 
of carnosine was still observed in our mice.  In particular, after only 30 min, about 20% 
and 12% of the plasma and kidney samples of wild-type mice, respectively, were in the 
form of carnosine hydrolysis products.  However, in Pept2 null mice, these same samples 
displayed little instability (<6% degradation) as did the urine samples for both genotypes 
(<5% degradation).  These results can be explained by the greater PEPT2-mediated 
uptake, and subsequent renal hydrolysis, of carnosine in wild-type animals.  Although 
other tissues may contribute to carnosine hydrolysis, this outcome is less likely given the 
kidney’s unique combination of high PEPT2 (Ocheltree et al; Shen et al, 2007) and 
carnosinase activity (Harding et al).  Amino acid transporters on the basolateral 
membrane of the renal epithelia (Broer) can then reabsorb the degradation products (i.e., 
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β-alanine and/or L-histidine) back into plasma.  Amino acid transporters on the apical 
membrane of renal epithelia (Broer) can efficiently reabsorb the degradation products of 
carnosine in renal filtrate and, thereby, minimize the extent of hydrolysis products found 
in the urine of both wild-type and Pept2 null mice.  The concerted transport-metabolic 
coupling of carnosine by PEPT2 and peptidases has been depicted for dipeptides 
previously in kidney (Daniel and Rubio-Aliaga) and demonstrated previously for 
glycylglutamine in choroid plexus epithelial cells (Hu et al, 2005).   
 Conclusion and Perspective.  Using a Pept2 knockout model in mice, we 
demonstrated for the first time that PEPT2 can substantially impact the in vivo tissue 
distribution, systemic and regional exposure, and renal disposition of an endogenous 
dipeptide.  Specifically, our results are definitive in showing that PEPT2 is responsible 
for the great majority of carnosine reabsorption in renal tubular epithelial cells, and in 
substantially reducing the exposure of dipeptide in the CSF compartment.  Moreover, 
PEPT2 functions to increase the exposure of carnosine to intracellular carnosinase, 
thereby affecting the metabolic profile of dipeptide and constituent amino acids.  These 
findings suggest that Pept2 may act as a modifier gene for a variety of pathophysiological 
conditions in the kidney and brain, and that the gene product may serve as a potential 




Table 6.1.  Systemic pharmacokinetics of carnosine in Pept2+/+ and Pept2-/- mice after a 1 
nmol/g intravenous bolus dose of drug 
Parameter Pept2+/+ Pept2-/-
AUC (min*uM) 73.0 ± 7.4 43.7 ± 5.0**
CL    (ml/min) 0.29 ± 0.03 0.50 ± 0.05***
V1    (ml) 1.4 ± 0.2 1.3 ± 0.2
Vdss (ml) 4.0 ± 0.3 5.5 ± 0.5*
MRT (min) 14.2 ± 1.2 11.7 ± 1.3
t1/2     (min) 10.6 ± 0.9 9.0 ± 0.9
r2 0.994 ±0.002 0.995 ±0.001  
Values are expressed as mean ± SE (n=10).  AUC is the area under the plasma 
concentration-time curve, CL is the total clearance, V1 is the volume of central 
compartment, Vdss is the volume of distribution steady-state, MRT is the mean residence 











Table 6.2.  Renal pharmacokinetics of carnosine in Pept2+/+ and Pept2-/- mice after a 1 
nmol/g intravenous bolus dose of drug 
Parameter Pept2+/+ Pept2-/- 
CLR  (µl/min) 11.5 ± 4.3 206 ± 16 ***
GFR (µl/min) 250 250
fu    1.0 1.0
fe30 0.023 ± 0.005 0.50 ± 0.03***
ER 0.06 ± 0.02 0.81 ± 0.08***
F 0.94 ± 0.02 0.19 ± 0.08***
F1 0.19 ± 0.08 0.19 ± 0.08
F2 0.92 ± 0.02 0
%PEPT1 16.9 ± 8.1 100
%PEPT2 83.1 ± 7.2 0  
Values are expressed as mean ± SE (n=7).  CLR is the renal clearance, GFR is the 
glomerular filtration rate (values taken from references 14, 15), fu is the fraction unbound 
in plasma, fe30 is the fraction excreted unchanged in the urine over 30 min, ER is the 
excretion ratio, F is the fraction of available dipeptide reabsorbed, F1 is the fraction of 
available dipeptide reabsorbed by PEPT1, F2 is the fraction of available dipeptide 
reabsorbed by PEPT2, %PEPT1 is percentage of reabsorbed carnosine that occurs via 
PEPT1, and PEPT2 is percentage of reabsorbed carnosine that occurs via PEPT2.  















Figure 6.1. Plasma concentration-time profiles of carnosine in Pept2+/+ and Pept2-/- mice  




















































Figure 6.2.Tissue-to-plasma concentration ratios of carnosine in Pept2+/+ and Pept2mice,  












































































































Figure 6.3. Stability of carnosine in plasma, kidney, and urine samples from Pept2+/+ and  



















































Figure 6.4. Renal clearance of carnosine in Pept2+/+ and Pept2-/- mice after a 1 nmol/g  
intravenous bolus dose of drug (mean ± SE, n=7).  The estimated GFR of 250 µl/min is  
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CONCLUSION TO PART II 
 
Major Findings 
The PEPT2 knockout mouse has become an important tool to evaluate the evolving role 
and relevance of this transporter in drug disposition, dynamics and toxicity. Although 
disruption of the PEPT2 gene itself does not result in obvious phenotypic changes in the 
knockout mouse, our studies emphasize the fact that challenging the knockout in a certain 
manner may bring about phenotypic abnormalities. This study and others conducted in 
our lab have challenged the PEPT2 knockout model with various substrates of 
physiological, pharmacological and toxicological relevance, and have consistently 
demonstrated the dual action of this transporter with respect to its apical localization in 
kidney and choroid plexus epithelial cells.  The results have clearly shown that in vivo: 1) 
PEPT2 effluxes carnosine from the CSF into choroid plexus, thereby affecting regional 
disposition in the brain; and 2) PEPT2 reabsorbs carnosine from renal tubular fluid, 
thereby affecting systemic pharmacokinetics and exposure. It also appears that the 
regional effect of PEPT2 in limiting exposure of L-carnosine to the CSF (and presumably 
ISF) of brain may be of more importance than its effect in increasing systemic exposure. 
These findings may have implications on the reported neuroprotective and 
neuromodulatory effects of L-carnosine, however, further studies will be needed to assess 
if PEPT2- mediated changes in disposition of L-carnosine translate directly into 




Proposed Future Studies 
 Future studies should aim to further investigate how PEPT2-induced changes in 
regional disposition of carnosine in the kidney and brain affect its pharmacodynamics. 
For example, carnosine can be administered in wild-type and Pept2 knockout mice 
induced with cerebral ischemia to determine the effect of PEPT2 on the neuroprotective 
action of carnosine. Based on our results, PEPT2 should significantly reduce the 
neuroprotective effects of carnosine in the brain while facilitating the reno-protective 
activity of the dipeptide in an ischemia/reperfusion-induced acute renal failure mouse 
model.  
 Future studies should further investigate the proposed transporter-metabolic 
interaction of PEPT2 and carnosinase by conducting metabolic stability studies of 
carnosine in wild-type and PEPT2 knockout mice in which the enzyme carnosinase is 
inhibited. Such a study would provide definitive evidence of how PEPT2 may increase 








Heterogeneity of Proton-Coupled Oligopeptide Transporters (POTs) 
a) Molecular Biology of POTs 
 The superfamily of POTs is characterized by the ability to transport small peptides 
and peptide-mimetic molecules across biological membranes.1,2) Uptake of peptides into 
epithelial cells by these transporters is driven by an inwardly-directed proton gradient and 
negative membrane potential. In mammals, the POT family consists of four members: 
PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 (SLC15A4) and PHT2 (SLC15A3) which 
vary in size from 572-729 amino acids and contain 12 transmembrane domains, with the 
N- and C-termini facing the cytosol. PEPT1 was the first mammalian POT cloned, using 
expression-cloning strategies from a rabbit intestinal cDNA library.3) PEPT2 was next 
identified and cloned from a human kidney cDNA library4). The more recent members 
PHT15) and PHT26) were cloned from a rat brain cDNA library. These transporters differ 
from PEPT1 and PEPT2 in that they recognize the amino acid L-histidine as a substrate. 
While both PEPT1 and PEPT2 have high inter-species homology (about 80% in rat, 
rabbit, human, and mouse), the sequence homology between these transporters for a 
given species is low (about 50%).7) Rat PHT1 and PHT2 have an amino acid identity of 
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about 50%, but they show little sequence homology to either PEPT1 or PEPT2 (less then 
20%). 
 PEPT1 and PEPT2 proteins are believed to share a high degree of overlapping 
substrate specificity, possessing the capability for sequence-independent transport of 400 
different dipeptides and 8000 different tripeptides. It is unclear whether or not the PHT1 
and PHT2 proteins can transport the same spectrum of di-/tripeptides. However, the 
ability of PHT1/PHT2 to transport L-histidine marks a distinct difference in functionality 
from PEPT1/PEPT2. Since a three-dimensional structure of the transporter proteins has 
yet to be developed, no precise pharmacophore model is currently available. However, 
preferred configurations and conformational features of PEPT1 and PEPT2 substrates 
include: 1) a peptide backbone of 2-3 amino acid residues, 2) both a free amino acid and 
carboxy terminus with the free amino group in the α or β positions, 3) the presence of 
hydrophobic sidechains, and 4) stereoselectivity with L-amino acids and trans-
conformers being preferred. It must be noted that these are not absolute criteria and some 
notable exceptions have been reported in the literature.1,2,8)   
b) Expression of POTs 
 Several studies have shown unique tissue distribution and expression patterns for the 
different POTs. PEPT1 protein is localized in the brush border (apical) membrane of 
absorptive epithelia cells of the small intestine 9) and the kidney.10,11) Intestinal PEPT1 is 
confined to duodenum, jejunum and ileum of the small intestine, while renal PEPT1 is 
localized predominantly in S1 segments of early convoluted proximal tubule (i.e., pars 
convoluta).10) PEPT1 mRNA is expressed at lower levels in the liver and pancreas.3,12)  
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 PEPT2 exhibits a different tissue expression pattern compared to PEPT1.4,13) In 
kidney, immunolocalization studies show it is localized predominantly in S3 segments of 
latter proximal tubule (i.e., pars recta)10). PEPT2 mRNA also exhibits strong levels of 
expression in the brain, lung and mammary gland, with weaker signals detected in the 
pancreas, skeletal muscle, heart, liver, spleen and colon.14)  In brain, PEPT2 mRNA has 
been specifically localized to astrocytes, subependymal cells, ependymal cells and 
epithelial cells of the choroid plexus.15) With immunohistochemistry, PEPT2 protein has 
been found in astrocytes, ependyma and choroid plexus epithelium, as well as in some 
neurons.16) The same study also found that PEPT2 expression in cerebral cortex 
(probably astrocytic) decreased with age. The choroid plexus epithelium is the site of the 
blood-cerebrospinal fluid barrier (BCSFB) and the presence of PEPT2 at that barrier has 
been demonstrated by immunoblot17,18) and functional analyses.18-20) PEPT2 appears to be 
absent at the blood-brain barrier of cerebral capillaries.16) Immunoblots show that PEPT2 
protein is expressed in whole brain homogenates16) as well as in peripheral nervous 
system glial cells.21) In the eye, in situ hybridization studies have localized PEPT2 
mRNA to the retina.15) In the lung, PEPT2 protein was expressed in alveolar type II 
pneumocytes, bronchial epithelium, and endothelium of small vessels.22)  Relatively less 
is known about the expression and distribution of PHT1 and PHT2. PHT1 mRNA has 
been found in the brain and eye, particularly in the choroid plexus and retina.5) PHT2 
transcripts were expressed primarily in the lymphatic system, lung, and spleen and 
detected faintly in the brain.6)  
c) Function of POTs 
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 As mentioned previously, an inwardly-directed electrochemical gradient for protons 
provides POTs with the driving force needed for active transport of peptides and peptide-
mimetic molecules across biological membranes.1,2) The pH of the extracellular 
microenvironment, therefore, plays an important role in determining the rate of transport. 
This is important in the intestine and kidney where low pH microenvironments are 
established by ion transporters at the microvilli of apical membrane epithelia.   
 Due to their unique tissue distribution and expression patterns, the POTs are thought 
to have distinct functions in vivo. Being the predominant (and perhaps only) POT located 
on the brush border membrane of the small intestine, PEPT1, a high-capacity and low-
affinity transporter, is the transporter responsible for the absorption of small peptide 
fragments from the digestion of dietary proteins.3) It may also to be the primary 
transporter responsible for absorption of peptide-mimetic drugs such as some ACE 
inhibitors and the antiviral prodrug valacyclovir. Despite the sequential expression of 
PEPT1 and PEPT2 in the proximal tubule of the nephron,10) recent in vivo studies have 
shown PEPT1 plays a relatively minor role in the reabsorption of a dipeptide and an 
aminocephalosporin from tubular fluid.23,24) In contrast, these studies have shown that 
PEPT2, a high-affinity and low-capacity transporter, is the major player involved in the 
renal handling and reabsorption of peptide substrates and peptide-mimetic drugs. The 
localization of PEPT2 on the apical membrane of choroid plexus epithelial cells at the 
BCSFB is thought to facilitate its mediation of neuropeptide homeostasis and removal of 
neurotoxins from the brain. This localization of PEPT2 also makes it an attractive target 
for manipulating delivery of peptide-mimetic drugs to the brain.25) Because little is 
known about the cellular localization, tissue distribution, and transport properties of 
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PHT1 and PHT2, little is also known about their functional activity in vivo. Functional 
studies17-20) in the choroid plexus have failed to show inhibition of dipeptide uptake by 
excess L-histidine, suggesting that PHT1/PHT2 are unlikely to be involved in peptide 
transport at the BCSFB. Some studies suggest they may play a role in intracellular 
trafficking of small peptides.6,26)  
d) Relevance to physiology, pharmacology and toxicology 
While in vitro studies are convenient to probe mechanism, they are limited by 
experimental designs that employ nonphysiologic conditions, such as the lack of an intact 
blood supply. Moreover, the presence of multiple transport systems with overlapping 
substrate specificities in a tissue or organ of interest confounds an accurate assessment of 
the significance of a specific transporter relative to other transporters. Studies using wild-
type and knockout mice offer a unique opportunity to study the role and relevance of a 
particular POT under physiological in vivo conditions. By challenging in vivo knockout 
models, unique phenotypes can be discovered, demonstrating the role and relevance of a 
particular POT with respect to drug disposition, dynamics, and toxicity. The rest of this 
review will address in vivo findings of PEPT2 with respect to the three model substrates 
glycylsarcosine,23) cefadroxil,24) and 5-aminolevulinic acid27), and attempt to illustrate the 
evolving relevance of this transporter to physiology, pharmacology, and toxicology using 
a PEPT2 knockout mouse model developed by our laboratory.28) 
Disposition of Glycylsarcosine (GlySar) 
 Our first study investigated the in vivo pharmacokinetics, tissue distribution, and renal 
handling of a synthetic dipeptide following an intravenous bolus dose (0.05 µmol/g body 
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weight) of [14C]GlySar in wild-type and gender-matched PEPT2 knockout mice.23) These 
findings showed that, in PEPT2 knockout mice, the clearance of GlySar was markedly 
increased (2-fold), resulting in significantly lower systemic exposure of GlySar. In 
addition, renal reabsorption was almost abolished and GlySar was eliminated almost 
exclusively by glomerular filtration. Of the 46% of GlySar reabsorbed in wild-type mice, 
PEPT2 accounted for 86% of this process. Null mice also had lower choroid plexus 
concentrations of GlySar and a 5-fold lower choroid plexus-to-cerebrospinal fluid (CSF) 
ratio compared with wild-type mice at 60 min. Despite a 2-fold lower systemic exposure, 
null mice exhibited a greater CSF/blood ratio at 60 min (0.9 versus 0.2) and area under 
the curve (AUCCSF/AUCblood) ratio over 60 min (0.45 versus 0.12), indicating that PEPT2 
significantly impacts GlySar exposure in the CSF compartment.   
 These findings were consistent with our hypothesis that PEPT2 is the predominant 
peptide transporter in kidney and that it acts as an efflux transporter in the choroid plexus 
(clearing peptides from CSF). However the next logical step was to determine whether or 
not these in vivo results hold when PEPT2 is challenged with a substrate of 
pharmacologic relevance.   
Disposition of Cefadroxil 
 Our second study investigated the in vivo pharmacokinetics, renal tubular 
reabsorption, and brain penetration of cefadroxil, a broad spectrum, first-generation 
aminocephalosporin antibiotic.24) In these experiments, [3H]cefadroxil was administered 
by a single intravenous bolus injection in wild-type and gender-matched PEPT2 knockout 
mice over a wide range of doses (i.e., 100, 50, 12.5, and 1 nmol/g body weight). Results 
showed that cefadroxil disposition was clearly nonlinear over the dose range studied, due 
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to both saturable renal tubular secretion and reabsorption of the antibiotic. After the 1 
nmol/g dose of cefadroxil, PEPT2 null mice exhibited a 3-fold greater total clearance and 
3-fold lower systemic concentrations of drug compared to wild-type animals. Further, the 
cefadroxil plasma concentrations produced at this dose (i.e., approximately 0.01-10 µM) 
are clinically relevant since they are in the minimal inhibitory concentration range of 
most bacteria.29) Renal reabsorption of cefadroxil was almost completely abolished in 
PEPT2 null mice versus wild-type animals (i.e., 3% versus 70%, respectively; p<0.001). 
Of the 70% of cefadroxil reabsorbed in wild-type mice, PEPT2 accounted for 95% of 
reabsorbed substrate. Tissue distribution studies indicated that PEPT2 had a dramatic 
effect on cefadroxil tissue exposure, especially in brain where the CSF-to-blood 
concentration ratio of cefadroxil was 6-fold greater in PEPT2 null mice compared with 
wild-type animals.           
 The results were consistent with our hypothesis that PEPT2 significantly limits the 
exposure of cefadroxil in CSF, despite its role in increasing systemic exposure of the 
cephalosporin by renal reabsorption.  Thus, cefadroxil (and possibly other 
aminocephalosporins) may be ineffective in the treatment of meningitis, at least in part, 
because of PEPT2-mediated efflux of antibiotic from CSF, thereby resulting in sub-
therapeutic levels of drug at its active site. However, while the results were encouraging, 
a question that remained unanswered was whether or not PEPT2-mediated changes in 
drug disposition would result in significant changes to the pharmacological or 





Disposition and Neurotoxicity of 5-Aminolevulinic Acid (ALA) 
 Our third study investigated the role of PEPT2 in modulating ALA concentrations in 
the CSF and brain, and whether or not these changes would translate into greater 
neuroprotection in vivo against challenge doses of ALA, an endogenous heme precursor. 
ALA was chosen for study because of its known neurotoxicity in patients with hepatic 
porphyria30-32) or lead toxicity33, and because it is a PEPT2 substrate.14,17,34) Studies below 
report the PEPT2-mediated changes in ALA pharmacokinetics and pharmacodynamics 
under different experimental conditions.   
 Preliminary studies were first performed to probe the pharmacokinetics of [14C]ALA 
after an intravenous bolus dose of drug (10 nmol/g body weight) in gender-matched wild-
type and PEPT2 knockout mice27). Results indicated that PEPT2 knockout mice had a 2-
fold higher clearance resulting in a 2-fold lower systemic exposure. Despite the reduction 
in systemic concentrations of ALA, knockout mice showed a 5-fold greater concentration 
of drug in CSF, an 8-fold greater CSF/blood concentration ratio, and significantly lower 
concentrations of drug in choroid plexus.  These results are very consistent with that of 
GlySar and cefadroxil, as described previously and in Figure 1. As shown in this figure, 
the CSF-to-plasma ratios increased to a similar extent for GlySar, cefadroxil, and ALA in 
PEPT2 knockout mice as compared to wild-type animals.  Similar reductions in the 
choroid plexus-to-CSF ratio were also observed in PEPT2 null vs. wild-type mice for all 
three PEPT2 substrates.  These findings underscore the impact of PEPT2 in limiting 
exposure of these substrates to the CSF compartment and emphasize the directionality of 
PEPT2 transport from CSF into the choroid plexus epithelium in vivo.  
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 With respect to pharmacodynamics, PEPT2 had a major impact on the ability of 
PEPT2 null mice to survive the toxic insult of a single high dose of ALA (4000 mg/kg 
s.c.).27) The time at which 50% of the animals died was 21 hr in wild-type mice as 
compared to only 4 hr in null mice (p<0.001), providing strong evidence that PEPT2 
confers a neuroprotective advantage against the toxicity of ALA. Further evidence of a 
neuroprotective role of PEPT2 was demonstrated under chronic dosing conditions of 
ALA (500 mg/kg s.c. each day) for 7 days, where wild-type mice showed no sign of a 
reduced ability to maintain balance on a rotating rod while for PEPT2 knockout mice, 
rotary rod times were progressively lower in response to chronic ALA administration.27) 
Neuromuscular dysfunction in the null mice was particularly evident after 4 days of ALA 
dosing, and balance times were reduced to 58% of control values at 7 days. This finding 
was even more obvious when chronic dosing conditions of ALA (100 mg/kg s.c each 
day) were examined for 30 days. Specifically, by 30 days, wild-type mice had balance 
times that were 91% of control values while PEPT2 knockout mice had balance times 
that were only 60% of control values. Two-way ANOVA showed these correlations were 
highly significant as a function of both time and genotype (p<0.001 for both factors). 
These differences could not be explained by plasma concentrations as there was little 
difference in the systemic exposure of ALA (after a single dose of 100 mg/kg s.c.) in 
wild-type and PEPT2 null mice. In contrast, the CSF concentrations were 8- and 30-fold 
greater in PEPT2 null mice at 30 min and 240 min (p<0.001 for both times), respectively, 
indicating that the observed pharmacodynamic differences between genotypes were the 
result of differences in brain, and not systemic, levels of ALA. Moreover, the results are 
clinically relevant since chronic dosing of ALA at 100 mg/kg s.c. produced plasma 
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concentrations (i.e. ~ 23 µM, on average) which are similar to those observed in patients 
during acute attacks of porphyria (i.e. 2-13 µM).31)      
 These findings are novel in that they demonstrate not only a neuroprotective 
phenotype for the POT family member PEPT2, but that PEPT2-mediated effects on 
disposition in the brain translate into significant changes in toxicity.27) This phenomenon 
demonstrates the ability of a transporter to modulate drug effects beyond the conventional 
role of mediating drug disposition. The ability of PEPT2 to limit ALA exposure in CSF 
suggests that it may act as a secondary genetic modifier in the sensitivity of the brain to 
diseases such as hepatic porphyria or to environmental challenges such as lead poisoning. 
Figure 2 shows a proposed model of ALA neurotoxicity and the protective role of PEPT2 
in reducing ALA concentrations in CSF and the interstitial fluid (ISF) surrounding 
parenchymal cells. As a result of higher ALA concentrations in the ISF of PEPT2 
knockout mouse (or in conditions where choroid plexus expression of PEPT2 is reduced), 
there would be more interactions of this neurotoxin with extracellular receptors (e.g., 
glutamatergic or GABAergic receptors30,35)), leading to an increased risk of toxicity. This 
scenario was demonstrated phenotypically as reduced survival and balancing times in our 
transgenic PEPT2 null mice.   
Translation to humans 
 Translation of the role and relevance of PEPT2 in drug disposition, dynamics, and 
toxicity from the mouse to human will depend on four important factors: 1) the degree of 
inter-species sequence homology between mouse and human PEPT2 protein, 2) the 
conservation of PEPT2 transport functionality between these species; 3) the concordance 
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in cellular localization, expression levels and tissue distribution patterns of PEPT2 in 
both species; and 4) the concordance in cellular localization, expression levels and 
distribution patterns of other transporters with overlapping substrate specificities to 
PEPT2. These criteria, with the exception of criterion 4, have been tested when 
comparing the human and monkey peptide transporters, PEPT1 and PEPT2.36) As 
mentioned previously, the sequence homology between the mouse and human PEPT2 is 
high at about 80%. The molecular and structural features of the POT superfamily is 
highly conserved37) and studies have shown the ability of human cell lines expressing 
PEPT2 to transport the same range of substrates as mouse PEPT2.38-40) Moreover, the 
apical localization of PEPT2 in the kidney38,41) and lung42) cells of human has been shown 
indicating the same directionality of transport. Further studies, however, will be needed 
to demonstrate the inter-species concordance in expression levels and tissue distribution 
patterns of PEPT2. Since more than one transporter may affect the tissue distribution and 
organ elimination of a drug, additional studies will need to be performed to probe the 
influence of transporters with overlapping substrate specificity.  
Pharmacogenomic Implications   
 As the PEPT2 transporter is continued to be challenged with various substrates or 
conditions, more phenotypes will be elucidated, further demonstrating the relevance of 
PEPT2 in mediating drug disposition, dynamics, and toxicity. To the extent that more 
PEPT2-mediated therapeutic agents are discovered, the transporter will become an 
important target for manipulating the delivery of drugs to intended sites of action (e.g., 
the brain), or manipulating the overall kinetic, dynamic, or toxic profiles of drugs. What 
is less clear, however, is the extent to which genetic variants of PEPT2 exist in the human 
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population, and whether or not these variants may lead to functional polymorphisms in 
drug disposition, dynamics, and toxicity.  
 A few investigators have reported that certain genetic variants of human PEPT2 
(hPEPT2) may lead to functional polymorphisms in transport. For example, Terada et 
al.43) showed that a single amino acid substitution (Arg57His) of hPEPT2 caused the 
complete loss of functional activity when expressed in Xenopus oocytes or HEH293 
cells, in spite of PEPT2 having a conserved protein expression at the plasma membrane. 
This phenotype, although believed to be rare in humans, is analogous to our PEPT2 
knockout mouse. Pinsonneault et al.44) conducted a haplotype analysis of 27 single 
nucleotide polymorphisms of hPEPT2 and found two main variants containing several 
phased amino acid substitutions (i.e., hPEPT2*1 and hPEPT2*2; about 45% each), being 
present in all ethnic groups tested. They found that CHO cells, transfected with both 
variants, displayed similar Vmax values for GlySar but significantly different values for 
Km (83 µM vs. 233 µM for hPEPT2*1 and hPEPT2*2, respectively). The two haplotypes 
also differed in their pH sensitivity of GlySar uptake. While these two in vitro studies43,44) 
point to an attenuation (or complete abolition) of PEPT2-mediated transport in some 
groups, the in vivo relevance of these genetic variants in the human population remains 
unclear. Further studies will be needed to determine the frequency and phenotypic 
significance of these (and other) genetic polymorphisms in PEPT2.  
Conclusions 
 The PEPT2 knockout mouse has become an important tool to evaluate the evolving 
role and relevance of this transporter in drug disposition, dynamics and toxicity. 
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Although disruption of the PEPT2 gene itself does not result in obvious phenotypic 
changes in the knockout mouse, our studies emphasize the latent fact that challenging the 
knockout in a certain manner may bring about phenotypic abnormalities. Our studies 
have challenged the PEPT2 knockout model with various substrates of physiological, 
pharmacological and toxicological relevance, and have consistently demonstrated the 
dual action of this transporter with respect to its apical localization in kidney and choroid 
plexus epithelial cells.  The results have clearly shown that in vivo: 1) PEPT2 effluxes 
GlySar, cefadroxil and ALA from the CSF into choroid plexus, thereby affecting regional 
disposition in the brain; and 2) PEPT2 reabsorbs these substrates from renal tubular fluid, 
thereby affecting systemic pharmacokinetics and exposure. It also appears that the 
regional effect of PEPT2 in limiting exposure of substrates to the CSF and ISF of brain 
may be of more importance for some compounds than its effect in increasing systemic 
exposure.  Specifically, in the case of ALA, the modulation of regional brain disposition 










Figure A.1. Top panel: cerebrospinal fluid (CSF)-to-plasma concentration ratios in 
PEPT2 null mice were 4.2, 5.6 and 7.3 times that of values in wild-type mice for 
glycylsarcosine (GlySar), cefadroxil and 5-aminolevulinic acid (ALA), respectively. 
Bottom panel: choroid plexus-to-CSF concentration ratios in PEPT2 null mice were 0.3, 
0.07 and 0.09 times that of values in wild-type mice for GlySar, cefadroxil and ALA, 
respectively. Samples were obtained 60 min after dosing GlySar (50 nmol/g body 
weight)23), 120 min after dosing cefadroxil (1 nmol/g body weight)24), and 60 min after 












Figure A.2 Schematic of how the proton-coupled oligopeptide transporter SLC15A2 
(PEPT2 displayed as PT2) affects the distribution of 5-aminolevulinic acid (ALA) in 
different compartments of the brain.27) In particular, the loss of PEPT2 results in 
substantially lower concentrations of ALA in choroid plexus (CP) epithelial cells, and 
substantially higher concentrations of ALA in cerebrospinal fluid (CSF) and interstitial 
fluid (ISF) surrounding the parenchymal cells. As a result of the higher concentrations of 
ALA in ISF, there may be more interactions with extracellular receptors, thereby, leading 
to an increased risk of neurotoxicity (as displayed by the “skull and crossbones” symbol). 
The top-half of the figure represents a scenario in wild-type (WT) mice while the bottom-












  CSF ISFCP Epithelial Cells  Parenchymal Cells 
L   ALA ALA ALA








1) Daniel, H. and Kottra, G.: The proton oligopeptide cotransporter family SLC15 in 
physiology and pharmacology. Pflugers Arch., 447: 610-618 (2004). 
2) Herrera-Ruiz, D. and Knipp, G.T.: Current perspectives on established and putative 
mammalian oligopeptide transporters. J. Pharm. Sci, 92: 691-714 (2002). 
3) Fei, Y., Kanai, Y., Boron, W.F. and Heidiger, M.A.: Expression cloning of a 
mammalian proton-coupled oligopeptide transporter. Nature (Lond), 368: 563-566 
(1994). 
4) Lui, W., Liang, R., Ganapathy, V. and Leibach, F.H.: Molecular cloning of PEPT2, 
a new member of the H+/peptide cotransporter family from human kidney. 
Biochem. Biophys. Acta., 1235: 461-466 (1995). 
5) Yamashita, T., Shimada, S., Tagaki, T. and Tohyama, M.: Cloning and functional 
expression of a brain peptide/histidine transporter. J Biol. Chem, 272: 10205-10211 
(1997). 
6) Sakata, K., Yamashita, T., Maeda, M. and Shimada, S.: Cloning of a lymphatic 
peptide/histidine transporter. J. Biochem., 356: 53-60 (2001). 
7) Botka, C., Wittig, T., Graul, R., Nielson, C., Amidon, G. and Sade’e, W.: Human 
proton/oligopeptide transporter (POT) genes: identification of putative human genes 
using bioinformatics. AAPS Pharm. Sci., 2: 1-22 (2000). 
8) Rubio-Aliaga, I. and Daniel, H.: Mammalian peptide transporters as targets for drug 
delivery. Trends pharmacol. Sci., 23: 434-440 (2002). 
9) Ogihara, H., Saito, H., Shin, B.C., Terado, T., Takenoshita, S., Nagamachi, Y., Inui, 
K. and Takata, K.: Immunolocalization of H+/peptide cotransporter in rat digestive 
tract. Biochem. Biophys. Res. Commun., 220: 848-52 (1996). 
10) Shen, H., Smith, D.E., Yang, T. and Brosius, F.: Localization of PEPT1 and PEPT2 
proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am. J. 
Physiol., 276: F658-F665 (1999). 
11) Terada, T., Saito, H. and Mukai, M.: Recognition of β-lactam antibiotics by rat 
peptide transporters, PEPT1 and PEPT2 in LLC-PK cells. Am. J. Physiol., 273: 
F706-F711 (1997).  
12) Gonzalez, D.E., Covitz, K. and Sadée, W.: An oligopeptide transporter is expressed 
at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer. 
Res., 58: 519-525 (1998). 
13) Boll, M., Herget, M., Wagener, M., Weber, W.M., Markovich, D., Biber, J., Clauss, 
W., Murer, H. and Daniel, H.: Expression cloning and functional characterization of 
the kidney cortex high-affinity proton-coupled peptide transporter. Proc. Natl. 
Acad. Sci. USA, 93: 284-289 (1996). 
14) Doring, F., Walter, J., Will, J., Focking, M., Boll, M., Amasheh, S., Clauss, W. and 
Daniel, H.: Delta-aminolevulinic acid transport by intestinal and renal peptide 
transporters and its physiological and clinical implications. J Clin. Invest., 101: 
2761-2767 (1998). 
15) Berger, U. and Hediger, M.: Distribution of peptide transporter PEPT2 mRNA in 
the rat nervous system. Anat. Embryol., 199: 439-449 (1999) 
157 
 
16) Shen, H., Smith, D.E., Keep, R.F. and Brosius, F.C.: Immunolocalization of the 
proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol. 
Pharm., 1: 248-256 (2004). 
17)  Novotny, A., Xiang, J., Stummer, W., Teuscher, N.S., Smith, D.E. and Keep, R.: 
Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem., 
75: 321-328 (2000). 
18) Shu, C., Shen, H., Keep, R.F. and Smith, D.E.: Role of PEPT2 in peptide/mimetic 
trafficking at the blood-cerebral fluid barrier: studies in rat choroid plexus epithelial 
cells in primary culture. J. Phar. Exp. Ther., 301: 820-829 (2002). 
19) Tuescher, N.S., Novotny, A., Keep R.F., and Smith, D.E.: Functional evidence for 
the presence of PEPT2 in rat choroid plexus: Studies with glycylsarcosine. J. 
Pharmacol. Exp. Ther., 294: 494-499 (2000). 
20) Teuscher, N.S., Keep, R.F. and Smith, D.E.: PEPT2-mediated uptake of 
neuropeptides in rat choroid plexus. Pharm. Res., 18: 807-813 (2001). 
21) Groneberg D.A., Doring, F., Nickolaus, M., Daniel, H. and Fischer, A..: Expression 
of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root 
ganglia. Neurosci. Lett., 304: 181-4 (2001). 
22) Groneberg, D.A., Nickolaus, M., Springer, J., Doring, F., Daniel, H. and Fischer, 
A..: Localization of the peptide transporter PEPT2 in the lung: implications for 
pulmonary oligopeptide uptake. Am. J. Pathol., 158: 707-714 (2001). 
23)  Ocheltree, M., Shen, H., Hu, Y., Keep, R.F. and Smith, D.E.: Role and relevance of 
peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with 
glycylsarcosine in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther., 
35: 240-247 (2005). 
24) Shen, H., Ocheltree, S., Hu, Y., Keep, R.F. and Smith, D.E.: Impact of genetic 
knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and 
brain penetration in mice. Drug Metab. & Disp., 35: 1209-1216 (2007). 
25) Smith, D.E., Johanson, C.E. and Keep, R.F.: Peptide and peptide analog transport 
systems at the blood-CSF barrier. Adv. Drug Deliv. Rev., 56: 1765-1791 (2004). 
26) Ocheltree, M., Keep, R.F., Shen, H., Yang, D., Hughes, B. and Smith, D.E.: 
Preliminary investigation into the expression of proton-coupled oligopeptide 
transporters in neural retina and retinal pigment epithelium (RPE): lack of 
functional activity in RPE plasma membranes. Pharm. Res., 20: 1364-1372 (2003). 
27) Hu, Y., Shen, H., Keep, R.F., and Smith, D.E.: Peptide transporter 2 (PEPT2) 
expression in brain protects against 5-aminolevulinic acid neurotoxicity. J. 
Neurochem., 103: 2058-2065 (2007). 
28) Shen H, Smith D, Keep R, Xiang J, Brosius III FC.: Targeted disruption of the 
PEPT2 gene markedly reduces dipeptide uptake in the choroid plexus. J. Biol. 
Chem., 278: 4786-4791 (2003). 
29) Courtieu, L. and Drugeon, H.: Compared sensitivities of 532 bacterial strains to six 
cephalosporins. Int. J. Clin. Pharmacol. Res., 3: 195-201 (1983). 
30) Anderson, E., Sassa, A., Bishop, F. and Desnick, J.: Disorders of heme 
biosynthesis: X-linked siderolblastic anemia and the porphyrias, in The Metabolic 
& Molecular Bases of Inherited Disease (Scriver, R., Beaudet, L., Sly, S. and Valle, 
D.), pp 2991-3062. McGraw-Hill, New York (2001).  
158 
 
31) Lindberg, P., Martini, R., Baumgartner, M., Erne, B., Borg, J., Zielasek, J., Ricker, 
K., Steck, A., Toyka, K.V. and Meyer U.A.: Motor neuropathy in porphobilinogen 
deaminase-deficient mice imitates the peripheral neuropathy of human acute 
porphyria. J. Clin. Invest., 103: 1127-1134 (1999). 
32) Albers, W. and Fink, K.: Porphyric neuropathy. Muscle Nerve, 30: 410-422 (2004) 
33) Klassen, D.: Heavy metals and heavy-metal antagonists, in Goodman & Gilman’s 
The Pharmacological Basis of Therapeutics (Brunton, L., Lazo, S. and Parker, L., 
eds), pp 1753-1775. Mcgraw-Hill, New York. 
34) Ocheltree, M., Shen, H., Hu, Y., Xiang, J., Keep, R.F. and Smith, D.E.: Role of 
PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulinic acid: 
studies in wild-type and null mice. Pharm. Res., 21: 1680-1685 (2004) 
35) Adhikari, A., Penatti, C.A., Resende, R., Ulrich, H., Britto, G. and Bechara, H.: 5- 
Aminolevulinate and 4, 5-diox-ovalerate ions decrease GABAA receptor density in 
neuronal cells, synaptosomes and rat brain. Brain Res., 1093: 95-104 (2006). 
36) Zhang, E., Emerick, R., Pak, Y., Wrighton, S. and Hillgren, K.: Comparison of 
human and monkey peptide transporters: PEPT1 and PEPT2. Mol. Pharmaceutics, 
1: 201-210 (2004).  
37) Fei, J., Ganapathy, V. and Leibach, F.: Molecular and structural features of the 
proton-coupled oligopeptide transporter superfamily. Prog. Nucleic Acid Res. & 
Mol. Biol., 58: 239-61 (1998).  
38) Ganapathy, M., Brandsch, M., Prasad, P., Ganapathy, V. and Leibach, F.: 
Differential recognition of β-lactam antibiotics by intestinal and renal peptide 
transporters, PEPT1 and PEPT2. J. Biol. Chem., 270: 25672:25677 (1995).  
39) Biegel, A., Knutter, I., Hartrodt, B., Gabauer, S., Theis, S., Luckner, P., Kottra, G., 
Rastetter, M., Zebisch, K., Thondorf, I., Daniel, H., Neubert, K. and Brandsch, M.: 
The renal type H+/peptide symporter PEPT2: structure-affinity relationships. Amino 
Acids, 31: 137-156 (2006).  
40) Sugawara, M., Huang, W., Fei, Y., Leibach, F., Ganapathy, V. and Ganapathy, M.: 
Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 
and PEPT2. J. Pharm. Sci., 89: 781-789 (2000). 
41) Ramamoorthy, S., Liu, W., Ma, Y., Yang-Feng, T., Ganapathy, V. and Leibach, F.: 
Proton/peptide cotransporter (PEPT2) from human kidney: functional 
characterization and chromosomal localization. Biochemica. et. Biophysica. Acta., 
1240: 1-4 (1995). 
42) Bahadurri, P., D’Souza, V., Pinsonneault, J., Sade’e, W., Bao, S., Knoell, D. and 
Swaan, P.: Functional characterization of the peptide transporter PEPT2 in primary 
cultures of human upper airway epithelium. Am. J. Resp. Cell & Mol. Biol., 32: 
319-25 (2005). 
43) Terada, T., Irie, M., Okuda, M. and Inui, K.: Genetic variant Arg57His in human 
H+/peptide cotransporter 2 causes a complete loss of transport function. Biochem. 
Biophys. Res. Commun., 316: 416-420 (2004). 
44)  Pinsonneault, J., Nielsen, U. and Sadée, W.: Genetic variants of the human 
H+/dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. 





NONMEM control streams for paroxetine, atomextine, lorazepam, and olanzapine 
PK models 
Atomextine PK Control Stream 
$PROB pkatom 1cmpt no tlag    
$INPUT STUD NMID=ID AGE WGT HT GEN HORM RACE DOSE AMT NTIM TIME DAY 
CONC=DV SCR CLCR EVID MDV TXT PER 
$DATA pop_pk_atomoxetine.csv IGNORE=#    
$SUBS   ADVAN=2 TRANS=2  INFN=infnci.txt  
 $PK 
    TVCL = THETA(1) 
    CL   = TVCL * EXP(ETA(1)) 
    TVV  = THETA(2)*(1-THETA(6)*(1-GEN)) 
    V    = TVV * EXP(ETA(2)) 
    TVKA = THETA(3) 
    KA   = TVKA * EXP(ETA(3)) 
    K=CL/V 
    KA=KA    
    S2=V/1000    
 $ERROR    
    IPRED=F         ;INDIVIDUAL PREDICTION 
   W=((THETA(4)**2)*(F**2)+THETA(5)**2)**0.5             ;1=Additive and F (or 
IPRED)=Constant CV 
   IRES=DV-IPRED   ;INDIVIDUAL RESIDUAL 
   IWRES=IRES/W     
    Y = IPRED+W*EPS(1) 
 $THETA (0 15 50)  ; CL TH1 
        (0 100 2000) ; V  TH2 
        (0 3 15)   ; KA TH3 
        ;(0 0.4 2)  ; ALAG1 TH4 
          (0 0.2) 
          (0 5) 
           (0 0.1) 
           
 $OMEGA BLOCK(2)  
    0.3  
    0.01 0.3  
$OMEGA BLOCK(1)  
    0.3            
 $SIGMA (1 FIXED) 
 $EST  METHOD=1 INTERACTION SIGDIGITS=3 MAXEVAL=9999 PRINT=5 POSTHOC  
  NOABORT MSFO=MSF1 
 $COV PRINT=E 
$TABLE NMID  CL V KA DOSE WGT GEN CLCR AGE RACE HT HORM ETA(1) 
  ETA(2) ETA(3) NOPRINT ONEHEADER FIRSTONLY FILE=pk_atom_12A.tab 
$TABLE NMID MDV  CL V KA DOSE WGT GEN CLCR AGE RACE HT HORM  
 TIME IPRED IRES IWRES NOPRINT ONEHEADER FILE=pk_atom_12.tab 
 $SCAT DV VS PRED IPRED UNIT 
  
NONMEM Control Stream for Paroxetine PK 
Paroxetine PK Output 
$PROB 01 One-Compartment Model with tlag 
$INPUT STUD NMID=ID AGE WGT HT GEN HORM RACE DOSE AMT NTIM TIME DAY 
CONC=DV SCR CLCR EVID MDV TXT PER 
$DATA pop_pk_paroxetine.csv IGNORE=#    




    TVCL = THETA(1) 
    CL   = TVCL * EXP(ETA(1)) 
    TVV  = THETA(2) 
    V    = TVV * EXP(ETA(2))   
    TVKA = THETA(3) 
    KA   = TVKA * EXP(ETA(3)) 
    TVLAG= THETA(4) 
    ALAG1= TVLAG  
    K=CL/V 
    KA=KA   
    S2=V/1000  
 $ERROR    
    IPRED=F         ;INDIVIDUAL PREDICTION 
   W=((THETA(5)**2)*(F**2)+THETA(6)**2)**0.5             ;1=Additive and F (or 
IPRED)=Constant CV 
    IRES=DV-IPRED   ;INDIVIDUAL RESIDUAL 
   IWRES=IRES/W  
    Y = IPRED+W*EPS(1)    
 $THETA (0 100)  ; CL TH1 
        (0 1000) ; V  TH2 
        (0 0.1)   ; KA TH3 
        (0 0.4 1)  ; ALAG1 TH4 
         (0 0.25)   ; TH(5) 
          (0 0.1)   ; TH(6) 
 $OMEGA 0.3 0.3 0.01          
 $SIGMA (1 FIXED) 
 $EST  METHOD=1 INTERACTION SIGDIGITS=3 MAXEVAL=9999 PRINT=5 POSTHOC  
  NOABORT MSFO=MSF1 
 $COV PRINT=E 
 $TABLE   NMID MDV TIME NTIM CL V KA DOSE WGT GEN CLCR RACE AGE ETA(1) ETA(2)  
  ETA(3) NOPRINT ONEHEADER FIRSTONLY FILE=pk_paro_16A.tab 
 $TABLE   NMID MDV TIME NTIM CL V KA DOSE WGT GEN CLCR RACE AGE IPRED IRES IWRES WRES RES 
  NOPRINT ONEHEADER  FILE=pk_paro_16.tab  
 $SCAT DV VS PRED IPRED UNIT 
  
NONMEM Control Stream for Lorazepam PK 
$PROB 04 Test 2 COMP Model without Tlag and etas on v3 
$INPUT STUD NMID=ID AGE WGT HT GEN HORM RACE DOSE AMT NTIM TIME DAY 
CONC=DV SCR CLCR EVID MDV TXT PER 
 
$DATA pop_pk_lorazepam.csv IGNORE=# 
$SUBS   ADVAN=4 TRANS=4  INFN=infnci.txt 
 $PK 
  
    TVCL = THETA(1)+THETA(6)*(CLCR-105) 
    CL   = TVCL * EXP(ETA(1)) 
 
    TVV  = THETA(2)+THETA(7)*(WGT-75) 
   V2    = TVV * EXP(ETA(2)) 
     
    TVKA = THETA(3) 
    KA   = TVKA* EXP(ETA(4))  
 
    Q = THETA(4) 
    V3= THETA(5)* EXP(ETA(3)) 
 
     
 
    K=CL/V2 
    K23 = Q/V2 
    K32 = Q/V3 
    KA=KA    
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    S2=V2/1000 
 $ERROR    
     
    IPRED=F         ;INDIVIDUAL PREDICTION 
    W=THETA(8)*(F)             ;1=Additive and F (or IPRED)=Constant CV 
    IRES=DV-IPRED   ;INDIVIDUAL RESIDUAL 
    IWRES=IRES/W 
      
    Y = IPRED+W*EPS(1)     
 
 $THETA (0 4 15)     ; CL TH1 
        (0 50 100)  ; V  TH2 
        (0 1 5)     ; KA TH3 
        (0 11 20)     ; Q  TH4 
        (0 37 100)  ; V3 TH5  
        (0 0.01); TH6 CRCL ON CL 
        (0 0.7) ; TH7 WGT ON V  
        (0 0.25); TH8  
$OMEGA  0.3 0.3  0.3  0.3           
 $SIGMA (1 FIXED) 
 $EST  METHOD=1 INTERACTION SIGDIGITS=3 MAXEVAL=9999 PRINT=5 POSTHOC  
  NOABORT MSFO=MSF1 
 $COV PRINT=E 
$TABLE NMID  CL V2 KA Q V3  DOSE WGT GEN CLCR AGE RACE HT HORM ETA(1) 
  ETA(2) ETA(3) ETA(4) IPRED IRES NOPRINT ONEHEADER FIRSTONLY  
  FILE=pk_lorA_28.tab 
$TABLE NMID MDV  CL V2 KA Q V3  DOSE WGT GEN CLCR AGE RACE HT HORM  
 TIME IPRED IRES IWRES  NOPRINT ONEHEADER FILE=pk_lor_28.tab 
 $SCAT DV VS PRED IPRED UNIT 
 
NONMEM Control Stream for Olanzapine PK 
$PROB 14b (Model 14) FINAL Model Calc WRES 
$INPUT STUD NMID=ID AGE WGT HT GEN HORM RACE DOSE AMT NTIM TIME DAY 
CONC=DV SCR CLCR EVID MDV TXT PER 
$DATA pop_pk_olanzapine.csv IGNORE=#     
$SUBS   ADVAN=4 TRANS=4  INFN=infnci.txt 
 $PK 
    TVCL = THETA(1) 
    CL   = TVCL * EXP(ETA(1)) 
    TVV  = THETA(2)*(1-THETA(7)*(1-GEN)) 
    V2    = TVV * EXP(ETA(2))   
    KA = THETA(3) 
    Q = THETA(4) * EXP(ETA(3)) 
    TVV3 = THETA(5) 
    V3= TVV3 * EXP(ETA(4)) 
    ALAG1 = THETA(6) 
    K=CL/V2 
    K23 = Q/V2 
    K32 = Q/V3 
    KA=KA   
    S2=V2/1000 
$ERROR    
    IPRED=F         ;INDIVIDUAL PREDICTION 
   W=((THETA(8)**2)*(F**2)+THETA(9)**2)**0.5         ;1=Additive and F (or 
IPRED)=Constant CV 
    IRES=DV-IPRED   ;INDIVIDUAL RESIDUAL 
   IWRES=IRES/W     
    Y = IPRED+W*EPS(1) 
 $THETA (0 15 50)     ; CL TH1 
        (0 300 2000)  ; V  TH2 
        (0 0.1 3)     ; KA TH3 
        (0 20 50)     ; Q  TH4 
        (0 600 2000)  ; V3 TH5  
        (0 0.4 2)     ; ALAG TH6 
        (0 0.1 0.8)   ; TH7 GDR on V   
        (1)           ; TH8 Factor for WRES 
        (0.2)           ; TH9 Factor for WRES 
 
 $OMEGA 0.3 0.3 0.1 0.1          
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 $SIGMA 1 
 $EST  METHOD=1 INTERACTION SIGDIGITS=3 MAXEVAL=9999 PRINT=5 POSTHOC  
  NOABORT MSFO=MSF1 
 $COV 
 $TABLE  ONEHEADER NMID TIME NTIM CL V2 KA V3 Q ALAG1 DOSE WGT GEN CLCR  
  AGE ETA(1) ETA(2) ETA(3) ETA(4) MDV IPRED IWRES NOPRINT FILE=pk_olan_14c.tab 




































NONMEM control streams of lorazepam sleepiness and dizziness  categorical 
models 
Lorazepam Sleepiness Categorical Model  
$PROB SRDEQ Lorazepam sleepiness model 
$INPUT STUD NMID=ID DOSE DAY=DROP NTIM=TIME SQTM RESP=DV 
MV3=MDV TPK=DROP CON2 ICL IV1 IKA IQ IV2 AGE WGT HT=DROP GEN  
RACE CRCL   





 ; Define Equations for PK in Central and Effect Comp 
    K10 = ICL/IV1 
    K12 = IQ/IV1 
    K21 = IQ/IV2 
    KKK1 = (K12 + K21 + K10) 
    KKK2 = K21*K10 
    ALPH = (KKK1+(KKK1**2-4*KKK2)**0.5)/2 
    BETA = (KKK1-(KKK1**2-4*KKK2)**0.5)/2    
   TI = TIME 
   IF (TI.LE.0) TI=0 
   AAA = IKA*DOSE*1000/IV1 
  BBB = (K21-ALPH)/((ALPH-BETA)*(ALPH-IKA)) 
   CCC = (BETA-K21)/((ALPH-BETA)*(BETA-IKA)) 
   DDD = (K21-IKA)/((ALPH-IKA)*(BETA-IKA)) 
   KE0 = THETA(7) 
   AAA2 = AAA*KE0 
   BBB2 = BBB/(KE0-ALPH) 
   CCC2 = CCC/(KE0-BETA) 
   DDD2 = DDD/(KE0-IKA) 
   EEE = (K21-KE0)/((ALPH-KE0)*(BETA-KE0)*(IKA-KE0)) 
 
   CONC = AAA*(BBB*EXP(-ALPH*TI)+CCC*EXP(-BETA*TI)+DDD*EXP(-IKA*TI)) 
    
  SUM1=BBB2*EXP(-ALPH*TI) 
    SUM2=CCC2*EXP(-BETA*TI) 
    SUM3=DDD2*EXP(-IKA*TI) 
    SUM4=EEE*EXP(-KE0*TI) 
 
   CE=AAA2*(SUM1+SUM2+SUM3+SUM4)  
  
  ; Define Parameters and Equation for Drug Effect 
 
   SLOPE = THETA(6) 
    DRUG = SLOPE*CE  
  ; Define Parameters and Equation for Placebo Effect 
 EST=MIXEST   
IF (MIXNUM.EQ.1) THEN 
       PLAC=0 
   ELSE 
       PLAC= THETA(8)*(EXP(-THETA(10)*TIME)-EXP((-THETA(10)*230)*TIME)) 
   ENDIF  
 
  ; Define Different Intercepts for n-1 scores  
 
   B1 = THETA(1) 
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   B2 = B1 + THETA(2) 
   B3 = B2 + THETA(3) 
   B4 = B3 + THETA(4) 
   B5 = B4 + THETA(5) 
  
  ; Define logits for Score 0, 1, 2 
  ; (Y=>1, Y=>2) 
   A1 = B1 +DRUG+PLAC+ETA(1) 
   A2 = B2 +DRUG+PLAC+ETA(1) 
   A3 = B3 +DRUG+PLAC+ETA(1) 
   A4 = B4 +DRUG+PLAC+ETA(1) 
   A5 = B5+DRUG+PLAC+ETA(1) 
   C1 = EXP(A1) 
   C2 = EXP(A2) 
   C3 = EXP(A3) 
   C4 = EXP(A4) 
   C5 = EXP(A5) 
          
   ; Define Probability for Each Score 
   ; (Y=>0, Y=>1, Y=>2) 
   P1 = C1/(1+C1)  ; Probability of Score=>1 
   P2 = C2/(1+C2)  ; Probability of Score=>2 
   P3 = C3/(1+C3)  ; Probability of Score=>3 
   P4 = C4/(1+C4)  ; Probability of Score=>4 
   P5 = C5/(1+C5)  ; Probability of Score=>4 
    
   PR0 = 1-P1       ; Probability of Score=0 
   PR1 = P1-P2      ; Probability of Score=1 
   PR2 = P2-P3      ; Probability of Score=2 
   PR3 = P3-P4      ; Probability of Score=3 
   PR4 =P4-P5       ; Probability of Score=4 
   PR5 = 1-(PR0+PR1+PR2+PR3+PR4)      ; Probability of Score=5  
     
   ; Expected Score OR Predicted Score 
   ;ESCR = 4*PR4+3*PR3+2*PR2+1*PR1 
   ; Select Appropriate P(Y=m) 
   IF (DV.EQ.5) Y=PR5    
   IF (DV.EQ.4) Y=PR4    
   IF (DV.EQ.3) Y=PR3    
   IF (DV.EQ.2) Y=PR2 
   IF (DV.EQ.1) Y=PR1 
   IF (DV.EQ.0) Y=PR0  
 $MIX 
  NSPOP=2 
  P(1)=THETA(9) 
  P(2)=1-P(1)   
    
    
$THETA (-2)          ; THETA2 B1 
$THETA (-2)         ; THETA3 B2  
$THETA (-2)         ; THETA4 B3 
$THETA (-2)         ; THETA5 B4 
$THETA (-2)         ; THETA6 B4 
$THETA (0.2)         ; SLOPE 
$THETA (3)         ; KEO 
 $THETA (3)         ; PLAC 
 $THETA (0 0.5 1)         ; PROP  
$THETA (0.1)         ; PROP   
;$THETA (1)         ; PROP   
        
 $OMEGA 1 
$COV PRINT=E 
 $ESTIMATION MAXEVAL=9999 PRINT=5 METHOD=COND LAPLACE LIKELIHOOD 
  NOABORT MSFO=MSF1 
 $TABLE ONEHEADER FIRSTONLY STUD NMID  NTIM  DOSE   
   ETA(1) P1 P2 P3 P4   PR0 PR1 PR2 PR3 PR4    










B) Lorazepam Dizziness Categorical Model 
 
$PROB SRDEQ PK/PD Model of Dizziness 
;BOTH TREATMENT AND PLACEBO DATA WITH PK POSTHOC 
$INPUT STUD NMID=ID DOSE DAY=DROP NTIM=TIME SQTM=DROP DIZZ=DV  











 ; Define Equations for PK in Central and Effect Comp 
    K10 = ICL/IV1 
    K12 = IQ/IV1 
    K21 = IQ/IV2 
 
   KKK1 = (K12 + K21 + K10) 
    KKK2 = K21*K10 
 
    ALPH = (KKK1+(KKK1**2-4*KKK2)**0.5)/2 
    BETA = (KKK1-(KKK1**2-4*KKK2)**0.5)/2 
         
   TI = TIME 
   IF (TI.LE.0) TI=0 
 
   AAA = IKA*DOSE*1000/IV1 
  BBB = (K21-ALPH)/((ALPH-BETA)*(ALPH-IKA)) 
   CCC = (BETA-K21)/((ALPH-BETA)*(BETA-IKA)) 
   DDD = (K21-IKA)/((ALPH-IKA)*(BETA-IKA)) 
 
    
   CONC = AAA*(BBB*EXP(-ALPH*TI)+CCC*EXP(-BETA*TI)+DDD*EXP(-IKA*TI)) 
    
  
  ; Define Parameters and Equation for Drug Effect 
 
    SLOPE = THETA(1) 
 
    DRUG = SLOPE*CONC 
    
  ; Define Parameters and Equation for Placebo Effect 
 
 EST=MIXEST   
IF (MIXNUM.EQ.1) THEN 
       PLAC=0 
   ELSE 
      PLAC= THETA(5)*(EXP(-THETA(7)*TIME)-EXP(-THETA(8)*TIME)) 
 
   ENDIF  
 
  ; Define Different Intercepts for n-1 scores  
 
   B1 = THETA(2) 
   B2 = B1 + THETA(3) 
   B3 = B2 + THETA(4) 
    
   
   
  ; Define logits for Score 0, 1, 2 
  ; (Y=>1, Y=>2) 
    
   A1 = B1 + DRUG +PLAC+ETA(1) 
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   A2 = B2 + DRUG +PLAC+ETA(1) 
   A3 = B3 + DRUG +PLAC+ETA(1) 
    
     
   C1 = EXP(A1) 
   C2 = EXP(A2) 
   C3 = EXP(A3) 
    
   
             
   ; Define Probability for Each Score 
   ; (Y=>0, Y=>1, Y=>2) 
 
   P1 = C1/(1+C1)  ; Probability of Score=>1 
   P2 = C2/(1+C2)  ; Probability of Score=>2 
   P3 = C3/(1+C3)  ; Probability of Score=>3 
   
   PR0 = 1-P1       ; Probability of Score=0 
   PR1 = P1-P2      ; Probability of Score=1 
   PR2 = P2-P3      ; Probability of Score=2 
   PR3 = 1-(PR0+PR1+PR2)      ; Probability of Score=3 
    
     
   ; Expected Score OR Predicted Score 
   
   ;ESCR = 4*PR4+3*PR3+2*PR2+1*PR1 
 
   ; Select Appropriate P(Y=m) 
     
   IF (DV.EQ.3) Y=PR3    
   IF (DV.EQ.2) Y=PR2 
   IF (DV.EQ.1) Y=PR1 
   IF (DV.EQ.0) Y=PR0 
    
    
 $MIX 
  NSPOP=2 
  P(1)=THETA(6) 
  P(2)=1-P(1)   
  
  
$THETA (0 0.2)      ; THETA1 SLOPE 
$THETA (-5)          ; THETA2 B1 
$THETA (-3)         ; THETA3 B2  
$THETA (-1)         ; THETA4 B3 
$THETA (0 5)         ; Plac 
$THETA (0 0.5 1)      ;PROPORTION nrsp 
$THETA (0.1)   
$THETA (1)     
 
        
 $OMEGA 1 
$COV PRINT=E 
 $ESTIMATION MAXEVAL=9999 PRINT=5 METHOD=COND LAPLACE LIKELIHOOD 
  NOABORT MSFO=MSF1 
 $TABLE ONEHEADER FIRSTONLY STUD NMID  NTIM  DOSE CON2   
   P1 P2 P3 PR0 PR1 PR2 PR3 ETA(1) 
















NONMEM control stream of  VAS Sleepiness model 
 
$PROB vas 01 Initial Model  
 
 
$INPUT STUD NMID=ID TPK=DROP CON2 ICL IV1 IKA IQ IV2  AGE  WGT HT=DROP    
GEN HORM=DROP RACE=DROP DOSE TXT=DROP NTIM=TIME DAY CLCR VAS1 ADJ  
LOGT=DV MV1=MDV  
 
 
$DATA vas_finalmodel.csv IGNORE=# 







  K10 = ICL/IV1 
    K12 = IQ/IV1 
    K21 = IQ/IV2 
 
    KKK1 = (K12 + K21 + K10) 
    KKK2 = K21*K10 
 
    ALPH = (KKK1+(KKK1**2-4*KKK2)**0.5)/2 
    BETA = (KKK1-(KKK1**2-4*KKK2)**0.5)/2 
         
   TI = TIME 
   IF (TI.LE.0) TI=0 
 
   AAA = IKA*DOSE*1000/IV1 
  BBB = (K21-ALPH)/((ALPH-BETA)*(ALPH-IKA)) 
   CCC = (BETA-K21)/((ALPH-BETA)*(BETA-IKA)) 
   DDD = (K21-IKA)/((ALPH-IKA)*(BETA-IKA)) 
 
   KE0 = THETA(4)*EXP(ETA(3)) 
 
   AAA2 = AAA*KE0 
   BBB2 = BBB/(KE0-ALPH) 
   CCC2 = CCC/(KE0-BETA) 
   DDD2 = DDD/(KE0-IKA) 
   EEE = (K21-KE0)/((ALPH-KE0)*(BETA-KE0)*(IKA-KE0)) 
 
   CONC = AAA*(BBB*EXP(-ALPH*TI)+CCC*EXP(-BETA*TI)+DDD*EXP(-IKA*TI)) 
    
   SUM1=BBB2*EXP(-ALPH*TI) 
    SUM2=CCC2*EXP(-BETA*TI) 
    SUM3=DDD2*EXP(-IKA*TI) 
    SUM4=EEE*EXP(-KE0*TI) 
 
   CE=AAA2*(SUM1+SUM2+SUM3+SUM4)  




    





   





   IPRED=F         ;INDIVIDUAL PREDICTION 
   IRES=DV-IPRED   ;INDIVIDUAL RESIDUAL 
   W=1            ; 1=Additive and F (or IPRED)=Constant CV 
   IWRES = IRES/W 
  
   Y =F+EPS(1)  
 
    
 $THETA (-3)    ; BSL 
  $THETA (0.1) ;SLOPE 
 $THETA (-5); PLAC 
  $THETA (3); Keo 
$THETA (0 0.01);  
;$THETA (0 1) 
 
$OMEGA 0.01  0.01  0.01 0.01 
 
 $SIGMA 1  
 
 $EST  METHOD=1 INTERACTION SIGDIGITS=3 MAXEVAL=9999 PRINT=5  
  POSTHOC NOABORT MSFO=MSF1 
 $COV PRINT=E 
 $TABLE  ONEHEADER NMID NTIM TIME DOSE CONC BSL    
WRES IWRES IPRED IRES NOPRINT FILE=vas_7aaaa.tab  





































SPLUS nonparametric bootstrap code 
 
data1<-read.table("C:\\nmv\\LOR.SLEEP.SRDEQ\\MOE.csv",sep=",",skip=1) 
#there are 20 subjects simple PK data 
sam<-seq(1,20,1) 
for (j in 1:1000) { 
                 BGSH<-NULL 
                 for (i in 1:20) { lucky<-sample(sam,size=1,replace=T)+1000 
                                 data2<-data1[data1[,2]==lucky,]  
                                 data2[,2]<-i  
                                  BGSH<-rbind(BGSH,data2) 
                               }  
                exportData(BGSH, 
file="c:\\nmv\\LOR.SLEEP.SRDEQ\\dumby.csv",colNames=F,quote=F) 
                dos(paste("nmfe5 c1.txt r1.txt"),multi=F,output=F) 
 








































Categorical sleepiness simulation code (SPLUS) 
 







##Get dumby file 
data<-importData("dumby1.csv",type="ASCII", stringsAsFactors=F) 
nr<-nrow(data) 




##LOOP OVER MICHA FILE (OUTER LOOP) 
## LOOP WITHIN STUDY (INNER LOOP) 
for(i in 1:250){ 
    #i<-1 
    #get row i of micha 
    vec<-tab4[i,] 
    names(vec)<-
c("th1","th2","th3","th4","th5","th6","th7","th8","th9","th10", 
    "om11") 
    temp<-matrix(NULL,ncol=7,nrow=400) 
    for (j in 1:nr){ 
    if (j==1) {oldid<- -1} 
     ##subject level stuff 
    if (data[j,2]!=oldid) { 
     test1<-runif(1,0,1) 
     eta<-rnorm(1,0,sd=sqrt(vec$om11)) 
    } 
    #j<-1 
    K10<- data$ICL[j]/data$IV1[j] 
              K12<- data$IQ[j]/data$IV1[j] 
               K21<- data$IQ[j]/data$IV2[j] 
              KKK1<- (K12 + K21 + K10) 
               KKK2<- K21*K10 
               ALPH <- (KKK1+(KKK1**2-4*KKK2)**0.5)/2 
              BETA<- (KKK1-(KKK1**2-4*KKK2)**0.5)/2 
              TI<- data$TIME[j] 
               if (TI<=0) { TI==0} 
               AAA<- data$IKA[j]*data$DOSE[j]*1000/data$IV1[j] 
             BBB <- (K21-ALPH)/((ALPH-BETA)*(ALPH-data$IKA[j])) 
             CCC <- (BETA-K21)/((ALPH-BETA)*(BETA-data$IKA[j])) 
            DDD <- (K21-data$IKA[j])/((ALPH-data$IKA[j])*(BETA-data$IKA[j])) 
            CONC<- AAA*(BBB*exp(-ALPH*TI)+CCC*exp(-BETA*TI)+DDD*exp(-
data$IKA[j]*TI)) 
             KE0<-vec$th7 
            AAA2 <- AAA*KE0 
           BBB2 <- BBB/(KE0-ALPH) 
           CCC2<- CCC/(KE0-BETA) 
171 
 
           DDD2 <- DDD/(KE0-data$IKA[j]) 
          EEE <- (K21-KE0)/((ALPH-KE0)*(BETA-KE0)*(data$IKA[j]-KE0)) 
         SUM1<-BBB2*exp(-ALPH*TI) 
        SUM2<-CCC2*exp(-BETA*TI) 
        SUM3<-DDD2*exp(-data$IKA[j]*TI) 
         SUM4<-EEE*exp(-KE0*TI) 
        CE<-AAA2*(SUM1+SUM2+SUM3+SUM4)  
        SLOPE<-vec$th6 
       DRUG<-SLOPE*CE 
PLAC<-as.numeric(test1<=vec$th9)*0+as.numeric(test1>vec$th9)*vec$th8*(exp(-
vec$th10*data$TIME[j])-exp(-vec$th10*230*data$TIME[j])) 
                                                     MIXNUM<-
as.numeric(test1>vec$th9)+1 
                                                     B1<-vec$th1 
                                                     B2<- B1 + vec$th2 
                                                     B3<- B2 + vec$th3 
                B4<- B3 + vec$th4 
                  B5<- B4 + vec$th5 
                                                     #  ; Define logits for 
Score 0, 1, 2 
                                                     #  ; (Y=>1, Y=>2) 
                                                     A1<- B1 + DRUG +PLAC+eta 
                                                     A2<- B2 + DRUG +PLAC+eta 
                                                     A3<- B3 + DRUG +PLAC+eta 
                                                     A4<- B4 + DRUG +PLAC+eta 
                    A5<- B5 + DRUG +PLAC+eta 
                                                     C1<-exp(A1) 
                                                     C2<-exp(A2) 
                                                     C3<-exp(A3) 
                                                     C4<-exp(A4) 
                 C5<-exp(A5) 
                                                     #; Define Probability for 
Each Score 
                                                     #; (Y=>1, Y=>2, Y=>3) 
                                                     P1<- C1/(1+C1)  #; 
Probability of Score=>1 
                                                     P2<- C2/(1+C2)  #; 
Probability of Score=>2 
                                                     P3<- C3/(1+C3)  #; 
Probability of Score=>3 
                P4<- C4/(1+C4)  #; 
Probability of Score=>4 
               P5<- C5/(1+C5)  #; 
Probability of Score=>5 
                                                    PR0<- 1-P1      # ; 
Probability of Score=0 
                                                     PR1<- P1-P2     # ; 
Probability of Score=1 
                                                     PR2<- P2-P3     # ; 
Probability of Score=2 
                                                      PR3<- P3-P4     # ; 
Probability of Score=3 
                                                      PR4<- P4-P5     # ; 
Probability of Score=4 
                                                     PR5<- 1-
(PR0+PR1+PR2+PR3+PR4)  
                #MAKE DATA 
                 temp[j,1]<-data$ID[j] 
                                                     temp[j,2]<-data$DOSE[j] 
                                                     temp[j,3]<-data$TIME[j] 
                                                     temp[j,4]<-eta 
                                                     temp[j,5]<-MIXNUM 
                                                     test2<-runif(1,0,1) 
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                                                     if (test2>P1) {temp[j,6]<-
0} 
                                                     if (test2<=P1 && test2>P2) 
{temp[j,6]<-1} 
                                                     if (test2<=P2 && test2>P3) 
{temp[j,6]<-2} 
                                                     if (test2<=P3 && test2>P4)  
{temp[j,6]<-3} 
                                                      if (test2<=P4 && 
test2>P5)  {temp[j,6]<-4} 
                                                       if (test2<=P5)  
{temp[j,6]<-5}      
                                                    temp[j,7]<-i 
 
                               oldid<-data[j,2] 
                              } 
               
              BGSH<-rbind(BGSH,temp) 
                     





for (i in 1:400) { 
               if (i==1) {oldid<- -1} 
               if (data$ID[i]!=oldid) {ind<-0} 
               if (data$DV[i]>0 && ind==0) {ind<-1 
                                            sum<-sum+1 
                                            } 
               oldid<-data$ID[i] 
               } 
ppcinc[1]<-sum 
#Get simulated values  
for (j in 1:50) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              sum<-0 
                 for (i in 1:400) { 
                   if (i==1) {oldid<- -1} 
                   if (temp[i,1]!=oldid) {ind<-0} 
                   if (temp[i,6]>0 && ind==0) {ind<-1 
                                                sum<-sum+1 
                                               } 
                   oldid<-temp[i,1] 
               } 
                  ppcinc[j+1]<-sum 
 
               
                } 









for (i in 1:400) { 
               if (i==1) {oldid<- -1} 
               if (data$ID[i]!=oldid) {ind<-0} 
               if (data$DV[i]>1 && ind==0) {ind<-1 
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                                            sum<-sum+1 
                                            } 
               oldid<-data$ID[i] 
               } 
ppcinc2[1]<-sum 
#Get simulated values  
for (j in 1:50) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              sum<-0 
                 for (i in 1:400) { 
                   if (i==1) {oldid<- -1} 
                   if (temp[i,1]!=oldid) {ind<-0} 
                   if (temp[i,6]>1 && ind==0) {ind<-1 
                                                sum<-sum+1 
                                               } 
                   oldid<-temp[i,1] 
               } 
                  ppcinc2[j+1]<-sum 
 
               








for (i in 1:400) { 
               if (i==1) {oldid<- -1} 
               if (data$ID[i]!=oldid) {ind<-0} 
               if (data$DV[i]>1 && ind==0) {ind<-1 
                                            sum<-sum+1 
                                            } 
               oldid<-data$ID[i] 
               } 
ppcinc2[1]<-sum 
#Get simulated values  
for (j in 1:50) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              sum<-0 
                 for (i in 1:400) { 
                   if (i==1) {oldid<- -1} 
                   if (temp[i,1]!=oldid) {ind<-0} 
                   if (temp[i,6]>1 && ind==0) {ind<-1 
                                                sum<-sum+1 
                                               } 
                   oldid<-temp[i,1] 
               } 
                  ppcinc2[j+1]<-sum 
 
               





 ####PPC 4 (Maximum Expected Score) 
par(mfrow=c(2,2))  








for (i in 1:200) { 
               if (i==1) {oldid<- 1001} 
               #if new subject write max score for previous subject, reset 
maxscore 
               if (data1$ID[i]!=oldid && i>1) { 
                                           sum<-sum+1 
                                           coll[sum]<-maxsc  
                                              maxsc<-0 
                                                oldid<-data1$ID[i] 
                                                } 
               if (data1$DV[i]>maxsc && data1$ID[i]==oldid) { 
                                                           maxsc<-data1$DV[i] 
                                                           } 
               oldid<-data1$ID[i] 
               #handle last subject 
               if (i==200) { 
                         sum<-sum+1 
                         coll[sum]<-maxsc 
                           } 
               } 
#the missing dv generates a character vector so change it to numeric  
ppc3[1]<-mean(as.numeric(coll)) 
#Get simulated values 
 BGSH1<-BGSH[BGSH[,2]==2,] 
for (j in 1:250) { 
               
              temp<-BGSH1[BGSH1[,7]==j,] 
              coll<-NULL 
                 maxsc<-0 
                 sum<-0 
 
                 for (i in 1:200) { 
                   if (i==1) {oldid<- 1001} 
                   if (temp[i,1]!=oldid && i>1) { 
                                              sum<-sum+1 
                                              coll[sum]<-maxsc  
                                                 maxsc<-0 
                                                   oldid<-temp[i,1] 
 
                                              } 
                   if (temp[i,6]>maxsc && temp[i,1]==oldid) { 
                                                            maxsc<-temp[i,6] 
                                                            } 
                   oldid<-temp[i,1] 
                   #handle last subject 
                           if (i==200) { 
                         sum<-sum+1 
                         coll[sum]<-maxsc 
                           } 
   
               } 
               ppc3[1+j]<-mean(as.numeric(coll)) 
 
                  
               
                } 













#subset those with dose>0 
data1<-data[data$DOSE>0,] 
ul<-nrow(data1) 
for (i in 1:ul) { 
               if (i==1) {oldid<- 1001 
                         oldtime<-0 
                         oldae<-as.numeric(data1$DV[i]) 
                         } 
               #if new subject write auc for previous subject, reset auc 
               if (data1$ID[i]!=oldid && i>1) { 
                                           sum<-sum+1 
                                           coll[sum]<-auc  
                                              auc<-0 
                                                oldid<-data1$ID[i] 
                                                } 
               if (data1$ID[i]==oldid && data1$TIME[i]>0)    { 
                                                           auc<-
auc+1/2*(oldae+as.numeric(data1$DV[i]))*(data1$TIME[i]-oldtime) 
                                                          } 
               oldid<-data1$ID[i] 
               oldtime<-data1$TIME[i] 
               oldae<-as.numeric(data1$DV[i]) 
               #handle last subject 
               if (i==ul) { 
                         sum<-sum+1 
                         coll[sum]<-auc 
                           } 
               } 
#the missing dv generates a character vector so change it to numeric  
ppc4[1]<-mean(as.numeric(coll)) 
#Get simulated values  
for (j in 1:250) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              temp1<-temp[temp[,2]>0,] 
              coll<-NULL 
                auc<-0 
                sum<-0 
 
                 for (i in 1:ul) { 
                   if (i==1) {oldid<- 1001 
                             oldtime<-0 
                             oldae<-as.numeric(temp1[i,6])  
                             } 
                   if (temp1[i,1]!=oldid && i>1) { 
                                              sum<-sum+1 
                                              coll[sum]<-auc 
                                                 auc<-0 
                                                   oldid<-temp1[i,1] 
 
                                              } 
                   if (temp1[i,3]>0 && temp1[i,1]==oldid) { 
                                                          auc<-
auc+1/2*(oldae+as.numeric(temp1[i,6]))*(temp1[i,3]-oldtime) 
                                                            } 
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                   oldid<-temp1[i,1] 
                   oldtime<-temp1[i,3] 
                   oldae<-temp1[i,6] 
                   #handle last subject 
                           if (i==ul) { 
                         sum<-sum+1 
                         coll[sum]<-auc 
                           } 
   
               } 
               ppc4[1+j]<-mean(as.numeric(coll)) 
 
                  
               













for (k in times) { 
               data3<-data2[data2$TIME==k,] 
               sum<-sum+1 
               #populate times 
               bill[sum,1]<-times[sum] 
               #populate observed 
               bill[sum,2]<-mean(as.numeric(data3$DV)) 
               #bill[sum,2]<-quantile(probs=0.5,as.numeric(data3$DV)) 
 
               } 
  
 #now for simulations 
 #loop over studies  
 #j<-1 
 #make big matrix cols=time rows = simnum 
 store<-matrix(NULL,nrow=250,ncol=10) 
 for (j in 1:250) {temp<-BGSH[BGSH[,7]==j,] 
                  temp1<-temp[temp[,2]>0,] 
                  sum<-0 
                    for (k in times) { 
                                   temp2<-temp1[temp1[,3]==k,] 
                                   sum<-sum+1 
                                   store[j,sum]<-mean(temp2[,6]) 
                                     } 
   
                 } 
 #now combine results 
 #put mean of simulations in billshit 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                bill[sum,3]<-mean(store[,sum]) 
                #bill[sum,3]<-quantile(probs=0.5,store[,sum]) 
 
                              
                  } 
177 
 
 #lower quantile 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                bill[sum,4]<-quantile(probs=0.1,store[,sum]) 
                              
                  } 
#what could be more fun? 
sum<-0 
 for (b in times) { 
                sum<-sum+1 
                bill[sum,5]<-quantile(probs=0.9,store[,sum]) 
                              
                } 
 
# PI placebo 
moe<-matrix(NULL,nrow=10,ncol=5) 





for (k in times) { 
               data3<-data2[data2$TIME==k,] 
               sum<-sum+1 
               #populate times 
               moe[sum,1]<-times[sum] 
               #populate observed 
               moe[sum,2]<-mean(as.numeric(data3$DV)) 
               #bill[sum,2]<-quantile(probs=0.5,as.numeric(data3$DV)) 
 
               } 
  
 #now for simulations 
 #loop over studies  
 #j<-1 
 #make big matrix cols=time rows = simnum 
 store<-matrix(NULL,nrow=250,ncol=10) 
 for (j in 1:250) {temp<-BGSH[BGSH[,7]==j,] 
                  temp1<-temp[temp[,2]==0,] 
                  sum<-0 
                    for (k in times) { 
                                   temp2<-temp1[temp1[,3]==k,] 
                                   sum<-sum+1 
                                   store[j,sum]<-mean(temp2[,6]) 
                                     } 
   
                 } 
 #now combine results 
 #put mean of simulations in bill 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                moe[sum,3]<-mean(store[,sum]) 
                #bill[sum,3]<-quantile(probs=0.5,store[,sum]) 
 
                              
                  } 
 #lower quantile 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                moe[sum,4]<-quantile(probs=0.1,store[,sum]) 
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                  } 
 
 
#what could be more fun? 
sum<-0 
 for (b in times) { 
                sum<-sum+1 
                moe[sum,5]<-quantile(probs=0.9,store[,sum]) 
                              
                } 
 graphsheet()   














polygon(c(bill[,1], rev(bill[,1])), c(bill[,4], rev(bill[,5])),col=4, 
density=20) 
polygon(c(moe[,1], rev(moe[,1])), c(moe[,4], rev(moe[,5])),col=4, density=20) 
 






































Categorical dizziness simulation code (SPLUS) 
 









names(data)<-c("STUD", "ID", "DOSE", "TIME", "DV" ,"MDV", "ICL", "IV1", "IKA", 
"IQ", "IV2")  
BGSH<-NULL 
#loop over micha 
#LEVEL=STUDY 
for (i in 1:350){ 
             
              #i<-10 
              #Get row i of micha 
              vec<-tab4[i,] 
              names(vec)<-
c("th1","th2","th3","th4","th5","th6","th7","th8","om11") 
              temp<-matrix(NULL,ncol=7,nrow=400)  
              for (j in 1:nr) { 
                            if (j==1) {oldid<- -1} 
                            #subject level stuff 
                            if (data[j,2]!=oldid) { 
                                                test1<-runif(1,0,1) 
                                                eta<-
rnorm(1,0,sd=sqrt(vec$om11)) 
                                                } 
                                                #j<-1 
                                                K10<- 
data$ICL[j]/data$IV1[j] 
                                                     K12<- 
data$IQ[j]/data$IV1[j] 
                                                     K21<- 
data$IQ[j]/data$IV2[j] 
                                                     KKK1<- (K12 + K21 + K10) 
                                                     KKK2<- K21*K10 
                                                     ALPH <- (KKK1+(KKK1**2-
4*KKK2)**0.5)/2 
                                                     BETA<- (KKK1-(KKK1**2-
4*KKK2)**0.5)/2 
                                                     TI<- data$TIME[j] 
                                                     if (TI<=0) { TI==0} 
                                                     AAA<- 
data$IKA[j]*data$DOSE[j]*1000/data$IV1[j] 
                                                     BBB <- (K21-ALPH)/((ALPH-
BETA)*(ALPH-data$IKA[j])) 




                                                     DDD <- (K21-
data$IKA[j])/((ALPH-data$IKA[j])*(BETA-data$IKA[j])) 
                                                     CONC<- AAA*(BBB*exp(-
ALPH*TI)+CCC*exp(-BETA*TI)+DDD*exp(-data$IKA[j]*TI)) 
                                                SLOPE<-vec$th1 
                                                     DRUG<-SLOPE*CONC 
                                                     PLAC<-
as.numeric(test1<=vec$th6)*0+as.numeric(test1>vec$th6)*vec$th5*(exp(-
vec$th7*data$TIME[j])-exp(-vec$th8*data$TIME[j])) 
                                                     MIXNUM<-
as.numeric(test1>vec$th6)+1 
                                                     B1<-vec$th2 
                                                     B2<- B1 + vec$th3 
                                                     B3<- B2 + vec$th4 
                                                     #  ; Define logits for 
Score 0, 1, 2 
                                                     #  ; (Y=>1, Y=>2) 
                                                     A1<- B1 + DRUG +PLAC+eta 
                                                     A2<- B2 + DRUG +PLAC+eta 
                                                     A3<- B3 + DRUG +PLAC+eta 
    
                                                     C1<-exp(A1) 
                                                     C2<-exp(A2) 
                                                     C3<-exp(A3) 
                                                     #; Define Probability for 
Each Score 
                                                     #; (Y=>1, Y=>2, Y=>3) 
                                                     P1<- C1/(1+C1)  #; 
Probability of Score=>1 
                                                     P2<- C2/(1+C2)  #; 
Probability of Score=>2 
                                                     P3<- C3/(1+C3)  #; 
Probability of Score=>3 
                                                     PR0<- 1-P1      # ; 
Probability of Score=0 
                                                     PR1<- P1-P2     # ; 
Probability of Score=1 
                                                     PR2<- P2-P3     # ; 
Probability of Score=2 
                                                     PR3<- 1-(PR0+PR1+PR2)  
                                                     #Make data 
                                                     temp[j,1]<-data$ID[j] 
                                                     temp[j,2]<-data$DOSE[j] 
                                                     temp[j,3]<-data$TIME[j] 
                                                     temp[j,4]<-eta 
                                                     temp[j,5]<-MIXNUM 
                                                     test2<-runif(1,0,1) 
                                                      if (test2>P1) 
{temp[j,6]<-0} 
                                                     if (test2<=P1 && test2>P2) 
{temp[j,6]<-1} 
                                                     if (test2<=P2 && test2>P3) 
{temp[j,6]<-2} 
                                                     if (test2<=P3)             
{temp[j,6]<-3} 
                                                     temp[j,7]<-i 
 
                               oldid<-data[j,2] 
                              } 
               
              BGSH<-rbind(BGSH,temp) 









for (i in 1:400) { 
               if (i==1) {oldid<- -1} 
               if (data$ID[i]!=oldid) {ind<-0} 
               if (data$DV[i]>0 && ind==0) {ind<-1 
                                            sum<-sum+1 
                                            } 
               oldid<-data$ID[i] 
               } 
ppcinc[1]<-sum 
#Get simulated values  
for (j in 1:50) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              sum<-0 
                 for (i in 1:400) { 
                   if (i==1) {oldid<- -1} 
                   if (temp[i,1]!=oldid) {ind<-0} 
                   if (temp[i,6]>0 && ind==0) {ind<-1 
                                                sum<-sum+1 
                                               } 
                   oldid<-temp[i,1] 
               } 
                  ppcinc[j+1]<-sum 
 
               
                } 









for (i in 1:400) { 
               if (i==1) {oldid<- -1} 
               if (data$ID[i]!=oldid) {ind<-0} 
               if (data$DV[i]>1 && ind==0) {ind<-1 
                                            sum<-sum+1 
                                            } 
               oldid<-data$ID[i] 
               } 
ppcinc2[1]<-sum 
#Get simulated values  
for (j in 1:50) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              sum<-0 
                 for (i in 1:400) { 
                   if (i==1) {oldid<- -1} 
                   if (temp[i,1]!=oldid) {ind<-0} 
                   if (temp[i,6]>1 && ind==0) {ind<-1 
                                                sum<-sum+1 
                                               } 
                   oldid<-temp[i,1] 
               } 




               




#The model does well here too!  
  
 










for (i in 1:200) { 
               if (i==1) {oldid<- 1001} 
               #if new subject write max score for previous subject, reset 
maxscore 
               if (data1$ID[i]!=oldid && i>1) { 
                                           sum<-sum+1 
                                           coll[sum]<-maxsc  
                                              maxsc<-0 
                                                oldid<-data1$ID[i] 
                                                } 
               if (data1$DV[i]>maxsc && data1$ID[i]==oldid) { 
                                                           maxsc<-data1$DV[i] 
                                                           } 
               oldid<-data1$ID[i] 
               #handle last subject 
               if (i==200) { 
                         sum<-sum+1 
                         coll[sum]<-maxsc 
                           } 
               } 
#the missing dv generates a character vector so change it to numeric  
ppc3[1]<-mean(as.numeric(coll)) 
#Get simulated values 
 BGSH1<-BGSH[BGSH[,2]==2,] 
for (j in 1:300) { 
               
              temp<-BGSH1[BGSH1[,7]==j,] 
              coll<-NULL 
                 maxsc<-0 
                 sum<-0 
 
                 for (i in 1:200) { 
                   if (i==1) {oldid<- 1001} 
                   if (temp[i,1]!=oldid && i>1) { 
                                              sum<-sum+1 
                                              coll[sum]<-maxsc  
                                                 maxsc<-0 
                                                   oldid<-temp[i,1] 
 
                                              } 
                   if (temp[i,6]>maxsc && temp[i,1]==oldid) { 
                                                            maxsc<-temp[i,6] 
                                                            } 
                   oldid<-temp[i,1] 
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                   #handle last subject 
                           if (i==200) { 
                         sum<-sum+1 
                         coll[sum]<-maxsc 
                           } 
   
               } 
               ppc3[1+j]<-mean(as.numeric(coll)) 
 
                  
               
                } 











#subset those with dose>0 
data1<-data[data$DOSE>0,] 
ul<-nrow(data1) 
for (i in 1:ul) { 
               if (i==1) {oldid<- 1001 
                         oldtime<-0 
                         oldae<-as.numeric(data1$DV[i]) 
                         } 
               #if new subject write auc for previous subject, reset auc 
               if (data1$ID[i]!=oldid && i>1) { 
                                           sum<-sum+1 
                                           coll[sum]<-auc  
                                              auc<-0 
                                                oldid<-data1$ID[i] 
                                                } 
               if (data1$ID[i]==oldid && data1$TIME[i]>0)    { 
                                                           auc<-
auc+1/2*(oldae+as.numeric(data1$DV[i]))*(data1$TIME[i]-oldtime) 
                                                          } 
               oldid<-data1$ID[i] 
               oldtime<-data1$TIME[i] 
               oldae<-as.numeric(data1$DV[i]) 
               #handle last subject 
               if (i==ul) { 
                         sum<-sum+1 
                         coll[sum]<-auc 
                           } 
               } 
#the missing dv generates a character vector so change it to numeric  
ppc4[1]<-mean(as.numeric(coll)) 
#Get simulated values  
for (j in 1:300) { 
               
              temp<-BGSH[BGSH[,7]==j,] 
              temp1<-temp[temp[,2]>0,] 
              coll<-NULL 
                auc<-0 
                sum<-0 
 
                 for (i in 1:ul) { 
184 
 
                   if (i==1) {oldid<- 1001 
                             oldtime<-0 
                             oldae<-as.numeric(temp1[i,6])  
                             } 
                   if (temp1[i,1]!=oldid && i>1) { 
                                              sum<-sum+1 
                                              coll[sum]<-auc 
                                                 auc<-0 
                                                   oldid<-temp1[i,1] 
 
                                              } 
                   if (temp1[i,3]>0 && temp1[i,1]==oldid) { 
                                                          auc<-
auc+1/2*(oldae+as.numeric(temp1[i,6]))*(temp1[i,3]-oldtime) 
                                                            } 
                   oldid<-temp1[i,1] 
                   oldtime<-temp1[i,3] 
                   oldae<-temp1[i,6] 
                   #handle last subject 
                           if (i==ul) { 
                         sum<-sum+1 
                         coll[sum]<-auc 
                           } 
   
               } 
               ppc4[1+j]<-mean(as.numeric(coll)) 
 
                  
               




#PIs ## Treatment 
 
bill<-matrix(NULL,nrow=10,ncol=5) 





for (k in times) { 
               data3<-data2[data2$TIME==k,] 
               sum<-sum+1 
               #populate times 
               bill[sum,1]<-times[sum] 
               #populate observed 
               bill[sum,2]<-mean(as.numeric(data3$DV)) 
               #bill[sum,2]<-quantile(probs=0.5,as.numeric(data3$DV)) 
 
               } 
  
 #now for simulations 
 #loop over studies  
 #j<-1 
 #make big matrix cols=time rows = simnum 
 store<-matrix(NULL,nrow=300,ncol=10) 
 for (j in 1:300) {temp<-BGSH[BGSH[,7]==j,] 
                  temp1<-temp[temp[,2]>0,] 
                  sum<-0 
                    for (k in times) { 
                                   temp2<-temp1[temp1[,3]==k,] 
                                   sum<-sum+1 
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                                   store[j,sum]<-mean(temp2[,6]) 
                                     } 
   
                 } 
 #now combine results 
 #put mean of simulations in bill 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                bill[sum,3]<-mean(store[,sum]) 
                #bill[sum,3]<-quantile(probs=0.5,store[,sum]) 
 
                              
                  } 
 #lower quantile 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                bill[sum,4]<-quantile(probs=0.1,store[,sum]) 
                              





 for (b in times) { 
                sum<-sum+1 
                bill[sum,5]<-quantile(probs=0.9,store[,sum]) 
                              
                } 
### PI placebo  
moe<-matrix(NULL,nrow=10,ncol=5) 





for (k in times) { 
               data3<-data2[data2$TIME==k,] 
               sum<-sum+1 
               #populate times 
               moe[sum,1]<-times[sum] 
               #populate observed 
               moe[sum,2]<-mean(as.numeric(data3$DV)) 
               #bill[sum,2]<-quantile(probs=0.5,as.numeric(data3$DV)) 
 
               } 
  
 #now for simulations 
 #loop over studies  
 #j<-1 
 #make big matrix cols=time rows = simnum 
 store<-matrix(NULL,nrow=300,ncol=10) 
 for (j in 1:300) {temp<-BGSH[BGSH[,7]==j,] 
                  temp1<-temp[temp[,2]==0,] 
                  sum<-0 
                    for (k in times) { 
                                   temp2<-temp1[temp1[,3]==k,] 
                                   sum<-sum+1 
                                   store[j,sum]<-mean(temp2[,6]) 
                                     } 
   
                 } 
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 #now combine results 
 #put mean of simulations in bill 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                moe[sum,3]<-mean(store[,sum]) 
                #bill[sum,3]<-quantile(probs=0.5,store[,sum]) 
 
                              
                  } 
 #lower quantile 
 sum<-0 
 for (b in times) { 
                sum<-sum+1 
                moe[sum,4]<-quantile(probs=0.1,store[,sum]) 
                              
                  } 
 
 
#what could be more fun? 
sum<-0 
 for (b in times) { 
                sum<-sum+1 
                moe[sum,5]<-quantile(probs=0.9,store[,sum]) 
                              




 graphsheet()   















polygon(c(bill[,1], rev(bill[,1])), c(moe[,4], rev(moe[,5])),col=4, density=20) 
key(corner=c(1,1), text=list(c("Lorazepam Dizziness","Placebo Dizziness")), 
lines=list(type="p",col=1,pch=c(16,1),transparent=T, border=T)) 
 













Table of final PK parameter estimates of four study CNS drugs 
 
 
Drug Parameter Mean 95% CI IIV(%CV) 95% CI
Olanzapine
CL/F (L/min) 13.4 11.26-15.54 22
V1/F (L) 321 227.6-414.4 80.7
V2/F (L) 684 511.2-856.8 44.6
Ka (h-1) 0.12 .091-0.15
Q (L/min) 33.2 28.32-38.08 18.8
Tlag (h) 0.94 0.87-1.01
Lorazepam
CL/F (L/min) 4.02 3.55 - 4.45 25.6 12.2 - 39
V1/F (L) 26.3 19.12 - 33.48 34.1 13.6 - 54.6
V2/F (L) 58.4 52.1 - 64.7
Ka (h-1) 0.5 0.34 - 0.66 13.3 6 - 20.6
Q (L/min) 16.4 13.92 - 18.88
Paroxetine
CL/F (L/min) 96.6 65
V1/F (L) 1200 19
Ka (h-1) 0.14 59
Tlag (h) 0.46
Atomoxetine
CL/F (L/min) 26.4 21.94-30.86 36.3 16.5-56.1
V1/F (L) 134 115.04-152.96 16 3.7-28.3












PK model goodness-of-fit plots 
 
A. Olanzapine 
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